

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## A qualitative meta-synthesis of barriers and facilitators that influence the implementation of community pharmacy services: perspectives of patients, nurses and general medical practitioners

|                                 |   |
|---------------------------------|---|
| Journal:                        | <i>BMJ Open</i>   |
| Manuscript ID                   | bmjopen-2016-015471   |
| Article Type:                   | Research  |
| Date Submitted by the Author:   | 08-Dec-2016   |
| Complete List of Authors:       | Hossain, Lutfun; University of Technology Sydney<br>Fernandez-Llimos, Fernando; Universidade de Lisboa<br>Lockett, Tim; University of Technology Sydney<br>Moullin, Joanna; University of California San Diego<br>Durks, Desire; University of Technology Sydney<br>Franco-Trigo, Lucia; University of Technology Sydney<br>Benrimoj, Charlie; University of Technology, Sydney<br>Sabater-Hernandez, Daniel; University of Technology Sydney |
| <b>Primary Subject Heading</b>: | Health services research  |
| Secondary Subject Heading:      | Qualitative research  |
| Keywords:                       | Community pharmacy services, health service research, qualitative meta-synthesis, barriers, facilitators, determinants of practice  |
|                                 |   |

SCHOLARONE™  
Manuscripts

1

2

3

4 1 **A qualitative meta-synthesis of barriers and facilitators that influence the implementation**

5

6 2 **of community pharmacy services: perspectives of patients, nurses and general medical**

7

8 3 **practitioners**

9

10

11 4 **Authors:**

12

13

14

15 5 **Lutfun N. Hossain.** BPharm. Master Student; Graduate School of Health, University of

16 6 Technology, Sydney, Australia. Email: [Lutfun.Hossain@student.uts.edu.au](mailto:Lutfun.Hossain@student.uts.edu.au)

17

18

19

20 7 **Fernando Fernandez-Llimos.** PharmD, PhD. Assistant Professor; Research Institute for

21 8 Medicines, Department of Social Pharmacy, Faculty of Pharmacy, University of Lisbon,

22 9 Portugal. Email: [f-llimos@ff.ul.pt](mailto:f-llimos@ff.ul.pt)

23

24

25

26

27

28 10 **Tim Luckett.** BSc (Hons), PhD. Senior Lecturer; Faculty of Health, University of Technology

29 11 Sydney, Australia Email: [Tim.Luckett@uts.edu.au](mailto:Tim.Luckett@uts.edu.au)

30

31

32

33 12 **Joanna C. Moullin.** BPharm. PhD; Research Fellow; Department of Psychiatry, University of

34 13 California, San Diego (USA). Email: [jcmoullin@gmail.com](mailto:jcmoullin@gmail.com)

35

36

37

38 14 **Desire Durks.** BPharm. Master Student; Graduate School of Health, University of Technology,

39 15 Sydney, Australia. Email: [desire.durks@student.uts.edu.au](mailto:desire.durks@student.uts.edu.au)

40

41

42

43 16 **Lucia Franco-Trigo.** MPharm. PhD Student; Graduate School of Health, University of

44 17 Technology, Sydney, Australia. Email: [lucia.francotrigo@student.uts.edu.au](mailto:lucia.francotrigo@student.uts.edu.au)

45

46

47

48

49 18 **Charlie Benrimoj.** PharmD, PhD. Head of School; Graduate School of Health, University of

50 19 Technology, Sydney, Australia. Email: [shalom.benrimoj@uts.edu.au](mailto:shalom.benrimoj@uts.edu.au)

51

52

53

54 20 **Daniel Sabater-Hernández.** PharmD, PhD. Chancellor's Postdoctoral Research Fellow;

55 21 Graduate School of Health, University of Technology, Sydney, Australia. Fellow; Academic

56

57

58

59

60

22 Centre in Pharmaceutical Care, University of Granada, Spain. Email:

23 [daniel.sabaterhernandez@uts.edu.au](mailto:daniel.sabaterhernandez@uts.edu.au); daniel.sabaterhernandez@outlook.com

24 **Corresponding author: Daniel Sabater-Hernández**

25 Graduate School of Health, University of Technology Sydney.

26 Level 4, Building 7, 67 Thomas St, Ultimo (PO Box 123)

27 Phone: +61 2 9514 7201; Email: daniel.sabaterhernandez@uts.edu.au;

28 [daniel.sabaterhernandez@outlook.com](mailto:daniel.sabaterhernandez@outlook.com)

29 **Word count (excluding title page, abstract, references, figures and tables): 3667**

**ABSTRACT**

**Objectives:** The integration of community pharmacy services (CPSs) into primary care practice can be enhanced by developing suitable implementation programs. A key early step in the development of such programs is assessing the elements that enable or hinder the implementation of such services. These elements have been widely researched from the perspective of community pharmacists but not from the perspectives of other stakeholders who can directly or indirectly interact with, and influence the implementation of CPSs. The aim of this study was to synthesise the literature on patients', general practitioners' (GPs) and nurses' perspectives of CPSs to identify elements that can hinder (i.e., barriers) or enable (i.e., facilitators) their implementation in Australia.

**Methods:** A meta-synthesis of qualitative studies was performed. A systematic literature search in PubMed, Scopus and Informit was conducted to identify qualitative studies that explored patients', GPs' or nurses' views about CPSs in Australia. Thematic synthesis was performed to identify the elements influencing CPS implementation, which were further classified using an ecological approach.

**Results:** Twenty nine articles were included in the review. Sixty three barriers or facilitators to the implementation of CPSs were identified. These elements were related to different ecological levels: (1) individual patient (n=14); (2) interpersonal, which was divided into two sub-levels: (a) individual healthcare professionals (n=17) and (b) relationships between individuals (n=7); (3) organizational, which was divided into (a) community pharmacy setting (n=8); and (b) the service itself (n=8); and (4) community and healthcare system (n=9).

**Conclusions:** Patients, GPs and nurses can identify a large number of barriers and facilitators to the implementation of CPSs in Australia. These influential elements should be taken into account together with those previously identified by pharmacists, to enhance the analysis of the

context in which CPSs are implemented and, thus, the development of implementation programs.

## KEY WORDS

Community pharmacy services [MeSH]; health service research [MeSH]; qualitative meta-synthesis; barriers; facilitators; determinants of practice.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Qualitative meta-synthesis aims to synthesise qualitative literature to provide a new, more comprehensive interpretation of the findings that goes beyond the depth and breadth of the original studies and to broaden the range of concepts identified. Therefore, it is an appropriate method to suitably achieve the aim of this study, which was to identify a comprehensive range of elements that, according to general practitioners, patients and nurses, can enable (i.e., facilitators) or hinder (i.e., barriers) the implementation of community pharmacy services in Australia.
- For the first time, a review focuses on synthesising the perspectives of these key stakeholders who can strongly influence the implementation of community pharmacy services at the primary care level.
- Qualitative studies in this review were checked against a minimum set of quality appraisal criteria, but a comprehensive quality assessment was not conducted. This decision was made due to the difficulty of using the information about studies' quality to inform the synthesis (e.g. even studies with flaws in methodology can provide valuable information), and to identify a larger number of possible influential elements.
- This review was purposively focused on a specific implementation context (i.e., Australia), to which its results are directly relevant and will be immediately applied and actions will be taken. Australia is a country with a large experience in research and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

78 implementation of community pharmacy services and, therefore, it is expected the  
79 results of this review may be relevant to start investigating barriers and facilitators to  
80 community pharmacy service implementation in contexts with less experience.  
81

For peer review only

## INTRODUCTION

The implementation of new health interventions and services into established healthcare practices and systems has been found to be challenging.<sup>1-4</sup> The inherent complexity of both health services and healthcare systems may be fundamental to the implementation problem.<sup>5, 6</sup> According to current health planning approaches, the implementation of health services can be enhanced by comprehensively assessing the context in which they will be delivered. Analysis of the context should consider the stakeholders who can influence or be affected by the health service, as well as the social, physical, economic and policy environments that can enable or hinder the normalization of the service.<sup>2, 7</sup> Early identification of these elements (including how they relate to or interact with each other) is a key step for developing suitable strategies and interventions to enhance health service implementation.

In the implementation science literature, several terms are used to refer to the elements that can influence service implementation and practice change. Some generally known examples, which are commonly used interchangeably in the literature,<sup>8</sup> are: barriers and facilitators,<sup>9</sup> determinants of practice;<sup>7</sup> implementation factors;<sup>10</sup> or constructs.<sup>2</sup> The current use of these terms encloses different concepts. For the purpose of this review and to avoid the terminological debate we have used the term 'influential element' as a neutral term.

In the community pharmacy setting, the implementation and sustainability of patient-centred services and the integration of community pharmacists into primary healthcare teams remains a challenge worldwide.<sup>11, 12</sup> Extensive research has been conducted to identify the elements that from the perspective of community pharmacists (i.e., service provider) can influence the implementation of community pharmacy services (CPSs).<sup>13-15</sup> However, considering the view of a single stakeholder group is insufficient to comprehensively analyse the complexity of a particular implementation context. These limited analyses can lead to the development of inadequate implementation strategies and interventions. Patients, general practitioners (GPs),



and primary care nurses are key stakeholders who interact with or are affected by CPSs and may be able to strongly influence the implementation of such services. These stakeholders may have their own particular views about CPSs and so can complement the findings from previous pharmacy-informed research. Patients', nurses' and GPs' views and experiences regarding CPSs have been explored in several qualitative studies<sup>16-20</sup> but no systematic review that collates and analyses such information exists. Qualitative meta-synthesis aims to synthesise qualitative literature to provide a new, more comprehensive interpretation of the findings that goes beyond the depth and breadth of the original studies and to broaden the range of concepts identified.<sup>21, 22</sup> Thus, the aim of this study was to synthesise such qualitative literature to describe the broad range of elements that, from the patients', GPs' and nurses' perspectives, can hinder or enable the implementation of CPSs in Australia.

**METHODS**

A systematic review was conducted following Cochrane handbook<sup>23</sup> and reported following the ENTREQ Statement.<sup>24</sup>

**Search strategy, screening and eligibility criteria.** A systematic search was conducted in May 2015 in three electronic databases (PubMed, Scopus and Informit), without time limits, to identify qualitative studies addressing patients', nurses' or GPs' views about CPSs in Australia. A CPS was assumed to refer to an action or set of actions delivered in or organised by a community pharmacy to optimise the process of care, with the aim of improving health outcomes and the value of healthcare.<sup>25</sup> For the purpose of this review, routine professional activities performed by community pharmacists, such as dispensing, were not considered as CPSs and so excluded. Articles that did not address a specific CPS but inter-professional collaboration (i.e. between community pharmacists and other healthcare professionals) were included as they can also provide insight into the elements influencing the implementation of

CPSs. Full search strategies are available on Appendix 1 (Supplementary File). In addition, the references from the included papers were searched manually for additional relevant studies. A two-step process was performed by one researcher to select studies for the analysis. As a first step, titles and abstracts were screened to identify and exclude non-relevant literature. In a second, full texts of the remaining articles were reviewed to exclude those that: (1) were not related to CPSs; (2) did not address patient, nurse and/or GP perspective; (3) did not use qualitative research methodology;<sup>26</sup> (4) did not clearly identify the stakeholder (i.e., patient, nurse or GP) as the source of the information; and (5) were not accessible in any of the research team university libraries, or unattainable following contact with the authors.

All the included articles were checked by the same researcher for 'elementary quality assessment' using the first three criteria delineated by Dixon-Woods et al<sup>27</sup> to appraise qualitative research: (1) was the research question clear? (2) Was the research questions suited to qualitative inquiry? (3) Were (a) sampling, (b) data collection, and (c) analysis clearly described? Articles were excluded when no answer, or an unclear answer, was given to at least one of the three questions.

**Synthesis.** Qualitative meta-synthesis was conducted by one researcher according to the three-stage method for thematic synthesis described by Thomas et al<sup>28</sup>. The first stage of analysis involved free line-by-line coding of the original data (study participants' quotes) and the study authors' interpretation of the original data. The process of coding involves summarising text from the results and discussion sections of each article into one or more descriptive issues (i.e. codes) to capture meaning. The second stage of the process involved grouping codes into one or more descriptive themes. Subsequent articles were coded into pre-existing themes, and new themes were created when considered necessary. To simplify the terminology throughout this article, themes were interpreted as elements (i.e., influential elements) that could positively (i.e., facilitators) or negatively (i.e., barriers) influence CPS implementation or practice change.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

A barrier was defined as *"any type of obstacle (material or immaterial) which can impede the dissemination, implementation and/or sustainability of a CPS"*; while a facilitator was defined as *"any type of element (material or immaterial) which can help to overcome barriers and/or accelerate the dissemination or implementation"* of a CPS.<sup>15</sup> Themes that were related to similar issues were further grouped to create one broad barrier or facilitator. The identified influential elements were reviewed by a second researcher to assess clarity, consistency, and understanding. At the third stage, barriers and facilitators were organised using an adapted version of the Ecological Model (Table 1),<sup>29</sup> which classified them into four different levels: patient, interpersonal, organisational, and community/system. Coding of papers that were identified manually was conducted last. NVivo Version 10 software (QSR International Pty Ltd; Australia) was used to help manage and analyse the data. Once all the influential elements were identified, a second round of analysis was conducted to explore for the relationships between them. Again, both study participants' quotes and study authors' data interpretation were reviewed for this purpose. A network representing the identified relationships was generated using a ForceAtlas2 layout<sup>30</sup> with Gephi, 0.8.

Table 1. Levels where elements that can influence the implementation of community pharmacy services can exist (adapted from McLeroy et al<sup>29</sup>)

|                      |  |
|----------------------|--|
| Individual patient   | Elements related to the personal characteristics and ideas concerning individual patients that can affect their utilisation of community pharmacy services.  |
| Interpersonal        | Elements related to the healthcare providers and non-healthcare personnel who are involved with the community pharmacy service and with whom patients associate (e.g., family, friends, pharmacists, pharmacy assistants, GPs, nurses) and the formal and informal relationships between patients and healthcare professionals and healthcare professionals with other healthcare professionals. |
| Organisational       | Elements related to characteristics of the community pharmacy setting and attributes of the community pharmacy service that can influence the success of implementation.   |
| Community and system | Elements related to the larger society, which consists of collectives of people in a geographical location, the relationships between organisations, the political players in the system and the rules, regulations and policies that have the power to control and/or influence the implementation of services.   |

## RESULTS

The systematic and manual search identified 243 articles once duplicates were removed. After title and abstract screening, 124 full-text articles were assessed for eligibility of which 29 articles were included in the qualitative meta-synthesis (all of them fulfilled the appraisal criteria) (Figure 1). A description of the papers included in the review can be found in Table 2. Of the 29 included papers, 15 addressed patients' perspectives only, 2 addressed nurses' perspectives only, 6 addressed GPs' perspectives only, 2 addressed nurses' and GPs' perspectives together, 3 addressed patients' and GPs' perspectives together and 1 addressed the views of all three participants. Twenty-three articles were related to a specific CPS, 2 were related specifically to

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

180 inter-professional collaboration, 3 were related to both CPSS and inter-professional  
181 collaboration, and 1 addressed concordance-based healthcare. The articles employed semi-  
182 structured interviews (n=23) and/or focus groups (n=11) as methods of data collection.

For peer review only

Table 2. General description of the articles included in the qualitative meta-synthesis

| Study                           | Description of participants (n)  | Explored/assessed topic                            | Method |
|---------------------------------|--|--|--------|
| McMillan et al <sup>31</sup>    | Patients with a chronic condition, diverse culture and socioeconomic background from three geographical locations in Queensland (Logan-Beaudesert and Mount Isa), New South Wales (Northern Rivers) and Western Australia (Greater Perth) (n=89) | Service for patients with chronic conditions       | SSI    |
| Rieck & Pettigrew <sup>32</sup> | GPs working in practices in low, medium or high socioeconomic status suburbs across Perth (Western Australia) (n=22)   | Chronic disease management service                 | SSI    |
| Barbara et al <sup>33</sup>     | Patients who are immigrants of Maltese ethnicity, residing in Australia, with a confirmed diagnosis of T2DM, >50 years of age, able to adequately communicate verbally in English or Maltese, located in Sydney (n=24)                           | Diabetes self-management service                   | SSI    |
| Bereznicki et al <sup>34</sup>  | Patients (n=6) and GPs (n=10) previously involved in a community pharmacy based asthma intervention, in Tasmania   | Asthma management service                          | SSI    |
| Cvetkovski et al <sup>16</sup>  | Patients >18 years of age with a diagnosis of asthma (n=10); and GPs in small rural centres (n=8), from different locations based on the Australian Standard Geographical Classification   | Asthma management service                          | SSI    |
| Saba et al <sup>35</sup>        | Patients >18 year of age, English speaking, current smoker, medical diagnosis of asthma and/or any other condition alongside asthma in Sydney Central Business District and South Western suburbs (n=24)   | Smoking cessation service for patients with asthma | SSI    |

|                              |  |  |        |
|------------------------------|--|--|--------|
| Shoukry et al <sup>36</sup>  | Patients who had bought/hired/trialled a Continuous Positive Airway Pressure machine (or accessories) through their pharmacy in the previous 12 months in the greater Sydney region (n=20)   | Obstructive sleep apnoea services                    | SSI    |
| Um et al <sup>37</sup>       | GPs with large expertise in weight management (n=3)  | Weight management service                            | SSI    |
| Snell et al <sup>38</sup>    | Patients >18 years of age, English speaking, enrolled in a specific weight loss program for >2 weeks from different urban and regional suburbs in Sydney (n=20)  | Weight management service                            | II     |
| Maher et al <sup>39</sup>    | Women who have at least one child <5 years old are able to read and speak English from different locations based on Australian Standard Geographical Classification (n=28)   | Maternal nutrition service                           | SSI    |
| Mey et al <sup>40</sup>      | Patients living independently, experiencing a mild to moderate mental illness (and carers) in Queensland, New South Wales and Western Australia (n=74*)  | Service for patients with mental health conditions   | FG/SSI |
| Hattingh et al <sup>41</sup> | Patients with a mental health condition (and carers) (n=74*) and healthcare professionals (n=13) located in urban, regional, rural and remote regions in Queensland, New South Wales and Western Australia                                       | Service for patients with mental health conditions   | FG/SSI |
| Clark et al <sup>42</sup>    | Refugee women (n=38)   | Primary healthcare service                           | FG     |
| O'Connor et al <sup>43</sup> | Palliative care nurses working in community-based palliative care, residential aged care adopting a palliative approach or working in a dedicated hospice or palliative care unit in a hospital (n=44); and practising GPs (n=10), in Australian | Services to community-based palliative care patients | FG/SSI |

|                             |  |   |        |
|-----------------------------|--|---|--------|
|                             | metropolitan and regional areas  |   |        |
| Carter et al <sup>44</sup>  | Patients who are English, Mandarin or Arabic speaking, who had received a home medicines review service within the last 6 months or had not received such a service but were eligible for it, in metropolitan or rural areas in Australia (n=80)                   | Home medicines review                                 | FG     |
| Lee et al <sup>45</sup>     | Patients living in retirement villages in Victoria who were using prescribed medicines (n=25); GPs (n=9) and nurses (n=1) with experience with home medicines review services and/or providing care to retirement-village residents.                               | Home medicines review                                 | FG/SSI |
| White et al <sup>46</sup>   | Patients of Chinese or Vietnamese origin who had never received a home medicines review service but were eligible for it, in two suburban areas in Sydney (n=17)   | Home medicines review                                 | FG     |
| White et al <sup>17</sup>   | Patients who had received a home medicines review service in the past 6 months or who had never received such a service but were eligible for it, in New South Wales, Victoria, Queensland and South Australia (n=77)  | Home medicines review                                 | FG     |
| Dhillon et al <sup>19</sup> | GPs practising in metropolitan medical centres in Perth (n=24)   | Home medicines review                                 | SSI    |
| Swain et al <sup>47</sup>   | Patients taking multiple medications, with a reasonable understanding of English and linked to an Aboriginal Health Service in urban, regional, rural and remote settings in Queensland, Northern Territory, South Australia, New South Wales and Victoria (n=101) | Service aimed at enhance the quality use of medicines | FG     |



|                                    |  |   |     |
|------------------------------------|--|---|-----|
| Du Pasquier & Aslani <sup>48</sup> | Patients >18 years of age, fluent in English, taking one prescription medication on a daily basis in Sydney (n=22) | Adherence support service   | SSI |
| Gilmartin et al <sup>18</sup>      | Nurses who worked at residential aged care facilities and used dose administration aids in Victoria (n=5)          | Dose administration aids service  | FG  |
| Bui et al <sup>49</sup>            | Nurses working in public, opioid substitution therapy clinics in NSW (n=9)   | Opioid substitution therapy services  | SSI |
| Van et al <sup>50</sup>            | GPs practising in private/medical/specialised settings in rural/suburb/city areas in Sydney (n=23)                 | Inter-professional collaboration and professional pharmacy services   | SSI |
| Van et al <sup>51</sup>            | GPs in metropolitan and rural areas in New South Wales (n=15)  | Inter-professional collaboration in the context of Diabetes Medication Assistance Service and home medicines review service | SSI |
| Dey et al <sup>52</sup>            | GPs working in Western Sydney (n=7)  | Inter-professional collaboration in the context of asthma management services   | SSI |
| Chong et al <sup>53</sup>          | GPs (n=4) and nurses (n=7) working with mental health consumers in a healthcare setting in New South Wales         | Inter-professional collaboration in the context of mental health services   | SSI |

|   |  |  |        |
|---|--|--|--------|
| Cheong et al <sup>54</sup>  | Patients >18 years of age, English speaking, with a diagnosis of asthma, in inner-west Sydney metropolitan region (n=16) | Inter-professional collaboration/multi-disciplinary care | SSI    |
| Bajramovic et al <sup>55</sup>  | Patients >18 years of age, taking at least one medication (n=7) and GPs (n=10) in Brisbane                               | Concordance based healthcare services                    | FG/SSI |
| GP: General Practitioner; SSI: Semi-structured interview; FG: Focus Group; II: In-depth Interview                                   |  |  |        |
| * Total number of patients and carers. Opinions of carers were clearly differentiated in the article and excluded from this review. |  |  |        |

183

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

184 During the first stage of data extraction, 181 patient, 30 nurse and 91 GP codes were created.  
185 At the completion of the coding process, 63 influential elements were identified (Table 3). In  
186 several studies patients, nurses and GPs were able to describe approaches or strategies to  
187 overcome specific barriers.<sup>16-19, 31-34, 37, 39, 41, 45, 49, 50, 55</sup> These strategies have been reported in  
188 Table 3 as additional facilitators (marked with an asterisk). During coding of the manually  
189 identified papers, it seemed that conceptual saturation may have been reached, since no new  
190 barriers or facilitators were identified.

Table 3. Elements that can hinder (i.e., barrier) or enable (i.e., facilitator) the implementation of community pharmacy services as identified by patients, general practitioners and nurses

|  | Effect on implementation and source of information (i.e., stakeholder)        |   |
|--|---|---|
|  | Barrier <sup>‡</sup>  | Facilitator <sup>†</sup>  |
| <i>Elements at the individual patient level</i>  |   |   |
| 1. Patients' real or perceived need for healthcare (according to patients' individual concerns, understanding or perception of their health problems). | Pt <sup>17, 44, 45, 53, 54</sup> ;<br>GP <sup>16</sup>                        | Pt <sup>17, 31, 33, 34, 39, 44, 46, 54, 55</sup> ; N <sup>49</sup> ; GP <sup>16</sup> |
| 2. Patients' awareness of the availability of CPS  | Pt <sup>31, 45, 46</sup> ; GP <sup>19, 45</sup>                               |   |
| 3. Patient personal desire or preference for CPSs  |   | Pt <sup>39, 44, 46, 54</sup>  |
| 4. Patients' understanding, perceptions and expectations of their own role in the CPS  | Pt <sup>34, 48, 54</sup>  | Pt <sup>16, 34, 54</sup>  |
| 5. Patients' understanding, perceptions and expectations of the role of community pharmacists in healthcare  | Pt <sup>16, 17, 33, 34, 39, 40, 54</sup> ; N <sup>49</sup> ; GP <sup>19</sup> | Pt <sup>33, 35, 36, 39, 40, 48, 54</sup>  |
| 6. Patients' understanding, perceptions and expectations of the role of the GP associated to the CPS   | Pt <sup>33, 34, 44-48, 54</sup>   |   |
| 7. Patients' understanding, perceptions and expectations of collaboration between healthcare professionals   | Pt <sup>54</sup>  | Pt <sup>54</sup>  |

|   |   |   |
|---|---|---|
| 8. Patients' availability, time to participate in CPSs  | Pt <sup>31, 38</sup>                            | Pt <sup>38, 54</sup>  |
| 9. Patients' previous/background experiences with CPSs and multidisciplinary care   | Pt <sup>39, 40, 45, 54</sup>                    | Pt <sup>36, 40, 44, 45, 47, 54</sup>                                  |
| 10. Patient abilities; i.e., to follow the procedures of the CPS or to self-manage their health problems                      | Pt <sup>38, 54</sup> , GP <sup>34, 50, 52</sup> | Pt <sup>35, 38, 46</sup>  |
| 11. Patients' satisfaction with the delivered CPSs and multidisciplinary care   |   | Pt <sup>34, 36, 38, 40, 44</sup> , N <sup>49</sup>                    |
| 12. Patients' motivation towards CPSs   | Pt <sup>44</sup>                                | Pt <sup>35, 38, 44</sup>  |
| 13. Patients' level of emotional intelligence; i.e. ability to cope with negative experiences.                                | Pt <sup>38</sup>                                | Pt <sup>38</sup>  |
| 14. Patients' language, communication and cultural issues   | Pt <sup>42, 46</sup> , GP <sup>19</sup>         |   |
| <i>Elements at interpersonal level</i>  |   |   |
| <i>a. Individual healthcare professionals (sub-level)</i>   |   |   |
| <i>a.1. Community pharmacist</i>  |   |   |
| 15. Knowledge, expertise, clinical and non-clinical skills (e.g. cultural competency) to adequately provide CPSs              | Pt <sup>40</sup> , GP <sup>32, 50</sup>         | Pt <sup>17*, 19, 36, 38, 39*, 40, 42, 46</sup> , GP <sup>37, 52</sup> |
| 16. Communication skills; including the capacity to speak other languages   | Pt <sup>46, 47</sup> , N <sup>43</sup>          | Pt <sup>17, 31, 33, 35, 39, 46-48</sup>                               |
| 17. Humanistic attributes (e.g. being respectful, caring, non-judgemental, friendly, empathetic, supportive and approachable) | Pt <sup>38</sup>                                | Pt <sup>31, 33, 34, 36, 38-41, 44, 54</sup>                           |

|   |  |                                      |
|---|--|--------------------------------------|
| 18. Willingness, interest, motivation to provide CPSs and/or participate in multidisciplinary collaboration | N <sup>31, 35, 49, 54</sup> , GP <sup>45</sup> | Pt <sup>33</sup>                     |
| <i>a.2. Other community pharmacy staff members (e.g. pharmacy assistants)</i>                               |  |                                      |
| 19. Technical knowledge (e.g., about a product)   | Pt <sup>39, 40</sup>                           | Pt <sup>39</sup>                     |
| 20. Communication skills  | Pt <sup>40</sup>                               | Pt <sup>39</sup>                     |
| 21. Humanistic attributes   |  | Pt <sup>39</sup>                     |
| 22. Ability to work professionally (e.g., uphold patient confidentiality)                                   | Pt <sup>40, 41</sup>                           |                                      |
| 23. Experience working in the pharmacy  | Pt <sup>39, 40</sup>                           | Pt <sup>39</sup>                     |
| <i>a.3. General Practitioner</i>  |  |                                      |
| 24. Understanding, perceptions and expectations of their individual role with regard CPSs                   | GP <sup>50, 52</sup>                           |                                      |
| 25. Understanding, perceptions and expectations of pharmacist's capabilities and role in healthcare         | GP <sup>32, 34, 50-52</sup>                    | GP <sup>52, 16, 32, 34, 37, 55</sup> |
| 26. Awareness of the availability of CPS  | GP <sup>19</sup>                               |                                      |
| 27. Willingness, interest, motivation to collaborate with CPSs  | GP <sup>19</sup>                               | GP <sup>19, 52</sup>                 |
| <i>a.4. Nurse</i>   |  |                                      |
| 28. Understanding, perceptions and expectations of their individual role within, or in regards to, CPSs     | N <sup>18</sup>                                |                                      |

|   |   |   |
|---|---|---|
| 29. Knowledge and skills to adequately participate in the delivery of CPS   | N <sup>18</sup>   | N <sup>18*</sup>  |
| 30. Attitude towards other healthcare professionals and their roles   |   | N <sup>18</sup>   |
| 31. Willingness, interest, motivation to collaborate with CPSs  | N <sup>18</sup>   | N <sup>18</sup>   |
| <i>b. Relationships (or interactions) between individuals (sub-level)</i>   |   |   |
| 32. Influence of friends and family on patients utilising CPSs (i.e., they may provide support, affect patient's adherence, or patient's enthusiasm with CPSs)                      | Pt <sup>38, 39, 46</sup>  | Pt <sup>16*, 33*, 39</sup>  |
| 33. Previous relationship between the patient and the pharmacist and its nature (e.g. trusting relationship)  | Pt <sup>17</sup> ; GP <sup>19</sup>                                       | Pt <sup>17, 31, 34, 36, 38-40, 44</sup> ; GP <sup>50</sup>                        |
| 34. Collaborative relationships between the pharmacist and other healthcare providers (e.g., GPs), and their nature   | Pt <sup>55</sup> ; N <sup>49</sup> ; GP <sup>32, 43, 45, 50, 51, 55</sup> | Pt <sup>33, 54</sup> ; N <sup>18, 49</sup> ; GP <sup>16*, 19, 50-52, 55</sup>     |
| 35. Communication channels and modes between pharmacists and other healthcare providers (e.g., GPs)   | N <sup>18, 43</sup> ; GP <sup>34, 50, 52, 53</sup>                        | Pt <sup>16, 17, 33</sup> ; N <sup>49</sup> ; GP <sup>16, 50-52</sup>              |
| 36. Existence of referral mechanisms between healthcare professionals, including also those between pharmacy support staff and pharmacists (i.e., care coordination and transition) | Pt <sup>40</sup> ; GP <sup>34, 50</sup> ; N <sup>49</sup>                 | Pt <sup>36, 39</sup> ; GP <sup>16, 19, 34, 37, 45, 50, 52</sup> ; N <sup>49</sup> |
| 37. Consistency in the information provided by the pharmacist with regards to the GP's recommendations  | GP <sup>43, 50, 51, 55</sup>  | GP <sup>50, 55</sup>  |
| 38. Availability of multidisciplinary education, training and meetings for pharmacists and GPs that   |   | Pt <sup>50*, 54*</sup> ; N <sup>49</sup>  |

|  |   |  |
|--|---|--|
| enhance integrated, collaborative care   |   | GP <sup>16, 32, 50, 51</sup>   |
| <i>Elements at the organisational level</i>  |   |  |
| <i>a. Community pharmacy setting (sub-level)</i>   |   |  |
| 39. Accessibility of the pharmacy setting (e.g. convenient location, co-location, no appointments required, opening hours)   | Pt <sup>16, 47</sup> ; N <sup>49</sup>                                | Pt <sup>16, 31, 33, 35, 36, 38, 39, 54*, 55</sup> ; N <sup>49</sup> ; GP <sup>45*, 50*, 51</sup> |
| 40. Structural characteristics of the pharmacy setting i.e. size, provision of counselling rooms, use of visual space for posters, child-friendly area                                       | Pt <sup>41</sup>  | Pt <sup>38, 39, 41*</sup>  |
| 41. Privacy of the setting, including the availability of a private consultation area and limited involvement of multiple staff members who would be aware of the patients' personal matters | Pt <sup>17, 39-41, 47, 54</sup> ; GP <sup>19</sup> ; N <sup>43</sup>  | Pt <sup>36, 38, 41</sup>   |
| 42. Availability of suitable material resources to support the service (e.g. educational material for patients, medical devices, patient data management system, etc.)                       |   | Pt <sup>39, 40, 42</sup>   |
| 43. Sufficient qualified staff to perform CPS  | Pt <sup>42</sup> ; GP <sup>19, 45, 55</sup>                           | Pt <sup>46</sup>   |
| 44. Organization of the pharmacist's workload and time to deliver CPSs   | Pt <sup>39, 46, 47, 54</sup> ; N <sup>49</sup> ; GP <sup>31, 45</sup> | Pt <sup>39, 55</sup>   |
| 45. Organisational commitment to implement a CPS   | Pt <sup>31, 39</sup> ; N <sup>49</sup>                                |  |
| 46. Promotion of the CPS to facilitate its uptake  |   | Pt <sup>31*, 33*, 45</sup> ; GP <sup>19</sup>  |



|  |   |   |
|--|---|---|
| <i>b. Community pharmacy service</i>   |   |   |
| 47. Extent to which the CPS meets and is tailored to fit individual patient's needs or fills existing gaps in healthcare practice (this enhances the value of the service for patients and healthcare professionals) | Pt <sup>17, 33, 34, 40, 44, 45, 54</sup> , GP <sup>50, 52</sup> | Pt <sup>17, 31, 33, 36, 39, 40, 44-47, 54</sup> , N <sup>45</sup> , GP <sup>19, 37, 45, 50-53, 55</sup> |
| 48. Quality of the CPS (e.g. validity, accuracy of the materials and tools used, CPSs provided in a timely manner, provision of both verbal and written information, professional advice and education, etc.)        | Pt <sup>44</sup> , GP <sup>45, 55</sup> , N <sup>18</sup>       | Pt <sup>17, 36, 38, 39</sup> , GP <sup>19</sup>   |
| 49. Complexity of the CPS for use by healthcare professionals  | GP <sup>19</sup> , N <sup>18, 49</sup>                          |   |
| 50. Extent to which CPSs provide ongoing support, follow-up and feedback to patients   | GP <sup>50</sup>  | Pt <sup>17, 31, 36, 38, 40, 41, 45</sup>  |
| 51. Flexibility to use different communication channels (e.g. telephone, website) to interact with patients and healthcare providers   |   | Pt <sup>36, 38, 41*</sup>   |
| 52. Consistency in the community pharmacist delivering the CPS   |   | Pt <sup>36, 39, 44</sup> , N <sup>18*</sup>   |
| 53. Involvement of other healthcare providers in delivering the CPS  |   | Pt <sup>39</sup> , N <sup>18*</sup> , GP <sup>19*</sup>   |
| 54. Costs and duration of the CPS consultation for the patient   | Pt <sup>54, 55</sup> , N <sup>49</sup>                          | Pt <sup>36, 55</sup> , GP <sup>16, 19</sup> , N <sup>49*</sup>  |
| <i>Elements at the community and health system level</i>   |   |   |

|  |                                     |  |
|--|-------------------------------------|--|
| 55. General consumer education about healthcare; promotion of CPS by the media   | Pt <sup>55</sup> ; GP <sup>55</sup> | Pt <sup>46, 55</sup> ; GP <sup>45*, 55</sup>                                       |
| 56. Collaboration, influences, conflicts between GP and pharmacist professional bodies   |                                     | GP <sup>32*</sup>  |
| 57. Organization of GPs' workload and time to collaborate with CPSs  | GP <sup>19, 45, 50, 52, 53</sup>    |  |
| 58. Complexity of system-level administrative processes (e.g. tedious paperwork) associated to the delivery of CPS; i.e., complying with the requirements of the department of health  | GP <sup>16, 19, 45, 51, 55</sup>    |  |
| 59. Availability of an electronic system for sharing information   | Pt <sup>17, 54</sup>                | Pt <sup>16*, 55</sup> ; N <sup>18*</sup> ; GP <sup>16, 19*, 34*, 48, 50*, 51</sup> |
| 60. Presence of agreed healthcare protocols, regulations, rules and policies to facilitate the delivery of CPSs  | Pt <sup>42</sup> ; N <sup>49</sup>  | Pt <sup>42</sup> ; GP <sup>19*, 50, 51</sup>                                       |
| 61. Limits on the healthcare budget; i.e., funding allocated to support CPS delivery   | GP <sup>16, 45, 52, 55</sup>        | Pt <sup>42, 54*</sup> ; GP <sup>16, 50, 55</sup>                                   |
| 62. Availability of financial incentives for service provision and inter-professional collaboration  |                                     | Pt <sup>54*</sup> ; N <sup>49*</sup>   |
| 63. Organisation of the healthcare system  | Pt <sup>54</sup> ; GP <sup>55</sup> |  |
| <p>CPS: Community Pharmacy Service; GP: General Practitioner; Pt: Patient; N: Nurse</p> <p>‡ Barrier: the element was mentioned to act as a BARRIER or hinder to the implementation of CPSs; † Facilitator: the element was mentioned to act as a FACILITATOR or enabler to the implementation of CPSs; (*) this element was reported as a potential strategy to overcome a barrier (i.e., facilitator).</p> |                                     |  |

192

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

193 **Individual patient level.** All the 16 elements at the patient level were identified by patients.  
194 GPs and nurses did not identify any additional patient-related barriers and facilitators.  
195 Influential elements at this level were related to the patients' needs, preferences, perceptions  
196 expectations, or previous experiences with community pharmacists and services. Patients'  
197 health-related concerns, understanding or perception of their health problems are important  
198 elements that influence patients' need for healthcare and so their decisions to utilise CPSs.  
199 Most patients held positive views about CPSs and the role of the pharmacist in providing  
200 such services.<sup>38, 39, 45</sup> Some articles highlighted that positive experiences were related to the  
201 patient feeling comfortable and welcomed in the pharmacy.<sup>36, 38, 40</sup> When CPSs required a  
202 formal referral from the GP, some patients deterred from requesting the services. These  
203 patients perceived that by requesting a CPS they would be bothering the GP<sup>34</sup> or offending  
204 and compromising their relationship with the GP.<sup>17, 45, 46</sup> Patients also reported that having  
205 negative experience with a CPS also deterred them from accessing and utilising such CPS  
206 in the future.<sup>40</sup>

207 **Interpersonal level.** Influential elements at the interpersonal level were related to two  
208 categories or sub-levels: (1) *individual healthcare professionals* (which also includes  
209 professional pharmacy staff), and (2) *relationships (or interactions) between individuals*  
210 (which includes both the relationships between healthcare professionals and between those  
211 professionals and patients). With respect to the *individual healthcare professionals*, 17  
212 elements were identified and related to characteristics of the community pharmacists (n=4),  
213 nurses (n=4) and GPs (n=4) and characteristics of non-provider personnel (i.e., other  
214 community pharmacy staff members -e.g., pharmacy assistant) (n=5). Articles reported that  
215 GPs' and nurses' service support varied depending on their perceptions or understanding of  
216 CPSs and the role of pharmacists. Home medicine review services had a great deal of  
217 approval and support from the GP perspective.<sup>45, 50</sup> On the other side, pharmacists providing  
218 immunisations raised some conflicting views among GPs since they believed this was the  
219 role of the GP or nurse practitioner.<sup>50</sup> Some studies highlighted that GPs had a limited

understanding of the capabilities of the pharmacist as service providers with pharmacists perceived as drug sellers in a retail environment.<sup>32-34, 51, 54</sup> Regarding the second sub-level (i.e., *relationships (or interactions) between individuals*), seven influential elements were identified. Articles reported that well-established relationships between the pharmacist and the nurse or the GP, were essential for the success of a CPS.<sup>19, 49</sup> Similarly, characteristics of the relationship between the patient and the pharmacist (e.g., trust) was a key element that influenced pharmacy choice, contributed to the patient adhering to the CPS, and accepting the intervention.<sup>17, 31, 34, 36, 38-40, 44</sup> Some articles reported the influence of family and friends on patient utilisation of CPSs (e.g., providing support, influencing motivation),<sup>33, 54</sup> and others commented on the integration of partners into the CPS (e.g., provision of group sessions with partners).<sup>33, 36</sup>

**Organizational level.** Also at the organisational level, influential elements were divided into two sub-levels: (1) *the community pharmacy setting* (n=8) and (2) *the service itself* (n=8). With respect to the pharmacy setting, many articles identified the accessibility of the pharmacy facilitated inter-professional relationships between GPs and pharmacists,<sup>50, 51</sup> and influenced patient<sup>16, 36, 39</sup> and nurse<sup>49</sup> participation in CPS. In some articles non-english speaking patients reported that the lack of multilingual staff limited their awareness and access to CPSs.<sup>42, 46</sup> Other articles noted GP and nurse concerns regarding the lack of pharmacies that provide CPSs<sup>49</sup> and insufficient accredited pharmacists to perform CPSs.<sup>45, 55</sup> Regarding the barriers and facilitators related to the CPS itself, concerns regarding the validity and accuracy of the tools and instruments used (e.g. medical devices, medication charts) were raised by GPs and nurses.<sup>18, 50</sup> Patients and nurses commented that having the same service provider at each encounter facilitated rapport building between the patient and the pharmacist,<sup>36, 39, 44</sup> and caused fewer errors when it came to preparing dose administration aids.<sup>18</sup> Furthermore, patients, nurses and GPs reported on the involvement/participation of healthcare professionals other than pharmacists in the provision of CPSs,<sup>39</sup> or to act as a point of liaison,<sup>19</sup> to improve the quality and efficiency of the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

247 service. The cost of the service was a key element, mentioned by all stakeholders, that could  
248 either discourage<sup>49, 54</sup> or motivate<sup>36</sup> patients to utilise services. In particular it was mentioned  
249 that smaller, manageable cost payments for patients could facilitate CPS use.<sup>49</sup>

250 **Community and healthcare system level.** Nine influential elements were identified at this  
251 level. Several articles identified the need for adequate remuneration for GPs and  
252 pharmacists for participating in and providing CPSs.<sup>16, 42, 50, 52</sup> GPs also cited the availability  
253 of competing, government-funded health programs as contributing to their low participation  
254 in CPSs.<sup>45</sup> Where services were available, remunerated and widely supported by GPs and  
255 patients, such as home medicine reviews (i.e., a medication review service), GPs mentioned  
256 complex bureaucratic procedures (e.g. completing tedious documents) may discourage their  
257 use.<sup>16, 19, 45, 51, 55</sup> Despite this, the home medicine review service was generally considered  
258 successful by GPs and a frequently reported reason for this was the presence of a clear  
259 protocol guiding service delivery.<sup>19, 50, 51</sup> Finally, some broad comments suggesting some  
260 additional issues at the higher levels of the healthcare system were mentioned, such as  
261 ‘better and more responsible organisation of the healthcare system’.<sup>55</sup>

262 With regards to the interactions between the identified influential elements, 12 articles out of  
263 29 mentioned some form of a relationship between certain elements.<sup>19, 31, 38, 40, 44, 46, 49-53, 56</sup> As  
264 shown in Appendix 2 (Supplementary File), a total of 27 relationships between 25 elements  
265 were found, with 10 elements presenting 2 or more relationships with others (2 elements  
266 showed 5 or more interactions). As a result of the limited, unsystematic information reported  
267 in the articles, a sparse network disclosing the recognized relationships between elements  
268 was obtained (Appendix 2 in Supplementary File).

269 **DISCUSSION**

270 To the best of our knowledge this is the first review that summarises comprehensive  
271 information on the elements that, according to patients, nurses and GPs, can enable or  
272 hinder the implementation of CPSs. Patients, GPs and nurses are key members of the

primary healthcare team and their support and expectations for CPSs can highly influence their implementation.<sup>1, 18, 50, 56-59</sup> Thus, by synthesising and organising the influential elements identified by these key stakeholders, this review can optimize future analyses of barriers and facilitators to the implementation of CPSs and so potentially enhance their integration into primary practice. Importantly, this work was intentionally restricted to a specific implementation context (i.e., Australia), to which its results are directly relevant and will be immediately applied. Focusing only on Australia is not considered a limitation of the study; rather it is a sensible decision that allows knowledge about a particular context of interest to be gained. Including studies conducted in contexts or healthcare systems other than Australia (e.g., United Kingdom, United States, etc.), where barriers and facilitators to CPS implementation can be dissimilar in nature and expressed differently, may have brought irrelevant or inappropriate information to this analysis, and so hinder the understanding of the context of interest. However, it should be noted that Australia is a country with a large experience in CPS implementation and where significant research has been conducted in this regard. Therefore, it is expected that the comprehensive list of influential elements demonstrated in this context may be relevant to start investigating barriers and facilitators to CPS implementation in contexts with fewer experience.

Barriers and facilitators to the implementation of CPSs in Australia have been well researched and reported from the perspective of community pharmacists.<sup>13, 14, 58, 60</sup> In this regard, the results of this review confirms that patients, nurses and GPs also recognise some of the influential elements reported in previous pharmacist-informed studies, such as the pharmacist's education and training, collaboration between the pharmacist and the GP, internal pharmacy layout, and financial remuneration. However, this study provides additional insight into further barriers and facilitators, across different ecological levels, that are relevant to other key stakeholder and so are less likely to be reported by pharmacists; for example: patients' capability to follow the procedures of the service, GPs' workload, nurses' attitudes towards other healthcare professionals/services, the actual relationships between

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

300 GP and pharmacy professional bodies, or the availability of multidisciplinary training and  
301 education. These results highlight the importance of engaging key stakeholders other than  
302 pharmacists to better understand the contexts in which CPSs are implemented. In other  
303 words, disregarding the input of these stakeholders (or considering only the views of  
304 pharmacists), may lead to an incomplete and biased understanding of the implementation  
305 context, which, in turn, can result in service underutilisation, unsuccessful implementation  
306 and limited service impact.<sup>61</sup> Generally, involving relevant stakeholders throughout the  
307 development, implementation and evaluation of health programs is crucial to increase the  
308 chances of any of those initiatives being effective and successfully implemented.<sup>6, 62-64</sup>  
309 Indeed, this is equally relevant to CPS planning.<sup>65, 66</sup>

310 The results of this review can assist pharmacy service planners and researchers to better  
311 identify the elements that may be enabling or hindering the implementation of existing CPSs.  
312 To do so the list of influential elements generated in this review must be combined with the  
313 previous findings in pharmacists-informed studies to produce a comprehensive framework to  
314 assess barriers and facilitators to CPS implementation. Assessing and understanding the  
315 elements influencing pharmacy practice and service implementation must be a key early  
316 step in developing appropriate, multilevel programs (i.e., including interventions targeting  
317 elements at different levels) aimed at enhancing the integration of CPSs into the healthcare  
318 system.<sup>62, 64, 66, 67</sup> Also, influential elements should be prompted and assessed when  
319 designing new CPSs. In this scenario, an early analysis of those elements may guide both  
320 the early adaptation of CPSs and the early development of tailored implementation programs  
321 to better fit the implementation context. The analysis conducted in this review revealed two  
322 concerns that must be considered to improve future studies aimed at identifying influential  
323 elements. On the one hand, some influential elements at the community and healthcare  
324 system level were too broadly described (i.e., ‘organisation of the health system’) and further  
325 exploration is needed to clearly understand the specific ‘items’ that they encompass.  
326 Presumably, the list determinants of practice described by Flottorp et al<sup>7</sup> (i.e., Tailored



Implementation in Chronic Disease checklist) can provide more detail regarding influential elements at the higher community and healthcare system level and so can initially assist to better frame future analysis of barriers and facilitators to CPS implementation. Particularly, the determinants under the domains 'Incentives and resources'; 'Capacity for organizational change'; and 'Social political and legal factors' seem particularly relevant for this purpose. Importantly, to bring further insight on the elements at the community and healthcare system level it would be important to include and explore the perspectives of other potential key stakeholders, such as other healthcare providers (e.g., specialists), caregivers, representatives of healthcare organisations and professional bodies, policy makers, etc. Furthermore, future studies aimed at identifying barriers and facilitators to CPS implementation must better describe and understand the relationships between elements.<sup>2, 7</sup> This may help to understand how elements influence each other and which elements are more suitable to be addressed (based on the overall effect that they can produce on other elements) when designing implementation efforts.

**Limitations.** The network analysis intended in this study was strongly constrained by the limited and unsystematically reported information about the relationships between influential elements. As a result, it was decided not to report further results of the network analysis beyond its pictorial representation. The potential of a full network analysis should be considered in future studies aimed at analysing elements that influence the implementation of CPSs. A suitable network analysis can help to better understand the complex relationships between these elements; detect the core elements that may primarily explain the implementation challenge; and provide insight on the key leverage points that should be targeted within the network to enhance service implementation. Ideally, accurate information on relevant attributes of the influential elements (and the interactions between them) should be collected by the authors of the primary studies to increase the potential of a network analysis; for example, the frequency of occurrence; the direction of the relationships; the domain or level where the element is located (i.e., patients, healthcare professionals,



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

professional interactions, etc.); the relative relevance of each element; or the effect on implementation outcomes (i.e., performance as barrier or facilitator). Following the particular method chosen for this review (i.e., qualitative meta-synthesis),<sup>21, 22</sup> only primary research articles that used qualitative methods were included. Meta-synthesis enabled a rich description of elements perceived by GPs, patients and nurses to influence implementation of CPSs in Australia. Future reviews that synthesise the quantitative literature on this topic are encouraged. Appraising qualitative research is controversial because of the difficulty of using information about quality to inform syntheses (e.g. even studies with flaws in methodology can provide valuable information).<sup>27</sup> Furthermore, there is no gold standard on appraising qualitative studies.<sup>24</sup> The elementary quality assessment conducted in the current review was aimed at ensuring minimal quality while identifying a broad range of elements that might influence CPS implementation.

**CONCLUSION**

This qualitative meta-synthesis identified a broad range of elements that, according to patients, GPs and nurses, can enable (i.e., facilitators) or hinder (i.e., barriers) the implementation of CPSs. These influential elements are located at different ecological levels and should be considered together with those previously identified in pharmacy-informed studies to comprehensively analyse the barriers and facilitators to the implementation of CPSs. Future studies aimed at that purpose must involve multiple stakeholder groups (i.e., others than only pharmacists) and better understand the relationships between influential elements to increase the usefulness and interest of their findings. Further to the identification of the influential elements, key stakeholders should keep involved in developing suitable, multilevel programs aimed at enhancing CPS implementation.

## 377 **ACKNOWLEDGEMENTS**

378 We would like to acknowledge Antonio E. Mendes (Universidade Federal do Parana, Brazil)  
379 for his collaboration in the network analysis.

## 380 **COMPETING INTERESTS**

381 All authors declare no competing interest

## 382 **FUNDING**

383 Lutfun N. Hossain was awarded a University of Technology Sydney (UTS) President's  
384 Scholarship and a UTS Chancellors Research Scholarship.

385 This work is part of a larger UTS Chancellor's Postdoctoral Research Fellowship awarded to  
386 Dr Daniel Sabater-Hernández (UTS ID number: 2013001605).

## 387 **DATA SHARING STATEMENT**

388 No additional data are available

## 389 **AUTHORS' CONTRIBUTION**

390 Conception or design of the work: Lutfun N. Hossain, Fernando Fernandez-Llimos, Tim  
391 Lockett and Daniel Sabater-Hernández.

392 Data collection: Lutfun N. Hossain, Desire Durks and Lucia Franco-Trigo.

393 Data analysis and interpretation: Lutfun N. Hossain, Joanna C. Moullin, Charlie Benrimoj and  
394 Daniel Sabater-Hernández.

395 Drafting the article: Lutfun N. Hossain, Fernando Fernandez-Llimos, Tim Lockett and Daniel  
396 Sabater-Hernández.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

397 Critical revision of the article: Lutfun N. Hossain, Joanna C. Moullin, Fernando Fernandez-  
398 Llimos, Tim Lockett and Daniel Sabater-Hernández.  
  
399 Final approval of the version to be published: Lutfun N. Hossain, Fernando Fernandez-  
400 Llimos, Tim Lockett, Joanna C. Moullin, Desire Durks, Lucia Franco-Trigo, Charlie Benrimoj  
401 and Daniel Sabater-Hernández.  
  
402

For peer review only

## Reference

1. Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of health innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures. *Implement Sci* 2013;8:22.
2. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci* 2009;4:50.
3. Haines A, Kuruvilla S, Borchert M. Bridging the implementation gap between knowledge and action for health. *Bull World Health Organ* 2004;82:724-31.
4. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. *Lancet* 2003;362:1225-30.
5. Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health care. *BMJ* 2001;323:625-8.
6. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655.
7. Flottorp SA, Oxman AD, Krause J, et al. A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. *Implement Sci* 2013;8:35.
8. Baker R, Camosso-Stepinovic J, Gillies C, et al. Tailored interventions to address determinants of practice. *Cochrane Database Syst Rev* 2015;4:CD005470.
9. Gastelurrutia MA, Benrimoj SI, Castrillon CC, et al. Facilitators for practice change in Spanish community pharmacy. *Pharm World Sci* 2009;31:32-9.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

10. Moullin JC, Sabater-Hernández D, Benrimoj SI. Model for the evaluation of implementation programs and professional pharmacy services. *Res Social Adm Pharm* 2016;12:515-22.

11. Mossialos E, Courtin E, Naci H, et al. From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management. *Health Policy* 2015;119:628-39.

12. Kaae S, Christensen ST. Exploring long term implementation of cognitive services in community pharmacies - a qualitative study. *Pharm Pract (Granada)* 2012;10:151-8.

13. Roberts A, Benrimoj S, Chen T, et al. Implementing cognitive services in community pharmacy: a review of facilitators used in practice change. *Int J Clin Pharm* 2006;14:163-70.

14. Berbatis C, Sunderland V, Joyce A, et al. Enhanced pharmacy services, barriers and facilitators in Australia's community pharmacies: Australia's National Pharmacy Database Project. *Int J Clin Pharm* 2007;15:185-91.

15. Gastelurrutia MA, Fernandez-Llimos F, Garcia-Delgado P, et al. Barriers and facilitators to the dissemination and implementation of cognitive services in Spanish community pharmacies *Seguimiento Farmacoterapeutico* 2005;3:65-77.

16. Cvetkovski B, Armour C, Bosnic-Anticevich S. Asthma management in rural New South Wales: Perceptions of health care professionals and people with asthma. *Austr J Rural Health* 2009;17:195-200.

17. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home Medicines Review Program: benefits and barriers. *Res Social Adm Pharm* 2012;8:4-16.

- 1  
2  
3 448 18. Gilmartin JF, Marriott JL, Hussainy SY. Exploring factors that contribute to dose  
4  
5 449 administration aid incidents and identifying quality improvement strategies: the views of  
6  
7 450 pharmacy and nursing staff. *Int J Pharm Pract* 2014;22:407-14.  
8  
9  
10 451 19. Dhillon AK, Hattingh HL, Stafford A, et al. General practitioners' perceptions on home  
11  
12 452 medicines reviews: a qualitative analysis. *BMC Fam Pract* 2015;16:16.  
13  
14  
15 453 20. Rayes IK, Abduelkarem AR. A qualitative study exploring physicians' perceptions on the  
16  
17 454 role of community pharmacists in Dubai. *Pharm Pract (Granada)* 2016;14:738.  
18  
19  
20 455 21. Mohammed MA, Moles RJ, Chen TF. Meta-synthesis of qualitative research: the  
21  
22 456 challenges and opportunities. *Int J Clin Pharm* 2016;38:695-704.  
23  
24  
25 457 22. Walsh D, Downe S. Meta-synthesis method for qualitative research: a literature review.  
26  
27 458 *J Adv Nurs* 2005;50:204-11.  
28  
29  
30 459 23. Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*.  
31  
32 460 Hoboken: Wiley-Blackwell; 2008.  
33  
34  
35 461 24. Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the  
36  
37 462 synthesis of qualitative research: ENTREQ. *BMC Med Res Methodol* 2012;12:181.  
38  
39  
40 463 25. Moullin JC, Sabater-Hernández D, Fernandez-Llimos F, et al. Defining professional  
41  
42 464 pharmacy services in community pharmacy. *Res Social Adm Pharm* 2013;9:989-95.  
43  
44  
45 465 26. Hennink MM, Hutter I, Bailey A. *Qualitative research methods*. Los Angeles, Calif. ;  
46  
47 466 London: SAGE; 2011.  
48  
49  
50 467 27. Dixon-Woods M, Shaw RL, Agarwal S, et al. The problem of appraising qualitative  
51  
52 468 research. *Qual Saf Health Care* 2004;13:223-5.  
53  
54  
55 469 28. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in  
56  
57 470 systematic reviews. *BMC Med Res Methodol* 2008;8:1-10.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

471 29. McLeroy KR, Bibeau D, Steckler A, et al. An ecological perspective on health promotion  
472 programs. *Health Educ Quart* 1988;15:351-77.

473 30. Jacomy M, Venturini T, Heymann S, et al. ForceAtlas2, a continuous graph layout  
474 algorithm for handy network visualization designed for the Gephi software. *PloS one*  
475 2014;9:e98679.

476 31. McMillan SS, Sav A, Kelly F, et al. How to attract them and keep them: The pharmacy  
477 attributes that matter to Australian residents with chronic conditions. *Int J Pharm Pract*  
478 2014;22:238-45.

479 32. Rieck A, Pettigrew S. How physician and community pharmacist perceptions of the  
480 community pharmacist role in Australian primary care influence the quality of  
481 collaborative chronic disease management. *Qual Prim Care* 2013;21:105-11.

482 33. Barbara S, Krass I. Self management of type 2 diabetes by Maltese immigrants in  
483 Australia: Can community pharmacies play a supporting role? *Int J Pharm Pract*  
484 2013;21:305-13.

485 34. Bereznicki B, Peterson G, Jackson S, et al. Perceived feasibility of a community  
486 pharmacy-based asthma intervention: A qualitative follow-up study. *J Clin Pharm Ther*  
487 2011;36:348-55.

488 35. Saba M, Dan E, Bittoun R, et al. Asthma and smoking--healthcare needs and  
489 preferences of adults with asthma who smoke. *J Asthma* 2014;51:934-42.

490 36. Shoukry G, Wong K, Bartlett D, et al. Treatment experience of people with obstructive  
491 sleep apnoea seeking continuous positive airways pressure device provision through  
492 community pharmacies: a role for pharmacists? *Int J Pharm Pract* 2011;19:318-27.

493 37. Um IS, Armour C, Krass I, et al. Weight management in community pharmacy: what do  
494 the experts think? *Int J Clin Pharm* 2013;35:447-54.

38. Snell L, White L. An exploratory study of the role of emotional intelligence and self-efficacy on service quality and adherence in a weight loss setting. *Serv Mark Q* 2011;32:228-46.
39. Maher JH, Hughes R, Anderson C, et al. An exploratory investigation amongst Australian mothers regarding pharmacies and opportunities for nutrition promotion. *Health Educ Res* 2013;28:1040-50.
40. Mey A, Knox K, Kelly F, et al. Trust and safe spaces: Mental health consumers' and carers' relationships with community pharmacy staff. *Patient* 2013;6:281-9.
41. Hattingh HL, Knox K, Fejzic J, et al. Privacy and confidentiality: perspectives of mental health consumers and carers in pharmacy settings. *Int J Pharm Pract* 2015;23:52-60.
42. Clark A, Gilbert A, Rao D, et al. 'Excuse me, do any of you ladies speak English?' Perspectives of refugee women living in South Australia: barriers to accessing primary health care and achieving the Quality Use of Medicines. *Aust J Prim Health* 2014;20:92-7.
43. O'Connor M, Fisher C, French L, et al. Exploring the community pharmacist's role in palliative care: Focusing on the person not just the prescription. *Patient Educ Couns* 2011;83:458-64.
44. Carter SR, Moles R, White L, et al. Exploring patients' motivation to participate in Australia's Home Medicines Review program. *Int J Clin Pharm* 2012;34:658-66.
45. Lee CY, George J, Elliott RA, et al. Exploring stakeholder perspectives on medication review services for older residents in retirement villages. *Int J Pharm Pract* 2012;20:249-58.
46. White L, Klinner C. Medicine use of elderly Chinese and Vietnamese immigrants and attitudes to home medicines review. *Aust J Prim Health* 2012;18:50-5.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

519 47. Swain L, Barclay L. They've given me that many tablets, I'm bushed: I don't know where  
520 I'm going: Aboriginal and Torres Strait Islander peoples' experiences with medicines.  
521 *Austr J Rural Health* 2013;21:216-9.

522 48. Du Pasquier S, Aslani P. Concordance-based adherence support service delivery:  
523 Consumer perspectives. *Pharm World Sci* 2008;30:846-53.

524 49. Bui J, Day C, Hanrahan J, et al. Senior nurses' perspectives on the transfer of opioid  
525 substitution treatment clients from clinics to community pharmacy. *Drug Alcohol Rev*  
526 2014;34:495-8.

527 50. Van C, Krass I, Mitchell B. General practitioner perceptions of extended pharmacy  
528 services and modes of collaboration with pharmacists. *J Pharm Pract Res* 2007;37:182-  
529 6.

530 51. Van C, Mitchell B, Krass I. General practitioner-pharmacist interactions in professional  
531 pharmacy services. *J Interprof Care* 2011;25:366-72.

532 52. Dey RM, De Vries MJW, Bosnic-Anticevich S. Collaboration in chronic care: Unpacking  
533 the relationship of pharmacists and general medical practitioners in primary care. *Int J*  
534 *Pharm Pract* 2011;19:21-9.

535 53. Chong WW, Aslani P, Chen TF. Multiple perspectives on shared decision-making and  
536 interprofessional collaboration in mental healthcare. *J Interprof Care* 2013;27:223-30.

537 54. Cheong LH, Armour CL, Bosnic-Anticevich SZ. Multidisciplinary collaboration in primary  
538 care: Through the eyes of patients. *Aust J Prim Health* 2013;19:190-7.

539 55. Bajramovic J, Emmerton L, Tett SE. Perceptions around concordance--focus groups  
540 and semi-structured interviews conducted with consumers, pharmacists and general  
541 practitioners. *Health Expect* 2004;7:221-34.

- 542 56. McMillan SS, Emmerton L. Nurse practitioners: an insight into their integration into  
543 Australian community pharmacies. *Res Social Adm Pharm* 2013;9:975-80.
- 544 57. Roberts AS, Benrimoj SI, Chen TF, et al. Understanding practice change in community  
545 pharmacy: a qualitative study in Australia. *Res Social Adm Pharm* 2005;1:546-64.
- 546 58. Roberts AS, Benrimoj SI, Chen TF, et al. Practice change in community pharmacy:  
547 quantification of facilitators. *Ann Pharmacother* 2008;42:861-8.
- 548 59. Alonso-Perales MD, Lasheras B, Beitia G, et al. Barriers to promote cardiovascular  
549 health in community pharmacies: a systematic review. *Health Prompt Int* 2015:1-14.
- 550 60. Lowres N, Krass I, Neubeck L, et al. Atrial fibrillation screening in pharmacies using an  
551 iPhone ECG: a qualitative review of implementation. *Int J Clin Pharm* 2015;37:1111-20.
- 552 61. Hughes CM, Cadogan CA, Ryan CA. Development of a pharmacy practice intervention:  
553 lessons from the literature. *Int J Clin Pharm* 2015;38:601-6.
- 554 62. Bartholomew LK, Markham CM, Ruiter RAC, et al. Planning health promotion programs:  
555 An Intervention Mapping approach. 4th ed. San Francisco, CA: Jossey-Bass; 2016.
- 556 63. McKenzie JF, Neiger BL, Thackeray R. Planning, implementing, and evaluating health  
557 promotion programs: a primer. 6th ed. San Francisco, CA: Pearson - Benjamin  
558 Cummings; 2013.
- 559 64. Green LW, Kreuter MW. Health program planning: An educational and ecological  
560 approach. 4th ed. Boston: McGraw-Hill; 2005.
- 561 65. Franco-Trigo L, Hossain LN, Durks D, et al. Stakeholder analysis for the development of  
562 a community pharmacy service aimed at preventing cardiovascular disease. *Res Social*  
563 *Adm Pharm Epub* 2016 Jun 30.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

564 66. Sabater-Hernández D, Moullin JC, Hossain LN, et al. Intervention mapping for  
565 developing pharmacy-based services and health programs: A theoretical approach. *Am*  
566 *J Health Syst Pharm* 2016;73:156-64.

567 67. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for  
568 characterising and designing behaviour change interventions. *Implement Sci* 2011;6:42.

569


For peer review only

570

Figure 1. PRISMA flow diagram


571

For peer review only



254x190mm (96 x 96 DPI)

| Appendix 1. Search strategy and key words used in database search |  |
|---|--|
| Database  | Search strategy and keywords   |
| PubMed  | ((opinion OR opinions) OR (view or views) OR (attitude or attitudes) OR (experience OR experiences) OR satisfaction OR (motivation or motivations) OR (perception OR perceptions) OR (preference OR preferences) OR "Attitude to Health"[MH] OR awareness[TW] OR (barrier OR barriers) OR (facilitator or facilitators)) AND (pharmacy OR pharmacies OR pharmacist OR pharmacists) AND ("Interviews as Topic"[MH] OR "Empirical Research"[MH] OR semi-structured OR qualitative OR ("Focus Groups"[TW] OR "focus group")) AND Australia[TIAB]  |
| Scopus  | ((((TITLE-ABS-KEY (opinion OR opinions)) OR (TITLE-ABS-KEY (view OR views) ) OR (TITLE-ABS-KEY (attitude OR attitudes)) OR (TITLE-ABS-KEY (experience OR experiences)) OR (TITLE-ABS-KEY (satisfaction)) OR (TITLE-ABS-KEY (motivation OR motivations)) OR (TITLE-ABS-KEY (perception OR perceptions)) OR (TITLE-ABS-KEY ( preference OR preferences)))) OR ((TITLE-ABS-KEY (awareness)) OR (TITLE-ABS-KEY (barrier OR barriers)) OR (TITLE-ABS-KEY (facilitator OR facilitators)) OR (KEY (patient attitude)) OR (KEY (patient satisfaction)) OR (KEY (health personnel attitude)) OR (KEY (patient preference)))) AND ((TITLE-ABS-KEY (pharmacy OR pharmacies)) OR (TITLE-ABS-KEY (pharmacist OR pharmacists))) AND ((KEY (semi structured interview)) OR ( TITLE-ABS-KEY (qualitative)) OR (KEY (qualitative research))) AND (TITLE-ABS-KEY (Australia))) |
| Informit  | Pharmacy AND qualitative   |



| Related elements |         | Description of the relationship   |
|------------------|---------|---|
| Pat09            | Pat12   | Patients who did not have a positive experience with CPSs were not motivated to receive future ones <sup>1</sup>  |
| Pat14            | Pat02   | Patients' language issues prevented them from becoming more aware of CPSs <sup>2</sup>  |
| Pat09            | Pharm15 | Patients' previous positive experiences of CPS were related to a suitable knowledge of the pharmacist <sup>3</sup>  |
| Pat09            | Pharm17 | Patients' previous positive experiences of CPS were related to positive humanistic attributes of the community pharmacist (i.e. friendly) <sup>3</sup>                                    |
| Pat09            | Rel33   | Patients' previous positive experiences in the pharmacy contributed to the formation of a closer relationship between the patient and the pharmacist <sup>3</sup>                         |
| Pat13            | Pharm15 | Patients with higher levels of emotional intelligence valued the knowledge and competency of community pharmacists <sup>4</sup>   |
| Pat13            | Pharm17 | Patients with lower levels of emotional intelligence valued the humanistic attributes of the community pharmacist in CPS <sup>4</sup>   |
| Pharm16          | Pat02   | Lack of multilingual community pharmacists prevented awareness of the availability of CPS in some ethnic patients <sup>2</sup>  |
| Pharm17          | Rel33   | The humanistic attributes of the pharmacist (e.g., approachability, sensitivity) shaped the relationships between the patient and the pharmacist <sup>3</sup>                             |
| Pharm17          | Serv47  | The humanistic attributes of the pharmacist (e.g., approachability) created an environment in which patients could ask questions, seek advice and better address their needs <sup>5</sup> |
| GP25             | Sys57   | GPs can see a higher value in CPSs when they address their time limitations <sup>6</sup>  |
| GP25             | Pharm15 | GPs' perceptions and understanding of the role of community   |



|         |        |   |
|---------|--------|---|
|         |        | pharmacists depends on whether pharmacists have received appropriate training and demonstrate suitable health-related knowledge and skills <sup>7</sup>                         |
| Rel38   | Rel34  | GP-Pharmacist combined meetings and training can promote collaborative relationships between the pharmacist and GP <sup>8</sup>   |
| Rel33   | Pat05  | Patients who had an on-going relationship with community pharmacists were more likely to see the value of pharmacists providing health services <sup>3</sup>                    |
| Rel33   | Serv50 | The existence of a relationship between the patient and the pharmacist can determine the success of follow-up mechanisms in the CPS <sup>4</sup>                                |
| Rel35   | GP25   | GPs who experienced a high level of communication with pharmacists saw value in the input pharmacists can make to their practice <sup>8</sup>                                   |
| Rel38   | GP25   | Developing multidisciplinary training with pharmacists and GPs could enhance GPs' understanding and perception of pharmacists' capabilities and role in healthcare <sup>8</sup> |
| PhSet39 | Rel34  | Physical accessibility and co-location of the pharmacy to the GP medical centre can promote collaborative relationships between the pharmacists and GPs <sup>8,9</sup>          |
| PhSet44 | Rel34  | Time constraints of the pharmacist limited the collaboration between the pharmacists and the nurse <sup>10</sup>  |
| Serv47  | Pat09  | When patients perceived that CPS were not patient-centred, they reported negative experiences <sup>3</sup>  |
| Serv47  | Rel33  | CPSs which are patient-centred can contribute to the development of a relationship between the patient and the pharmacist <sup>3,11</sup>                                       |
| Serv52  | Rel33  | Having the same pharmacist delivering the CPS each time can contribute to the development of a relationship between the patient and the pharmacist <sup>1</sup>                 |

|        |       |  |
|--------|-------|--|
| Serv53 | Sys57 | Involving healthcare providers other than pharmacists (e.g., practice nurses) in the provision/coordination of CPS and related processes can positively influence GP time and workload constraints <sup>12</sup> |
| Sys57  | Rel35 | The workload and time of GPs influence the mode through which they interact and communicate with community pharmacists <sup>9</sup>  |
| Sys58  | GP27  | Complex administrative processes (e.g., tedious paperwork to refer patients to CPS) that require extra time from the GP (Sys57) may affect GPs' willingness to collaborate with CPSs <sup>12</sup>               |
| Sys59  | Rel34 | A system for sharing information can promote collaborative relationships between the pharmacist and GP <sup>8</sup>  |
| Sys60  | Rel34 | The presence of protocols to guide CPS delivery can contribute to improved GP–pharmacist relationships <sup>9</sup>  |

References

1. Carter SR, Moles R, White L, et al. Exploring patients' motivation to participate in Australia's Home Medicines Review program. *Int J Clin Pharm* 2012;34:658-66.

2. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home Medicines Review Program: benefits and barriers. *Res Social Adm Pharm* 2012;8:4-16.

3. Mey A, Knox K, Kelly F, et al. Trust and safe spaces: Mental health consumers' and carers' relationships with community pharmacy staff. *Patient* 2013;6:281-9.

4. Snell L, White L. An exploratory study of the role of emotional intelligence and self-efficacy on service quality and adherence in a weight loss setting. *Serv Mark Q* 2011;32:228-46.

5. McMillan SS, Emmerton L. Nurse practitioners: an insight into their integration into Australian community pharmacies. *Res Social Adm Pharm* 2013;9:975-80.

6. Chong WW, Aslani P, Chen TF. Multiple perspectives on shared decision-making and interprofessional collaboration in mental healthcare. *J Interprof Care* 2013;27:223-30.

7. Dey RM, De Vries MJW, Bosnic-Anticevich S. Collaboration in chronic care: Unpacking the relationship of pharmacists and general medical practitioners in primary care. *Int J Pharm Pract* 2011;19:21-9.

8. Van C, Krass I, Mitchell B. General practitioner perceptions of extended pharmacy services and modes of collaboration with pharmacists. *J Pharm Pract Res* 2007;37:182-6.

9. Van C, Mitchell B, Krass I. General practitioner-pharmacist interactions in professional pharmacy services. *J Interprof Care* 2011;25:366-72.

10. Bui J, Day C, Hanrahan J, et al. Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. *Drug Alcohol Rev* 2014;34:495-8.

11. McMillan SS, Sav A, Kelly F, et al. How to attract them and keep them: The pharmacy attributes that matter to Australian residents with chronic conditions. *Int J Pharm Pract* 2014;22:238-45.

- 1  
2  
3 12. Dhillon AK, Hattingh HL, Stafford A, et al. General practitioners' perceptions on home  
4 medicines reviews: a qualitative analysis. *BMC Fam Pract* 2015;16:16.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

| Assessment of the synthesis of qualitative research using the ENTREQ Statement for enhancing transparency in reporting the synthesis of qualitative research |                                 |
|--|---------------------------------|
| Item   | Page number                     |
| Aim  | 7                               |
| Synthesis methodology  | 8                               |
| Approach to searching  | 7-8                             |
| Inclusion criteria   | 7-8                             |
| Data sources   | 7                               |
| Electronic Search strategy   | Appendix 1 (Supplementary file) |
| Study screening methods  | 7-8                             |
| Study characteristics  | 12 (table 2)                    |
| Study selection results  | Figure 1                        |
| Rationale for appraisal  | 8                               |
| Appraisal items  | 8                               |
| Appraisal process  | 8                               |
| Appraisal results  | 10                              |
| Data extraction  | 8-9                             |
| Software   | 9                               |
| Number of reviewers  | 8-9                             |
| Coding   | 8-9                             |
| Study comparison   | 8                               |
| Derivation of themes   | 8-9                             |
| Quotations   | Not in this version             |
| Synthesis output   | 18 (table 3)                    |

# BMJ Open

## A qualitative meta-synthesis of barriers and facilitators that influence the implementation of community pharmacy services: perspectives of patients, nurses and general medical practitioners

|                                 |   |
|---------------------------------|---|
| Journal:                        | <i>BMJ Open</i>   |
| Manuscript ID                   | bmjopen-2016-015471.R1  |
| Article Type:                   | Research  |
| Date Submitted by the Author:   | 26-May-2017   |
| Complete List of Authors:       | Hossain, Lutfun; University of Technology Sydney<br>Fernandez-Llimos, Fernando; Universidade de Lisboa<br>Lockett, Tim; University of Technology Sydney<br>Moullin, Joanna; University of California San Diego<br>Durks, Desire; University of Technology Sydney<br>Franco-Trigo, Lucia; University of Technology Sydney<br>Benrimoj, Charlie; University of Technology, Sydney<br>Sabater-Hernandez, Daniel; University of Technology Sydney |
| <b>Primary Subject Heading</b>: | Health services research  |
| Secondary Subject Heading:      | Qualitative research  |
| Keywords:                       | Community pharmacy services, health service research, qualitative meta-synthesis, barriers, facilitators, determinants of practice  |
|                                 |   |

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**A qualitative meta-synthesis of barriers and facilitators that influence the implementation of community pharmacy services: perspectives of patients, nurses and general medical practitioners**

**Authors:**

**Lutfun N. Hossain.** BPharm. Master Student; Graduate School of Health, University of Technology, Sydney, Australia. Email: [Lutfun.Hossain@student.uts.edu.au](mailto:Lutfun.Hossain@student.uts.edu.au)

**Fernando Fernandez-Llimos.** PharmD, PhD. Assistant Professor; Research Institute for Medicines, Department of Social Pharmacy, Faculty of Pharmacy, University of Lisbon, Portugal. Email: [f-llimos@ff.ul.pt](mailto:f-llimos@ff.ul.pt)

**Tim Luckett.** BSc (Hons), PhD. Senior Lecturer; Faculty of Health, University of Technology Sydney, Australia Email: [Tim.Luckett@uts.edu.au](mailto:Tim.Luckett@uts.edu.au)

**Joanna C. Moullin.** BPharm. PhD; Research Fellow; Department of Psychiatry, University of California, San Diego (USA). Email: [jcmoullin@gmail.com](mailto:jcmoullin@gmail.com)

**Desire Durks.** BPharm. Master Student; Graduate School of Health, University of Technology, Sydney, Australia. Email: [desire.durks@student.uts.edu.au](mailto:desire.durks@student.uts.edu.au)

**Lucia Franco-Trigo.** MPharm. PhD Student; Graduate School of Health, University of Technology, Sydney, Australia. Email: [lucia.francotrigo@student.uts.edu.au](mailto:lucia.francotrigo@student.uts.edu.au)

**Charlie Benrimoj.** PharmD, PhD. Head of School; Graduate School of Health, University of Technology, Sydney, Australia. Email: [shalom.benrimoj@uts.edu.au](mailto:shalom.benrimoj@uts.edu.au)

**Daniel Sabater-Hernández.** PharmD, PhD. Chancellor’s Postdoctoral Research Fellow; Graduate School of Health, University of Technology, Sydney, Australia. Fellow; Academic

22 Centre in Pharmaceutical Care, University of Granada, Spain. Email:

23 [daniel.sabaterhernandez@uts.edu.au](mailto:daniel.sabaterhernandez@uts.edu.au); daniel.sabaterhernandez@outlook.com

24 **Corresponding author: Daniel Sabater-Hernández**

25 Graduate School of Health, University of Technology Sydney.

26 Level 4, Building 7, 67 Thomas St, Ultimo (PO Box 123)

27 Phone: +61 2 9514 7201; Email: daniel.sabaterhernandez@uts.edu.au;

28 [daniel.sabaterhernandez@outlook.com](mailto:daniel.sabaterhernandez@outlook.com)

29 **Word count (excluding title page, abstract, references, figures and tables): 4263**



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Objectives:** The integration of community pharmacy services (CPSs) into primary care practice can be enhanced by assessing (and further addressing) the elements that enable (i.e., facilitators) or hinder (i.e., barriers) the implementation of such CPSs. These elements have been widely researched from the perspective of pharmacists but not from the perspectives of other stakeholders who can interact with, and influence the implementation of CPSs. The aim of this study was to synthesise the literature on patients', general practitioners' (GPs) and nurses' perspectives of CPSs to identify barriers and facilitators to their implementation in Australia.

**Methods:** A meta-synthesis of qualitative studies was performed. A systematic search in PubMed, Scopus and Informit was conducted to identify studies that explored patients', GPs' or nurses' views about CPSs in Australia. Thematic synthesis was performed to identify elements influencing CPS implementation, which were further classified using an ecological approach.

**Results:** Twenty nine articles were included in the review, addressing sixty three elements influencing CPS implementation. Elements were identified as a barrier, facilitator or both, and were related to four ecological levels: individual patient (n=14); interpersonal (n=24); organizational (n=16); and community and healthcare system (n=9). It was found that patients, nurses and GPs identified elements reported in previous pharmacist-informed studies, such as pharmacist's training/education or financial remuneration, but also new elements, such as patients' capability to follow service's procedures, the relationships between GP and pharmacy professional bodies, or the availability of multidisciplinary training/education.

**Conclusions:** Patients, GPs and nurses can describe a large number of elements influencing CPS implementation. These elements can be combined with previous findings in pharmacists-informed studies to produce a comprehensive framework to assess barriers and facilitators to

CPS implementation. This framework can be used by pharmacy service planners and policy makers to improve the analysis of the contexts in which CPSs are implemented.

## KEY WORDS

Community pharmacy services [MeSH]; health service research [MeSH]; qualitative meta-synthesis; barriers; facilitators; determinants of practice.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Qualitative meta-synthesis aims to synthesise qualitative literature to provide a new, more comprehensive interpretation of the findings that goes beyond the depth and breadth of the original studies and to broaden the range of concepts identified. Therefore, it is an appropriate method to suitably achieve the aim of this study, which was to identify a comprehensive range of elements that, according to general practitioners, patients and nurses, can enable (i.e., facilitators) or hinder (i.e., barriers) the implementation of community pharmacy services in Australia.
- For the first time, a review focuses on synthesising the perspectives of these key stakeholders who can strongly influence the implementation of community pharmacy services at the primary care level.
- Qualitative studies in this review were checked against a minimum set of quality appraisal criteria, but a comprehensive quality assessment was not conducted. This decision was made due to the difficulty of using the information about studies' quality to inform the synthesis (e.g. even studies with flaws in methodology can provide valuable information), and to identify a larger number of possible influential elements.
- This review was purposively focused on a specific implementation context (i.e., Australia), to which its results are directly relevant and will be immediately applied and actions will be taken. Australia is a country with a large experience in research and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

77 implementation of community pharmacy services and, therefore, it is expected the  
78 results of this review may be relevant to start investigating barriers and facilitators to  
79 community pharmacy service implementation in contexts with less experience.  
80

For peer review only

## INTRODUCTION

The implementation of new health interventions and services into established healthcare practices and systems has been found to be challenging.<sup>1-4</sup> The inherent complexity of both health services and healthcare systems may be fundamental to the implementation problem.<sup>5, 6</sup> According to current health planning approaches, the implementation of health services can be enhanced by comprehensively assessing the context in which they will be delivered. Analysis of the context should consider the stakeholders who can influence or be affected by the health service, as well as the social, physical, economic and policy environments that can enable or hinder the normalization of the service.<sup>2, 7</sup> Early identification of these elements (including how they relate to or interact with each other) is a key step for developing suitable strategies and interventions to enhance health service implementation.

In the implementation science literature, several terms are used to refer to the elements that can influence service implementation and practice change. Some generally known examples, which are commonly used interchangeably in the literature,<sup>8</sup> are: barriers and facilitators,<sup>9</sup> determinants of practice;<sup>7</sup> implementation factors;<sup>10</sup> or constructs.<sup>2</sup> The current use of these terms encloses different concepts. For the purpose of this review and to avoid the terminological debate we have used the term 'influential element' as a neutral term.

Amid increasing awareness of the uniqueness of the community pharmacy setting and the positive contribution pharmacists can make to healthcare,<sup>11</sup> there has been a shift towards pharmacists providing more professional, patient-centred services. However the implementation and sustainability of community pharmacy services (CPSs) and the integration of community pharmacists into primary healthcare teams remains a challenge worldwide.<sup>12, 13</sup> In consistence with this international trend, Australian community pharmacies are eager to provide CPSs, receive remuneration from the government for its provision, but are experiencing challenges in the implementation, uptake and sustainability of CPSs.<sup>14</sup> Extensive research has

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

been conducted to identify the elements that from the perspective of community pharmacists (i.e., service provider) can influence the implementation of CPSs.<sup>14-16</sup> However, considering the view of a single stakeholder group is insufficient to comprehensively analyse the complexity of a particular implementation context. These limited analyses can lead to the development of inadequate implementation strategies and interventions. Patients, general practitioners (GPs), and primary care nurses are key stakeholders who interact with or are affected by CPSs and may be able to strongly influence the implementation of such services. These stakeholders may have their own particular views about CPSs and so can complement the findings from previous pharmacy-informed research.<sup>14, 15</sup> Patients', nurses' and GPs' views and experiences regarding CPSs have been explored in several qualitative studies<sup>17-21</sup> but no review that collates and analyses such information exists. Qualitative meta-synthesis aims to synthesise qualitative literature to provide a new, more comprehensive interpretation of the findings that goes beyond the depth and breadth of the original studies and to broaden the range of concepts identified.<sup>22, 23</sup> Thus, the aim of this study was to synthesise such qualitative literature to describe the broad range of elements that, from the patients', GPs' and nurses' perspectives, can hinder or enable the implementation of CPSs in Australia.

**METHODS**

**Search strategy, screening and eligibility criteria.** A systematic search was conducted in May 2015 in three electronic databases (i.e., PubMed, Scopus and Informit), without time limits, to identify qualitative studies addressing patients', nurses' or GPs' views about CPSs in Australia. A CPS was assumed to refer to an action or set of actions delivered in or organised by a community pharmacy to optimise the process of care, with the aim of improving health outcomes and the value of healthcare.<sup>24</sup> For the purpose of this review, CPSs are specific health programs that are implemented in addition to routine professional activities performed by community pharmacists, which do not require any specific or extra implementation effort (i.e.,

they are part of normal community pharmacy practice). Since medicines dispensing is the main routine activity in the community pharmacy, it was not considered as a CPS and so excluded. Articles that did not address a specific CPS but inter-professional collaboration (i.e. between community pharmacists and other healthcare professionals) were included as they can also provide insight into the elements influencing the implementation of CPSs. Full search strategies are available on Appendix 1 (Supplementary File). In addition, the references from the included papers were searched manually for additional relevant studies. A two-step process was performed by one researcher to select studies for the analysis. As a first step, titles and abstracts were screened to identify and exclude non-relevant literature. In a second, full texts of the remaining articles were reviewed to exclude those that: (1) were not related to CPSs; (2) did not address patient, nurse and/or GP perspective; (3) did not use qualitative research methodology;<sup>25</sup> (4) did not clearly identify the stakeholder (i.e., patient, nurse or GP) as the source of the information; and (5) were not accessible in any of the research team university libraries, or unattainable following contact with the authors.

All the included articles were checked by the same researcher for 'elementary quality assessment' using the first three criteria delineated by Dixon-Woods et al<sup>26</sup> to appraise qualitative research: (1) was the research question clear? (2) Was the research questions suited to qualitative inquiry? (3) Were (a) sampling, (b) data collection, and (c) analysis clearly described? Articles were excluded when no answer, or an unclear answer, was given to at least one of the three questions.

**Synthesis.** Qualitative meta-synthesis was conducted by one researcher according to the three-stage method for thematic synthesis described by Thomas et al<sup>27</sup> The first stage of analysis involved free line-by-line coding of the original data (study participants' quotes) and the study authors' interpretation of the original data. The process of coding involves summarising text from the results and discussion sections of each article into one or more descriptive issues

1  
2  
3 156 (i.e. codes) to capture meaning. The second stage of the process involved grouping codes into  
4  
5 157 one or more descriptive themes. Subsequent articles were coded into pre-existing themes, and  
6  
7 158 new themes were created when considered necessary. To simplify the terminology throughout  
8  
9 159 this article, themes were interpreted as elements (i.e., influential elements) that could positively  
10  
11 160 (i.e., facilitators) or negatively (i.e., barriers) influence CPS implementation or practice change.  
12  
13 161 A barrier was defined as *"any type of obstacle (material or immaterial) which can impede the*  
14  
15 162 *dissemination, implementation and/or sustainability of a CPS"*; while a facilitator was defined as  
16  
17 163 *"any type of element (material or immaterial) which can help to overcome barriers and/or*  
18  
19 164 *accelerate the dissemination or implementation"* of a CPS.<sup>16</sup> Themes that were related to similar  
20  
21 165 issues were further grouped to create one broad barrier or facilitator. The identified influential  
22  
23 166 elements were reviewed by a second researcher to assess clarity, consistency, and  
24  
25 167 understanding. At the third stage, barriers and facilitators were organised using an adapted  
26  
27 168 version of the Ecological Model (Table 1),<sup>28</sup> which classified them into four different levels:  
28  
29 169 patient, interpersonal, organisational, and community/system. The four levels defined in Table 1  
30  
31 170 were used as an overarching structure, with further sub-headings created during analysis, for  
32  
33 171 appropriate allocation and organisation of the influential elements into the levels. The ecological  
34  
35 172 model has been widely and successfully used for planning services in a variety of settings,  
36  
37 173 targeting different populations and problems.<sup>29, 30</sup> Coding of papers that were identified manually  
38  
39 174 was conducted last. NVivo Version 10 software (QSR International Pty Ltd; Australia) was used  
40  
41 175 to help manage and analyse the data. Once all the influential elements were identified, a second  
42  
43 176 round of analysis was conducted to identify where a connection or relationship was mentioned  
44  
45 177 between two or more elements. Again, both study participants' quotes and study authors' data  
46  
47 178 interpretation were reviewed for this purpose. A network representing the identified relationships  
48  
49 179 was generated using a ForceAtlas2 layout<sup>31</sup> with Gephi, 0.8. This article has been written  
50  
51 180 following existing guidelines for reporting the synthesis of qualitative research (the ENTREQ  
52  
53 181 Statement).<sup>32</sup>  
54  
55  
56  
57  
58  
59  
60



Table 1. Levels where elements that can influence the implementation of community pharmacy services can exist (adapted from McLeroy et al<sup>28</sup>)

|                      |  |
|----------------------|--|
| Individual patient   | Influential elements related to the personal characteristics and ideas concerning individual patients (i.e., individual determinants), such as their knowledge, beliefs and skills, that can affect their utilisation of community pharmacy services.  |
| Interpersonal        | Influential elements related to the healthcare providers and non-healthcare personnel (i.e., individual determinants) who are involved with the community pharmacy service and with whom patients associate (e.g., family, friends, pharmacists, pharmacy assistants, GPs, nurses) and the formal and informal relationships between patients and healthcare professionals and healthcare professionals with other healthcare professionals. |
| Organisational       | Influential elements related to characteristics of the community pharmacy setting and their decision processes, and attributes of the community pharmacy service that can influence the success of implementation.   |
| Community and system | Influential elements related to the larger society (i.e., environmental determinants), which consists of collectives of people in a geographical location, the relationships between organisations, the political players in the system and the rules, regulations and policies that have the power to control and/or influence the implementation of services.  |

## RESULTS

The systematic and manual search identified 243 articles once duplicates were removed. After title and abstract screening, 124 full-text articles were assessed for eligibility of which 29 articles were included in the qualitative meta-synthesis (all of them fulfilled the appraisal criteria) (Figure 1). A description of the papers included in the review can be found in Table 2. Of the 29 included papers, 15 addressed patients' perspectives only, 2 addressed nurses' perspectives only, 6 addressed GPs' perspectives only, 2 addressed nurses' and GPs' perspectives together,



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

189 3 addressed patients' and GPs' perspectives together and 1 addressed the views of all three  
190 participants. Twenty-three articles were related to a specific CPS, 2 were related specifically to  
191 inter-professional collaboration, 3 were related to both CPSs and inter-professional  
192 collaboration, and 1 addressed concordance-based healthcare. The articles employed semi-  
193 structured interviews (n=23), and/or focus groups (n=11) as methods of data collection.

For peer review only

Table 2. General description of the articles included in the qualitative meta-synthesis

| Study                           | Description of participants  |    |   |    | Service explored/assessed topic  | Method |
|---------------------------------|--|----|---|----|--|--------|
|                                 | (n)  | Pt | N | GP |  |        |
| McMillan et al <sup>33</sup>    | Patients with a chronic condition, diverse culture and socioeconomic background from three geographical locations in Queensland (Logan-Beaudesert and Mount Isa), New South Wales (Northern Rivers) and Western Australia (Greater Perth) (n=89) | X  |   |    | Disease management and Medication management (i.e., chronic management service)                    | SSI    |
| Rieck & Pettigrew <sup>34</sup> | GPs working in practices in low, medium or high socioeconomic status suburbs across Perth (Western Australia) (n=22)   |    |   | X  | Disease management (i.e., chronic disease management service) and inter-professional collaboration | SSI    |
| Barbara et al <sup>35</sup>     | Patients who are immigrants of Maltese ethnicity, residing in Australia, with a confirmed diagnosis of T2DM, >50 years of  | X  |   |    | Disease management and Medication management (i.e., diabetes self-                                 | SSI    |

|                                |  |   |  |   |   |     |
|--------------------------------|--|---|--|---|---|-----|
|                                | age, able to adequately communicate verbally in English or Maltese, located in Sydney (n=24)   |   |  |   | management service)   |     |
| Bereznicki et al <sup>36</sup> | Patients (n=6) and GPs (n=10) previously involved in a community pharmacy based asthma intervention, in Tasmania   | X |  | X | Disease management (i.e., Asthma management service)                          | SSI |
| Cvetkovski et al <sup>17</sup> | Patients >18 years of age with a diagnosis of asthma (n=10); and GPs in small rural centres (n=8), from different locations based on the Australian Standard Geographical Classification                 | X |  | X | Disease management (i.e., Asthma management service)                          | SSI |
| Saba et al <sup>37</sup>       | Patients >18 year of age, English speaking, current smoker, medical diagnosis of asthma and/or any other condition alongside asthma in Sydney Central Business District and South Western suburbs (n=24) | X |  |   | Disease management (i.e., smoking cessation service for patients with asthma) | SSI |
| Shoukry et al <sup>38</sup>    | Patients who had bought/hired/trialled a Continuous Positive Airway Pressure machine (or accessories) through their pharmacy in the previous 12 months in the greater Sydney region (n=20)               | X |  |   | Disease management (i.e., obstructive sleep apnoea services)                  | SSI |

|                              |  |   |  |   |  |        |
|------------------------------|--|---|--|---|--|--------|
| Um et al <sup>39</sup>       | GPs with large expertise in weight management (n=3)  |   |  | X | Disease management (i.e., weight management service)                             | SSI    |
| Snell et al <sup>40</sup>    | Patients >18 years of age, English speaking, enrolled in a specific weight loss program for >2 weeks from different urban and regional suburbs in Sydney (n=20)  | X |  |   | Disease management (i.e., weight management service)                             | SSI    |
| Maher et al <sup>41</sup>    | Women who have at least one child <5 years old are able to read and speak English from different locations based on Australian Standard Geographical Classification (n=28)                                 | X |  |   | Condition management (i.e., Maternal nutrition service)                          | SSI    |
| Mey et al <sup>42</sup>      | Patients living independently, experiencing a mild to moderate mental illness (and carers) in Queensland, New South Wales and Western Australia (n=74*)  | X |  |   | Medication management (i.e., service for patients with mental health conditions) | FG/SSI |
| Hattingh et al <sup>43</sup> | Patients with a mental health condition (and carers) (n=74*) and healthcare professionals (n=13) located in urban, regional, rural and remote regions in Queensland, New South Wales and Western Australia | X |  |   | Disease management (i.e., service for patients with mental health conditions)    | FG/SSI |

|                              |  |   |   |   |   |        |
|------------------------------|--|---|---|---|---|--------|
| Clark et al <sup>44</sup>    | Refugee women (n=38)**   | X |   |   | Medication management (i.e., primary healthcare service)  | FG     |
| O'Connor et al <sup>45</sup> | Palliative care nurses working in community-based palliative care, residential aged care adopting a palliative approach or working in a dedicated hospice or palliative care unit in a hospital (n=44); and practising GPs (n=10), in Australian metropolitan and regional areas |   | X | X | Disease management and medication management (i.e., services to community-based palliative care patients) | FG/SSI |
| Carter et al <sup>46</sup>   | Patients who are English, Mandarin or Arabic speaking, who had received a home medicines review service within the last 6 months or had not received such a service but were eligible for it, in metropolitan or rural areas in Australia (n=80)                                 | X |   |   | Medication management (i.e., home medicines review)   | FG     |
| Lee et al <sup>47</sup>      | Patients living in retirement villages in Victoria who were using prescribed medicines (n=25); GPs (n=9) and nurses (n=1) with experience with home medicines review services and/or providing care to retirement-village residents.   | X | X | X | Medication management (i.e., home medicines review)   | FG/SSI |
| White et al <sup>48</sup>    | Patients of Chinese or Vietnamese origin who   | X |   |   | Medication management (i.e., home   | FG     |

|                                    |  |   |   |   |   |     |
|------------------------------------|--|---|---|---|---|-----|
|                                    | had never received a home medicines review service but were eligible for it, in two suburban areas in Sydney (n=17)  |   |   |   | medicines review)   |     |
| White et al <sup>18</sup>          | Patients who had received a home medicines review service in the past 6 months or who had never received such a service but were eligible for it, in New South Wales, Victoria, Queensland and South Australia (n=77)  | X |   |   | Medication management (i.e., home medicines review)                                 | FG  |
| Dhillon et al <sup>20</sup>        | GPs practising in metropolitan medical centres in Perth (n=24)   |   |   | X | Medication management (i.e., home medicines review)                                 | SSI |
| Swain et al <sup>49</sup>          | Patients taking multiple medications, with a reasonable understanding of English and linked to an Aboriginal Health Service in urban, regional, rural and remote settings in Queensland, Northern Territory, South Australia, New South Wales and Victoria (n=101) | X |   |   | Medication management (i.e., service aimed at enhance the quality use of medicines) | FG  |
| Du Pasquier & Aslani <sup>50</sup> | Patients >18 years of age, fluent in English, taking one prescription medication on a daily basis in Sydney (n=22)   | X |   |   | Medication management (i.e., adherence support service)                             | SSI |
| Gilmartin et                       | Nurses who worked at residential aged care   |   | X |   | Medication management (i.e., dose   | FG  |

|                           |  |   |   |   |  |     |
|---------------------------|--|---|---|---|--|-----|
| al <sup>19</sup>          | facilities and used dose administration aids in Victoria (n=5)   |   |   |   | administration aids service)   |     |
| Bui et al <sup>51</sup>   | Nurses working in public, opioid substitution therapy clinics in NSW (n=9)                                 |   | X |   | Disease management (i.e., opioid substitution therapy services)  | SSI |
| Van et al <sup>52</sup>   | GPs practising in private/medical/specialised settings in rural/suburb/city areas in Sydney (n=23)         |   |   | X | Inter-professional collaboration in the context of disease management and medication management (i.e., professional pharmacy services)   | SSI |
| Van et al <sup>53</sup>   | GPs in metropolitan and rural areas in New South Wales (n=15)**  |   |   | X | Inter-professional collaboration in the context of a disease management (i.e., diabetes medication assistance service) and medication management (i.e., home medicines review service) | SSI |
| Dey et al <sup>54</sup>   | GPs working in Western Sydney (n=7)**  |   |   | X | Inter-professional collaboration in the context of disease management (i.e., asthma management services)   | SSI |
| Chong et al <sup>55</sup> | GPs (n=4) and nurses (n=7) working with mental health consumers in a healthcare setting in New South Wales |   | X | X | Inter-professional collaboration in the context of disease management (i.e., mental health services)   | SSI |
| Cheong et                 | Patients >18 years of age, English speaking,   | X |   |   | Inter-professional collaboration in the  | SSI |

|  |  |   |  |   |   |        |
|--|--|---|--|---|---|--------|
| al <sup>56</sup>   | with a diagnosis of asthma, in inner-west Sydney metropolitan region (n=16)                |   |  |   | context of disease management (i.e., asthma management service)     |        |
| Bajramovic et al <sup>57</sup>   | Patients >18 years of age, taking at least one medication (n=7) and GPs (n=10) in Brisbane | X |  | X | Medication management (i.e., concordance based healthcare services) | FG/SSI |
| <p>GP: General Practitioner; N: Nurse; Pt: Patient; SSI: Semi-structured interview; FG: Focus Group;</p> <p>* Total number of patients and carers. Opinions of carers were clearly differentiated in the article and excluded from this review.</p> <p>** No further description of participants was provided in the paper</p> |  |   |  |   |   |        |

194



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

During the first stage of data extraction, 181 patient, 30 nurse and 91 GP codes were created.  
At the completion of the coding process, 63 influential elements were identified (Table 3). These  
elements were found to exist as a barrier, facilitator or both. In several studies patients, nurses  
and GPs were able to describe approaches or strategies to overcome specific barriers.<sup>17-20, 33-36,</sup>  
<sup>39, 41, 43, 47, 51, 52, 57</sup> These strategies have been reported in Table 3 as additional facilitators  
(marked with an asterisk). During coding of the manually identified papers, it seemed that  
conceptual saturation may have been reached, since no new barriers or facilitators were  
identified.

Table 3. Elements that can hinder (i.e., barrier) or enable (i.e., facilitator) the implementation of community pharmacy services as identified by patients, general practitioners and nurses

|  | Effect on implementation and source of information (i.e., stakeholder)        |   |
|--|---|---|
|  | Barrier <sup>†</sup>  | Facilitator <sup>†</sup>  |
| <i>Elements at the individual patient level</i>  |   |   |
| 1. Patients' real or perceived need for healthcare (according to patients' individual concerns, understanding or perception of their health problems). | Pt <sup>18, 46, 47, 55, 56</sup> , GP <sup>17</sup>                           | Pt <sup>18, 33, 35, 36, 41, 46, 48, 56, 57</sup> , N <sup>51</sup> , GP <sup>17</sup> |
| 2. Patients' awareness of the availability of CPS  | Pt <sup>33, 47, 48</sup> , GP <sup>20, 47</sup>                               |   |
| 3. Patient personal desire or preference for CPSs  |   | Pt <sup>41, 46, 48, 56</sup>  |
| 4. Patients' understanding, perceptions and expectations of their own role in the CPS  | Pt <sup>36, 50, 56</sup>  | Pt <sup>17, 36, 56</sup>  |
| 5. Patients' understanding, perceptions and expectations of the role of community pharmacists in healthcare  | Pt <sup>17, 18, 35, 36, 41, 42, 56</sup> , N <sup>51</sup> , GP <sup>20</sup> | Pt <sup>35, 37, 38, 41, 42, 50, 56</sup>  |
| 6. Patients' understanding, perceptions and expectations of the role of the GP associated to the CPS   | Pt <sup>35, 36, 46-50, 56</sup>   |   |
| 7. Patients' understanding, perceptions and expectations of collaboration between healthcare professionals   | Pt <sup>56</sup>  | Pt <sup>56</sup>  |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

|   |   |   |
|---|---|---|
| 8. Patients' availability, time to participate in CPSs  | Pt <sup>33, 40</sup>                            | Pt <sup>40, 56</sup>  |
| 9. Patients' previous/background experiences with CPSs and multidisciplinary care   | Pt <sup>41, 42, 47, 56</sup>                    | Pt <sup>38, 42, 46, 47, 49, 56</sup>                                  |
| 10. Patient abilities; i.e., to follow the procedures of the CPS or to self-manage their health problems                      | Pt <sup>40, 56</sup> ; GP <sup>36, 52, 54</sup> | Pt <sup>37, 40, 48</sup>  |
| 11. Patients' satisfaction with the delivered CPSs and multidisciplinary care   |   | Pt <sup>36, 38, 40, 42, 46</sup> ; N <sup>51</sup>                    |
| 12. Patients' motivation towards CPSs   | Pt <sup>46</sup>                                | Pt <sup>37, 40, 46</sup>  |
| 13. Patients' level of emotional intelligence; i.e. ability to cope with negative experiences.                                | Pt <sup>40</sup>                                | Pt <sup>40</sup>  |
| 14. Patients' language, communication and cultural issues   | Pt <sup>44, 48</sup> ; GP <sup>20</sup>         |   |
| <i>Elements at interpersonal level</i>  |   |   |
| <i>a. Individual healthcare professionals (sub-level)</i>   |   |   |
| <i>a.1. Community pharmacist</i>  |   |   |
| 15. Knowledge, expertise, clinical and non-clinical skills (e.g. cultural competency) to adequately provide CPSs              | Pt <sup>42</sup> ; GP <sup>34, 52</sup>         | Pt <sup>18*, 20, 38, 40, 41*, 42, 44, 48</sup> ; GP <sup>39, 54</sup> |
| 16. Communication skills; including the capacity to speak other languages   | Pt <sup>48, 49</sup> ; N <sup>45</sup>          | Pt <sup>18, 33, 35, 37, 41, 48-50</sup>                               |
| 17. Humanistic attributes (e.g. being respectful, caring, non-judgemental, friendly, empathetic, supportive and approachable) | Pt <sup>40</sup>                                | Pt <sup>33, 35, 36, 38, 40-43, 46, 56</sup>                           |

|   |  |                                      |
|---|--|--------------------------------------|
| 18. Willingness, interest, motivation to provide CPSs and/or participate in multidisciplinary collaboration | N <sup>33, 37, 51, 56, GP<sup>47</sup></sup> | Pt <sup>35</sup>                     |
| <i>a.2. Other community pharmacy staff members (e.g. pharmacy assistants)</i>                               |  |                                      |
| 19. Technical knowledge (e.g., about a product)   | Pt <sup>41, 42</sup>                         | Pt <sup>41</sup>                     |
| 20. Communication skills  | Pt <sup>42</sup>                             | Pt <sup>41</sup>                     |
| 21. Humanistic attributes   |  | Pt <sup>41</sup>                     |
| 22. Ability to work professionally (e.g., uphold patient confidentiality)                                   | Pt <sup>42, 43</sup>                         |                                      |
| 23. Experience working in the pharmacy  | Pt <sup>41, 42</sup>                         | Pt <sup>41</sup>                     |
| <i>a.3. General Practitioner</i>  |  |                                      |
| 24. Understanding, perceptions and expectations of their individual role with regard CPSs                   | GP <sup>52, 54</sup>                         |                                      |
| 25. Understanding, perceptions and expectations of pharmacist's capabilities and role in healthcare         | GP <sup>34, 36, 52-54</sup>                  | GP <sup>54, 17, 34, 36, 39, 57</sup> |
| 26. Awareness of the availability of CPS  | GP <sup>20</sup>                             |                                      |
| 27. Willingness, interest, motivation to collaborate with CPSs  | GP <sup>20</sup>                             | GP <sup>20, 54</sup>                 |
| <i>a.4. Nurse</i>   |  |                                      |
| 28. Understanding, perceptions and expectations of their individual role within, or in regards to,          | N <sup>19</sup>                              |                                      |

|   |   |   |
|---|---|---|
| CPSs  |   |   |
| 29. Knowledge and skills to adequately participate in the delivery of CPS   | N <sup>19</sup>   | N <sup>19*</sup>  |
| 30. Attitude towards other healthcare professionals and their roles   |   | N <sup>19</sup>   |
| 31. Willingness, interest, motivation to collaborate with CPSs  | N <sup>19</sup>   | N <sup>19</sup>   |
| <i>b. Relationships (or interactions) between individuals (sub-level)</i>   |   |   |
| 32. Influence of friends and family on patients utilising CPSs (i.e., they may provide support, affect patient's adherence, or patient's enthusiasm with CPSs)                      | Pt <sup>40, 41, 48</sup>  | Pt <sup>17*, 35*, 41</sup>  |
| 33. Previous relationship between the patient and the pharmacist and its nature (e.g. trusting relationship)  | Pt <sup>18</sup> ; GP <sup>20</sup>                                       | Pt <sup>18, 33, 36, 38, 40-42, 46</sup> ; GP <sup>52</sup>                        |
| 34. Collaborative relationships between the pharmacist and other healthcare providers (e.g., GPs), and their nature   | Pt <sup>57</sup> ; N <sup>51</sup> ; GP <sup>34, 45, 47, 52, 53, 57</sup> | Pt <sup>35, 56</sup> ; N <sup>19, 51</sup> ; GP <sup>17*, 20, 52-54, 57</sup>     |
| 35. Communication channels and modes between pharmacists and other healthcare providers (e.g., GPs)   | N <sup>19, 45</sup> ; GP <sup>36, 52, 54, 55</sup>                        | Pt <sup>17, 18, 35</sup> ; N <sup>51</sup> ; GP <sup>17, 52-54</sup>              |
| 36. Existence of referral mechanisms between healthcare professionals, including also those between pharmacy support staff and pharmacists (i.e., care coordination and transition) | Pt <sup>42</sup> ; GP <sup>36, 52</sup> ; N <sup>51</sup>                 | Pt <sup>38, 41</sup> ; GP <sup>17, 20, 36, 39, 47, 52, 54</sup> ; N <sup>51</sup> |
| 37. Consistency in the information provided by the pharmacist with regards to the GP's recommendations  | GP <sup>45, 52, 53, 57</sup>  | GP <sup>52, 57</sup>  |

|  |  |   |
|--|--|---|
| 38. Availability of multidisciplinary education, training and meetings for pharmacists and GPs that enhance integrated, collaborative care   |  | Pt <sup>52*, 56*</sup> ; N <sup>51</sup> ;<br>GP <sup>17, 34, 52, 53</sup>                          |
| <i>Elements at the organisational level</i>  |  |   |
| <i>a. Community pharmacy setting (sub-level)</i>   |  |   |
| 39. Accessibility of the pharmacy setting (e.g. convenient location, co-location, no appointments required, opening hours)   | Pt <sup>17, 49</sup> ; N <sup>51</sup>                                   | Pt <sup>17, 33, 35, 37, 38, 40, 41, 56*, 57</sup> ; N <sup>51</sup> ;<br>GP <sup>47*, 52*, 53</sup> |
| 40. Structural characteristics of the pharmacy setting i.e. size, provision of counselling rooms, use of visual space for posters, child-friendly area                                       | Pt <sup>43</sup>   | Pt <sup>40, 41, 43*</sup>   |
| 41. Privacy of the setting, including the availability of a private consultation area and limited involvement of multiple staff members who would be aware of the patients' personal matters | Pt <sup>18, 41-43, 49, 56</sup> ; GP <sup>20</sup> ;<br>N <sup>45</sup>  | Pt <sup>38, 40, 43</sup>  |
| 42. Availability of suitable material resources to support the service (e.g. educational material for patients, medical devices, patient data management system, etc.)                       |  | Pt <sup>41, 42, 44</sup>  |
| 43. Sufficient qualified staff to perform CPS  | Pt <sup>44</sup> ; GP <sup>20, 47, 57</sup>                              | Pt <sup>48</sup>  |
| 44. Organization of the pharmacist's workload and time to deliver CPSs   | Pt <sup>41, 48, 49, 56</sup> ; N <sup>51</sup> ;<br>GP <sup>33, 47</sup> | Pt <sup>41, 57</sup>  |
| 45. Organisational commitment to implement a CPS   | Pt <sup>33, 41</sup> ; N <sup>51</sup>                                   |   |

|  |  |  |
|--|--|--|
| 46. Promotion of the CPS to facilitate its uptake  |  | Pt <sup>33*, 35*, 47.</sup> , GP <sup>20</sup>   |
| <i>b. Community pharmacy service</i>   |  |  |
| 47. Extent to which the CPS meets and is tailored to fit individual patient's needs or fills existing gaps in healthcare practice (this enhances the value of the service for patients and healthcare professionals) | Pt <sup>18, 35, 36, 42, 46, 47, 56.,</sup><br>GP <sup>52, 54</sup> | Pt <sup>18, 33, 35, 38, 41, 42, 46-49, 56.,</sup> N <sup>47.</sup> , GP <sup>20, 39, 47, 52-55, 57</sup> |
| 48. Quality of the CPS (e.g. validity, accuracy of the materials and tools used, CPSs provided in a timely manner, provision of both verbal and written information, professional advice and education, etc.)        | Pt <sup>46.</sup> , GP <sup>47, 57.</sup> , N <sup>19</sup>        | Pt <sup>18, 38, 40, 41.</sup> , GP <sup>20</sup>   |
| 49. Complexity of the CPS for use by healthcare professionals  | GP <sup>20.</sup> , N <sup>19, 51</sup>                            |  |
| 50. Extent to which CPSs provide ongoing support, follow-up and feedback to patients   | GP <sup>52</sup>   | Pt <sup>18, 33, 38, 40, 42, 43,</sup><br>47  |
| 51. Flexibility to use different communication channels (e.g. telephone, website) to interact with patients and healthcare providers   |  | Pt <sup>38, 40, 43*</sup>  |
| 52. Consistency in the community pharmacist delivering the CPS   |  | Pt <sup>38, 41, 46.</sup> , N <sup>19*</sup>   |
| 53. Involvement of other healthcare providers in delivering the CPS  |  | Pt <sup>41.</sup> , N <sup>19*</sup> , GP <sup>20*</sup>   |
| 54. Costs and duration of the CPS consultation for the patient   | Pt <sup>56, 57.</sup> , N <sup>51</sup>                            | Pt <sup>38, 57.</sup> , GP <sup>17, 20.,</sup><br>N <sup>51*,</sup>                                      |

*Elements at the community and health system level*

|   |                                     |   |
|---|-------------------------------------|---|
| 55. General consumer education about healthcare; promotion of CPS by the media  | Pt <sup>57</sup> ; GP <sup>57</sup> | Pt <sup>48, 57</sup> ; GP <sup>47*, 57</sup>  |
| 56. Collaboration, influences, conflicts between GP and pharmacist professional bodies  |                                     | GP <sup>34*</sup>   |
| 57. Organization of GPs' workload and time to collaborate with CPSs   | GP <sup>20, 47, 52, 54, 55</sup>    |   |
| 58. Complexity of system-level administrative processes (e.g. tedious paperwork) associated to the delivery of CPS; i.e., complying with the requirements of the department of health | GP <sup>17, 20, 47, 53, 57</sup>    |   |
| 59. Availability of an electronic system for sharing information  | Pt <sup>18, 56</sup>                | Pt <sup>17*, 57</sup> ; N <sup>19*</sup> ;<br>GP <sup>17, 20*, 36*, 50, 52*, 53</sup> |
| 60. Presence of agreed healthcare protocols, regulations, rules and policies to facilitate the delivery of CPSs   | Pt <sup>44</sup> ; N <sup>51</sup>  | Pt <sup>44</sup> ; GP <sup>20*, 52, 53</sup>  |
| 61. Limits on the healthcare budget; i.e., funding allocated to support CPS delivery  | GP <sup>17, 47, 54, 57</sup>        | Pt <sup>44, 56*</sup> ; GP <sup>17, 52, 57</sup>                                      |
| 62. Availability of financial incentives for service provision and inter-professional collaboration   |                                     | Pt <sup>56*</sup> ; N <sup>51*</sup>  |
| 63. Organisation of the healthcare system   | Pt <sup>56</sup> ; GP <sup>57</sup> |   |

CPS: Community Pharmacy Service; GP: General Practitioner; Pt: Patient; N: Nurse

‡ Barrier: the element was mentioned to act as a BARRIER or hinder to the implementation of CPSs; † Facilitator: the element was mentioned to act as a FACILITATOR or enabler to the implementation of CPSs; (\*) this element was reported as a potential strategy to overcome a barrier



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

(i.e., facilitator).

204

For peer review only

205 **Individual patient level.** All the 16 elements at the patient level were identified by patients.  
206 GPs and nurses did not identify any additional patient-related barriers and facilitators.  
207 Influential elements at this level were related to the patients' needs, preferences, perceptions  
208 and expectations, capabilities or previous experiences with community pharmacists and  
209 services. Patients' health-related concerns, understanding or perception of their health  
210 problems are important elements that influence patients' need for healthcare and so their  
211 decisions to utilise CPSs. Most patients held positive views about CPSs and the role of the  
212 pharmacist in providing such services.<sup>40, 41, 47</sup> Some articles highlighted that positive  
213 experiences were related to the patient feeling comfortable and welcomed in the  
214 pharmacy.<sup>38, 40, 42</sup> When CPSs required a formal referral from the GP, some patients deterred  
215 from requesting the services. These patients perceived that by requesting a CPS they would  
216 be bothering the GP<sup>36</sup> or offending and compromising their relationship with the GP.<sup>18, 47, 48</sup>  
217 Patients also reported that having a negative experience with a CPS also deterred them  
218 from accessing and utilising such CPSs in the future.<sup>42</sup>

219 **Interpersonal level.** Influential elements at the interpersonal level were related to two  
220 categories or sub-levels: (1) *individual healthcare professionals* (which also includes  
221 professional pharmacy staff), and (2) *relationships (or interactions) between individuals*  
222 (which includes both the relationships between healthcare professionals and between those  
223 professionals and patients).

224 *Individual healthcare professionals.* 17 elements were identified and related to  
225 characteristics of the community pharmacists (n=4), nurses (n=4) and GPs (n=4) and  
226 characteristics of non-provider personnel (i.e., other community pharmacy staff members -  
227 e.g., pharmacy assistant) (n=5). Articles reported that GPs' and nurses' service support  
228 varied depending on their perceptions or understanding of CPSs and the role of  
229 pharmacists. Home medicine review services had a great deal of approval and support from  
230 the GP perspective.<sup>47, 52</sup> On the other side, pharmacists providing immunisations raised  
231 some conflicting views among GPs since they believed this was the role of the GP or nurse

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

232 practitioner.<sup>52</sup> Some studies highlighted that GPs had a limited understanding of the  
233 capabilities of the pharmacist as service providers with pharmacists perceived as drug  
234 sellers in a retail environment.<sup>34-36, 53, 56</sup> Both patients and GPs implied the need for  
235 pharmacists to undergo upskilling and training to be qualified to provide some CPSs.<sup>34, 39, 48</sup>

236 *Relationships (or interactions) between individuals.* Seven influential elements were  
237 identified. Articles reported that well-established relationships between the pharmacist and  
238 the nurse or the GP, including collaborative relationships, were essential for the success of a  
239 CPS.<sup>17, 19, 20, 35, 51, 54</sup> Multidisciplinary education and training for healthcare professionals was  
240 suggested as a way to improve healthcare professional competence.<sup>56</sup> Similarly,  
241 characteristics of the relationship between the patient and the pharmacist (e.g., trust) was a  
242 key element that influenced pharmacy choice, contributed to the patient adhering to the  
243 CPS, and accepting the intervention.<sup>18, 33, 36, 38, 40-42, 46</sup> Some articles reported the influence of  
244 family and friends on patient utilisation of CPSs (e.g., providing support, influencing  
245 motivation),<sup>35, 56</sup> and others commented on the integration of partners into the CPS (e.g.,  
246 provision of group sessions with partners).<sup>35, 38</sup>

247 **Organizational level.** Also at the organisational level, influential elements were divided into  
248 two sub-levels: (1) *the community pharmacy setting* (n=8) and (2) *the service itself* (n=8).

249 *The community pharmacy setting.* Some articles identified the accessibility of the pharmacy  
250 facilitated inter-professional relationships between GPs and pharmacists,<sup>52, 53</sup> and influenced  
251 patient<sup>17, 38, 41</sup> and nurse<sup>51</sup> participation in CPS. In some articles non-english speaking  
252 patients reported that the lack of multilingual staff limited their awareness and access to  
253 CPSs.<sup>44, 48</sup> Other articles noted GP and nurse concerns regarding the lack of pharmacies  
254 that provide CPSs<sup>51</sup> and insufficient accredited pharmacists to perform CPSs.<sup>47, 57</sup>

255 *The community pharmacy service.* Concerns regarding the validity and accuracy of the tools  
256 and instruments used (e.g. medical devices, medication charts) were raised by GPs and  
257 nurses.<sup>19, 52</sup> Patients and nurses commented that having the same service provider at each

258 encounter facilitated rapport building between the patient and the pharmacist,<sup>38, 41, 46</sup> and  
259 caused fewer errors when it came to preparing dose administration aids.<sup>19</sup> Furthermore,  
260 patients, nurses and GPs reported on the involvement/participation of healthcare  
261 professionals other than pharmacists in the provision of CPSs,<sup>41</sup> or to act as a point of  
262 liaison,<sup>20</sup> to improve the quality and efficiency of the service. The cost of the service was a  
263 key element, mentioned by all stakeholders, that could either discourage<sup>51, 56</sup> or motivate<sup>38</sup>  
264 patients to utilise services. In particular it was mentioned that smaller, manageable cost  
265 payments for patients could facilitate CPS use.<sup>51</sup>

266 **Community and healthcare system level.** Nine influential elements were identified at this  
267 level. Several articles identified the need for adequate remuneration for GPs and  
268 pharmacists for participating in and providing CPSs,<sup>17, 44, 52, 54</sup> as well as the implementation  
269 of an electronic system of information sharing between these two healthcare professionals.<sup>19,</sup>  
270 <sup>20, 36, 57</sup> GPs also cited the availability of competing, government-funded health programs,  
271 and their high level of workload and lack of time as contributing to their low participation in  
272 CPSs.<sup>47</sup> Where services were available, remunerated and widely supported by GPs and  
273 patients, such as home medicine reviews (i.e., a medication review service), GPs mentioned  
274 complex bureaucratic procedures (e.g. completing tedious documents) may discourage their  
275 use.<sup>17, 20, 47, 53, 57</sup> Despite this, the home medicine review service was generally considered  
276 successful by GPs and a frequently reported reason for this was the presence of a clear  
277 protocol guiding service delivery.<sup>20, 52, 53</sup> GPs also suggested increased and improved  
278 collaboration between pharmacy and GP professional representative bodies may improve  
279 awareness of the services and encourage participation. The media was perceived to have  
280 an important role in improving awareness of and promoting CPSs. Finally, some broad  
281 comments suggesting some additional issues at the higher levels of the healthcare system  
282 were mentioned, such as 'better and more responsible organisation of the healthcare  
283 system'.<sup>57</sup>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

284 With regards to the interactions between the identified influential elements, 12 articles out of  
285 29 mentioned some form of a relationship between certain elements.<sup>20, 33, 40, 42, 46, 48, 51-55, 58</sup> As  
286 shown in Appendix 2 (Supplementary File), a total of 27 relationships between 25 elements  
287 were found, with 10 elements presenting 2 or more relationships with others (2 elements  
288 showed 5 or more interactions). As a result of the limited, unsystematic information reported  
289 in the articles, a sparse network disclosing the recognized relationships between elements  
290 was obtained (Appendix 2 in Supplementary File).

291 **DISCUSSION**

292 To the best of our knowledge this is the first review that summarises comprehensive  
293 information on the elements that, according to patients, nurses and GPs, can enable or  
294 hinder the implementation of CPSs. Patients, GPs and nurses are key members of the  
295 primary healthcare team and their support and expectations for CPSs can highly influence  
296 their implementation.<sup>1, 19, 52, 58-61</sup> Thus, by synthesising and organising the influential elements  
297 identified by these key stakeholders, this review can optimize future analyses of barriers and  
298 facilitators to the implementation of CPSs and so potentially enhance their integration into  
299 primary practice. Importantly, this work was intentionally restricted to a specific  
300 implementation context (i.e., Australia), to which its results are directly relevant and will be  
301 immediately applied. Focusing only on Australia is not considered a limitation of the study;  
302 rather it is a sensible decision that allows knowledge about a particular context of interest to  
303 be gained. Including studies conducted in contexts or healthcare systems other than  
304 Australia (e.g., United Kingdom, United States, etc.), where barriers and facilitators to CPS  
305 implementation can be dissimilar in nature and expressed differently, may have brought  
306 irrelevant or inappropriate information to this analysis, and so hinder the understanding of  
307 the context of interest. However, it should be noted that Australia is a country with a large  
308 experience in CPS implementation and where significant research has been conducted in  
309 this regard compared to other countries worldwide. Therefore, it is expected that the  
310 comprehensive list of influential elements identified in this context may be relevant to start

investigating barriers and facilitators to CPS implementation in countries with less experience. Furthermore, the elements identified in this review can provide insight to pharmacy service planners in other countries to guess and avoid some problems in the implementation of CPSs beforehand.

Barriers and facilitators to the implementation of CPSs in Australia have been well researched and reported from the perspective of community pharmacists.<sup>14, 15, 60, 62</sup> In this regard, the results of this review confirms that patients, nurses and GPs also recognise some of the influential elements reported in previous pharmacist-informed studies, such as the pharmacist's education and training, collaboration between the pharmacist and the GP, accessibility of the pharmacy setting, and financial remuneration. However, this study provides additional insight into further barriers and facilitators, across different ecological levels, that are relevant to other key stakeholder and so are less likely to be reported by pharmacists; for example: patients' capability to follow the procedures of the service, GPs' workload, nurses' attitudes towards other healthcare professionals/services, the actual relationships between GP and pharmacy professional bodies, or the availability of multidisciplinary training and education. These results highlight the importance of engaging key stakeholders other than pharmacists to better understand the contexts in which CPSs are implemented. In other words, disregarding the input of these stakeholders (or considering only the views of pharmacists), may lead to an incomplete and biased understanding of the implementation context, which, in turn, can result in service underutilisation, unsuccessful implementation and limited service impact.<sup>63</sup> Generally, involving relevant stakeholders throughout the development, implementation and evaluation of health programs is crucial to increase the chances of any of those initiatives being effective and successfully implemented.<sup>6, 29, 30, 64</sup> Indeed, this is equally relevant to CPS planning.<sup>65, 66</sup>

Semi-structured interviews, and/or focus group with healthcare professionals and patients appear to be appropriate methods to identify a large number of unique influential elements.<sup>67</sup>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

338 Thus pharmacy service planners can continue to utilise these methods to identify  
339 determinants of pharmacy practice in their own context. Although, the type of qualitative  
340 method used may affect the type of barriers/facilitators identified, it is more likely that the  
341 aims of the studies included in this review, their target population and/or the specific  
342 service/topic addressed by the study may have had a stronger influence in the type of  
343 barriers or facilitator identified.

344 The results of this review can assist pharmacy service planners and researchers to better  
345 identify the elements that may be enabling or hindering the implementation of existing CPSs.  
346 By combining the list of influential elements generated in this review with previous findings in  
347 pharmacists-informed studies a comprehensive framework to assess barriers and facilitators  
348 to CPS implementation can be produced. Assessing and understanding the elements  
349 influencing pharmacy practice and service implementation must be a key early step in  
350 developing appropriate, multilevel programs (i.e., including interventions targeting elements  
351 at different levels) aimed at enhancing the integration of CPSs into the healthcare system.<sup>29,</sup>  
352 <sup>30, 66, 68</sup> Also, influential elements should be prompted and assessed when designing new  
353 CPSs. Identifying elements prior to designing a new CPS may guide both the early  
354 adaptation of the service to the context, as well as the early development of tailored  
355 implementation programs to better fit (or change) the implementation context. As an analysis  
356 of influential elements is likely to yield a large number of items, it would not be feasible to  
357 address each and every one of those elements. Thus once elements have been identified for  
358 a specific context, further efforts are required to prioritise those elements that are most  
359 relevant and can be practically addressed.<sup>8, 69</sup> In this regard, McMillan et al<sup>70</sup> provide a  
360 summary of methods used to determine priorities and how they have been used in pharmacy  
361 practice research, which can guide pharmacy service planners in this regard.

362 The analysis conducted in this review revealed three concerns that must be considered to  
363 improve future studies aimed at identifying influential elements. On the one hand, some  
364 influential elements at the community and healthcare system level were too broadly



described (i.e., 'organisation of the health system') and further exploration is needed to clearly understand the specific 'items' that they encompass. Presumably, the list of determinants of practice described by Flottorp et al<sup>7</sup> (i.e., Tailored Implementation in Chronic Disease checklist) can provide more detail regarding influential elements at the higher community and healthcare system level and so can initially assist to better frame future analysis of barriers and facilitators to CPS implementation. Particularly, the determinants under the domains 'Incentives and resources'; 'Capacity for organizational change'; and 'Social political and legal factors' seem particularly relevant for this purpose. Importantly, to bring further insight on the elements at the community and healthcare system level it would be important to include and explore the perspectives of other potential key stakeholders, such as other healthcare providers (e.g., specialists), caregivers, representatives of healthcare organisations and professional bodies, policy makers, etc. Furthermore, future studies aimed at identifying barriers and facilitators to CPS implementation must better describe and understand the relationships between elements.<sup>2, 7</sup> This may help to understand how elements influence each other and which elements are more suitable to be addressed (based on the overall effect that they can produce on other elements) when designing implementation efforts.

**Limitations.** The network analysis intended in this study was strongly constrained by the limited and unsystematically reported information about the relationships between influential elements. As a result, it was decided not to report further results of the network analysis beyond its pictorial representation. The potential of a full network analysis should be considered in future studies aimed at analysing elements that influence the implementation of CPSs. A suitable network analysis can help to better understand the complex relationships between these elements; detect the core elements that may primarily explain the implementation challenge; and provide insight on the key leverage points that should be targeted within the network to enhance service implementation. Ideally, accurate information on relevant attributes of the influential elements (and the interactions between them) should



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

392 be collected by the authors of the primary studies to increase the potential of a network  
393 analysis; for example, the frequency of occurrence; the direction of the relationships; the  
394 domain or level where the element is located (i.e., patients, healthcare professionals,  
395 professional interactions, etc.); the relative relevance of each element; or the effect on  
396 implementation outcomes (i.e., performance as barrier or facilitator).

397 Following the particular method chosen for this review (i.e., qualitative meta-synthesis),<sup>22, 23</sup>  
398 only primary research articles that used qualitative methods were included. Meta-synthesis  
399 enabled a rich description of elements perceived by GPs, patients and nurses to influence  
400 implementation of CPSs in Australia. Future reviews that synthesise the quantitative  
401 literature on this topic are encouraged. Appraising qualitative research is controversial  
402 because of the difficulty of using information about quality to inform syntheses (e.g. even  
403 studies with flaws in methodology can provide valuable information).<sup>26</sup> Furthermore, there is  
404 no gold standard on appraising qualitative studies.<sup>32</sup> The elementary quality assessment  
405 conducted in the current review was aimed at ensuring minimal quality while identifying a  
406 broad range of elements that might influence CPS implementation. Lastly, the papers  
407 included in this review were not restricted by the time at which they were published, since  
408 the aim of the study was to include all relevant papers that can inform about any influential  
409 element that has been noted in practice. It is important to acknowledge that as contexts can  
410 change over time, the effect of influential elements can also change, cease to exist or new  
411 elements can emerge. It is therefore important to regularly monitor elements and prioritise  
412 those that must be addressed.

413 **CONCLUSION**

414 This qualitative meta-synthesis identified a broad range of elements that, according to  
415 patients, GPs and nurses, can enable (i.e., facilitators) or hinder (i.e., barriers) the  
416 implementation of CPSs. These influential elements are located at different ecological levels  
417 and should be considered together with those previously identified in pharmacy-informed

1  
2  
3 418 studies to comprehensively analyse the barriers and facilitators to the implementation of  
4  
5 419 CPSs. Future studies aimed at that purpose must involve multiple stakeholder groups (i.e.,  
6  
7 420 others than only pharmacists) and better understand the relationships between influential  
8  
9 421 elements to increase the usefulness and interest of their findings. Further to the identification  
10  
11 422 of the influential elements, key stakeholders should keep involved in developing suitable,  
12  
13 423 multilevel programs aimed at enhancing CPS implementation.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ACKNOWLEDGEMENTS**

We would like to acknowledge Antonio E. Mendes (Universidade Federal do Parana, Brazil) for his collaboration in the network analysis.

**COMPETING INTERESTS**

All authors declare no competing interest

**FUNDING**

Lutfun N. Hossain was awarded a University of Technology Sydney (UTS) President's Scholarship and a UTS Chancellors Research Scholarship.

This work is part of a larger UTS Chancellor's Postdoctoral Research Fellowship awarded to Dr Daniel Sabater-Hernández (UTS ID number: 2013001605).

**DATA SHARING STATEMENT**

No additional data are available

**AUTHORS' CONTRIBUTION**

Conception or design of the work: Lutfun N. Hossain, Fernando Fernandez-Llimos, Tim Lockett and Daniel Sabater-Hernández.

Data collection: Lutfun N. Hossain, Desire Durks and Lucia Franco-Trigo.

Data analysis and interpretation: Lutfun N. Hossain, Joanna C. Moullin, Charlie Benrimoj and Daniel Sabater-Hernández.

Drafting the article: Lutfun N. Hossain, Fernando Fernandez-Llimos, Tim Lockett and Daniel Sabater-Hernández.

444 Critical revision of the article: Lutfun N. Hossain, Joanna C. Moullin, Fernando Fernandez-  
445 Llimos, Tim Lockett and Daniel Sabater-Hernández.

446 Final approval of the version to be published: Lutfun N. Hossain, Fernando Fernandez-  
447 Llimos, Tim Lockett, Joanna C. Moullin, Desire Durks, Lucia Franco-Trigo, Charlie Benrimoj  
448 and Daniel Sabater-Hernández.

449

For peer review only

REFERENCE

1. Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of health innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures. *Implement Sci* 2013;8:22.

2. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci* 2009;4:50.

3. Haines A, Kuruvilla S, Borchert M. Bridging the implementation gap between knowledge and action for health. *Bull World Health Organ* 2004;82:724-31.

4. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. *Lancet* 2003;362:1225-30.

5. Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health care. *BMJ* 2001;323:625-8.

6. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655.

7. Flottorp SA, Oxman AD, Krause J, et al. A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. *Implement Sci* 2013;8:35.

8. Baker R, Camosso-Stefinovic J, Gillies C, et al. Tailored interventions to address determinants of practice. *Cochrane Database Syst Rev* 2015;4:CD005470.

9. Gastelurrutia MA, Benrimoj SI, Castrillon CC, et al. Facilitators for practice change in Spanish community pharmacy. *Pharm World Sci* 2009;31:32-9.

- 1  
2  
3 473 10. Moullin JC, Sabater-Hernández D, Benrimoj SI. Model for the evaluation of  
4  
5 474 implementation programs and professional pharmacy services. *Res Social Adm Pharm*  
6  
7 475 2016;12:515-22.  
8  
9  
10 476 11. Sabater-Hernández D, Sabater-Galindo M, Fernandez-Llimos F, et al. A Systematic  
11  
12 477 Review of Evidence-Based Community Pharmacy Services Aimed at the Prevention of  
13  
14 478 Cardiovascular Disease. *J Manag Care Spec Pharm* 2016;22:699-713.  
15  
16  
17 479 12. Mossialos E, Courtin E, Naci H, et al. From "retailers" to health care providers:  
18  
19 480 Transforming the role of community pharmacists in chronic disease management.  
20  
21 481 *Health Policy* 2015;119:628-39.  
22  
23  
24 482 13. Kaae S, Christensen ST. Exploring long term implementation of cognitive services in  
25  
26 483 community pharmacies - a qualitative study. *Pharm Pract (Granada)* 2012;10:151-8.  
27  
28  
29 484 14. Berbatis C, Sunderland V, Joyce A, Bulsara M, Mills C. Enhanced pharmacy services,  
30  
31 485 barriers and facilitators in Australia's community pharmacies: Australia's National  
32  
33 486 Pharmacy Database Project. *Int J Clin Pharm* 2007;15:185-91.  
34  
35  
36 487 15. Roberts A, Benrimoj S, Chen T, et al. Implementing cognitive services in community  
37  
38 488 pharmacy: a review of facilitators used in practice change. *Int J Clin Pharm*  
39  
40 489 2006;14:163-70.  
41  
42  
43 490 16. Gastelurrutia MA, Fernandez-Llimos F, Garcia-Delgado P, et al. Barriers and facilitators  
44  
45 491 to the dissemination and implementation of cognitive services in Spanish community  
46  
47 492 pharmacies *Seguim Farmacoter* 2005;3:65-77.  
48  
49  
50 493 17. Cvetkovski B, Armour C, Bosnic-Anticevich S. Asthma management in rural New South  
51  
52 494 Wales: Perceptions of health care professionals and people with asthma. *Austr J Rural*  
53  
54 495 *Health* 2009;17:195-200.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

18. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home Medicines Review Program: benefits and barriers. *Res Social Adm Pharm* 2012;8:4-16.

19. Gilmartin JF, Marriott JL, Hussainy SY. Exploring factors that contribute to dose administration aid incidents and identifying quality improvement strategies: the views of pharmacy and nursing staff. *Int J Pharm Pract* 2014;22:407-14.

20. Dhillon AK, Hattingh HL, Stafford A, et al. General practitioners' perceptions on home medicines reviews: a qualitative analysis. *BMC Fam Pract* 2015;16:16.

21. Rayes IK, Abduelkarem AR. A qualitative study exploring physicians' perceptions on the role of community pharmacists in Dubai. *Pharm Pract (Granada)* 2016;14:738.

22. Mohammed MA, Moles RJ, Chen TF. Meta-synthesis of qualitative research: the challenges and opportunities. *Int J Clin Pharm* 2016;38:695-704.

23. Walsh D, Downe S. Meta-synthesis method for qualitative research: a literature review. *J Adv Nurs* 2005;50:204-11.

24. Moullin JC, Sabater-Hernández D, Fernandez-Llimos F, Benrimoj SI. Defining professional pharmacy services in community pharmacy. *Res Social Adm Pharm* 2013;9:989-95.

25. Hennink MM, Hutter I, Bailey A. Qualitative research methods. Los Angeles, Calif. ; London: SAGE; 2011.

26. Dixon-Woods M, Shaw RL, Agarwal S, et al. The problem of appraising qualitative research. *Qual Saf Health Care* 2004;13:223-5.

27. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. *BMC Med Res Methodol* 2008;8:1-10.

- 1  
2  
3 519 28. McLeroy KR, Bibeau D, Steckler A, et al. An ecological perspective on health promotion  
4 programs. *Health Educ Quart* 1988;15:351-77.  
5  
6  
7  
8 521 29. Bartholomew LK, Markham CM, Ruiter RAC, Fernández ME, Kok G, Parcel GS.  
9 Planning health promotion programs: An Intervention Mapping approach. 4th ed. San  
10 Francisco, CA: Jossey-Bass; 2016.  
11  
12 523  
13  
14 524 30. Green LW, Kreuter MW. Health program planning: An educational and ecological  
15 approach. 4th ed. Boston: McGraw-Hill; 2005.  
16  
17 525  
18  
19 526 31. Jacomy M, Venturini T, Heymann S, et al. ForceAtlas2, a continuous graph layout  
20 algorithm for handy network visualization designed for the Gephi software. *PloS one*  
21 2014;9:e98679.  
22  
23 527  
24 528  
25  
26 529 32. Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the  
27 synthesis of qualitative research: ENTREQ. *BMC Med Res Methodol* 2012;12:181.  
28  
29 530  
30  
31 531 33. McMillan SS, Sav A, Kelly F, et al. How to attract them and keep them: The pharmacy  
32 attributes that matter to Australian residents with chronic conditions. *Int J Pharm Pract*  
33 2014;22:238-45.  
34  
35 532  
36 533  
37  
38 534 34. Rieck A, Pettigrew S. How physician and community pharmacist perceptions of the  
39 community pharmacist role in Australian primary care influence the quality of  
40 collaborative chronic disease management. *Qual Prim Care* 2013;21:105-11.  
41  
42 535  
43 536  
44  
45 537 35. Barbara S, Krass I. Self management of type 2 diabetes by Maltese immigrants in  
46 Australia: Can community pharmacies play a supporting role? *Int J Pharm Pract*  
47 2013;21:305-13.  
48  
49 538  
50 539  
51  
52 540 36. Bereznicki B, Peterson G, Jackson S, et al. Perceived feasibility of a community  
53 pharmacy-based asthma intervention: A qualitative follow-up study. *J Clin Pharm Ther*  
54 2011;36:348-55.  
55  
56 541  
57 542  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

543 37. Saba M, Dan E, Bittoun R, et al. Asthma and smoking--healthcare needs and  
544 preferences of adults with asthma who smoke. *J Asthma* 2014;51:934-42.

545 38. Shoukry G, Wong K, Bartlett D, et al. Treatment experience of people with obstructive  
546 sleep apnoea seeking continuous positive airways pressure device provision through  
547 community pharmacies: a role for pharmacists? *Int J Pharm Pract* 2011;19:318-27.

548 39. Um IS, Armour C, Krass I, et al. Weight management in community pharmacy: what do  
549 the experts think? *Int J Clin Pharm* 2013;35:447-54.

550 40. Snell L, White L. An exploratory study of the role of emotional intelligence and self-  
551 efficacy on service quality and adherence in a weight loss setting. *Serv Mark Q*  
552 2011;32:228-46.

553 41. Maher JH, Hughes R, Anderson C, et al. An exploratory investigation amongst  
554 Australian mothers regarding pharmacies and opportunities for nutrition promotion.  
555 *Health Educ Res* 2013;28:1040-50.

556 42. Mey A, Knox K, Kelly F, et al. Trust and safe spaces: Mental health consumers' and  
557 carers' relationships with community pharmacy staff. *Patient* 2013;6:281-9.

558 43. Hattingh HL, Knox K, Fejzic J, et al. Privacy and confidentiality: perspectives of mental  
559 health consumers and carers in pharmacy settings. *Int J Pharm Pract* 2015;23:52-60.

560 44. Clark A, Gilbert A, Rao D, et al. 'Excuse me, do any of you ladies speak English?'  
561 Perspectives of refugee women living in South Australia: barriers to accessing primary  
562 health care and achieving the Quality Use of Medicines. *Aust J Prim Health* 2014;20:92-  
563 7.

564 45. O'Connor M, Fisher C, French L, et al. Exploring the community pharmacist's role in  
565 palliative care: Focusing on the person not just the prescription. *Patient Educ Couns*  
566 2011;83:458-64.

46. Carter SR, Moles R, White L, et al. Exploring patients' motivation to participate in Australia's Home Medicines Review program. *Int J Clin Pharm* 2012;34:658-66.
47. Lee CY, George J, Elliott RA, et al. Exploring stakeholder perspectives on medication review services for older residents in retirement villages. *Int J Pharm Pract* 2012;20:249-58.
48. White L, Klinner C. Medicine use of elderly Chinese and Vietnamese immigrants and attitudes to home medicines review. *Aust J Prim Health* 2012;18:50-5.
49. Swain L, Barclay L. They've given me that many tablets, I'm bushed: I don't know where I'm going: Aboriginal and Torres Strait Islander peoples' experiences with medicines. *Austr J Rural Health* 2013;21:216-9.
50. Du Pasquier S, Aslani P. Concordance-based adherence support service delivery: Consumer perspectives. *Pharm World Sci* 2008;30:846-53.
51. Bui J, Day C, Hanrahan J, et al. Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. *Drug Alcohol Rev* 2014;34:495-8.
52. Van C, Krass I, Mitchell B. General practitioner perceptions of extended pharmacy services and modes of collaboration with pharmacists. *J Pharm Pract Res* 2007;37:182-6.
53. Van C, Mitchell B, Krass I. General practitioner-pharmacist interactions in professional pharmacy services. *J Interprof Care* 2011;25:366-72.
54. Dey RM, De Vries MJW, Bosnic-Anticevich S. Collaboration in chronic care: Unpacking the relationship of pharmacists and general medical practitioners in primary care. *Int J Pharm Pract* 2011;19:21-9.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

590 55. Chong WW, Aslani P, Chen TF. Multiple perspectives on shared decision-making and  
591 interprofessional collaboration in mental healthcare. *J Interprof Care* 2013;27:223-30.

592 56. Cheong LH, Armour CL, Bosnic-Anticevich SZ. Multidisciplinary collaboration in primary  
593 care: Through the eyes of patients. *Aust J Prim Health* 2013;19:190-7.

594 57. Bajramovic J, Emmerton L, Tett SE. Perceptions around concordance--focus groups  
595 and semi-structured interviews conducted with consumers, pharmacists and general  
596 practitioners. *Health Expect* 2004;7:221-34.

597 58. McMillan SS, Emmerton L. Nurse practitioners: an insight into their integration into  
598 Australian community pharmacies. *Res Social Adm Pharm* 2013;9:975-80.

599 59. Roberts AS, Benrimoj SI, Chen TF, et al. Understanding practice change in community  
600 pharmacy: a qualitative study in Australia. *Res Social Adm Pharm* 2005;1:546-64.

601 60. Roberts AS, Benrimoj SI, Chen TF, et al. Practice change in community pharmacy:  
602 quantification of facilitators. *Ann Pharmacother* 2008;42:861-8.

603 61. Alonso-Perales MD, Lasheras B, Beitia G, et al. Barriers to promote cardiovascular  
604 health in community pharmacies: a systematic review. *Health Prompt Int* 2015:1-14.

605 62. Lowres N, Krass I, Neubeck L, et al. Atrial fibrillation screening in pharmacies using an  
606 iPhone ECG: a qualitative review of implementation. *Int J Clin Pharm* 2015;37:1111-20.

607 63. Hughes CM, Cadogan CA, Ryan CA. Development of a pharmacy practice intervention:  
608 lessons from the literature. *Int J Clin Pharm* 2015;38:601-6.

609 64. McKenzie JF, Neiger BL, Thackeray R. Planning, implementing, and evaluating health  
610 promotion programs: a primer. 6th ed. San Francisco, CA: Pearson - Benjamin  
611 Cummings; 2013.

- 612 65. Franco-Trigo L, Hossain LN, Durks D, et al. Stakeholder analysis for the development of  
613 a community pharmacy service aimed at preventing cardiovascular disease. *Res Social*  
614 *Adm Pharm* Epub 2016 Jun 30.
- 615 66. Sabater-Hernández D, Moullin JC, Hossain LN, et al. Intervention mapping for  
616 developing pharmacy-based services and health programs: A theoretical approach. *Am*  
617 *J Health Syst Pharm* 2016;73:156-64.
- 618 67. Krause J, Van Lieshout J, Klomp R, et al. Identifying determinants of care for tailoring  
619 implementation in chronic diseases: an evaluation of different methods. *Implement Sci*  
620 2014;9:102.
- 621 68. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for  
622 characterising and designing behaviour change interventions. *Implement Sci* 2011;6:42.
- 623 69. Durks D, Fernandez-Llimos F, Hossain LN, Franco-Trigo L, Benrimoj SI, Sabater-  
624 Hernández D. Use of Intervention Mapping to enhance healthcare professional practice:  
625 a systematic review. *Health Educ Behav* *Forthcoming* 2017.
- 626 70. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques.  
627 *Int J Clin Pharm* 2016;38:655-62.


628

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

629  
  
630  
631  
632




For peer review only



254x190mm (300 x 300 DPI)

| Appendix 1. Search strategy and key words used in database search |  |
|---|--|
| Database  | Search strategy and keywords   |
| PubMed  | ((opinion OR opinions) OR (view or views) OR (attitude or attitudes) OR (experience OR experiences) OR satisfaction OR (motivation or motivations) OR (perception OR perceptions) OR (preference OR preferences) OR “Attitude to Health”[MH] OR awareness[TW] OR (barrier OR barriers) OR (facilitator or facilitators)) AND (pharmacy OR pharmacies OR pharmacist OR pharmacists) AND (“Interviews as Topic”[MH] OR “Empirical Research”[MH] OR semi-structured OR qualitative OR (“Focus Groups”[TW] OR “focus group”)) AND Australia[TIAB]  |
| Scopus  | ((((TITLE-ABS-KEY (opinion OR opinions)) OR (TITLE-ABS-KEY (view OR views) ) OR (TITLE-ABS-KEY (attitude OR attitudes)) OR (TITLE-ABS-KEY (experience OR experiences)) OR (TITLE-ABS-KEY (satisfaction)) OR (TITLE-ABS-KEY (motivation OR motivations)) OR (TITLE-ABS-KEY (perception OR perceptions)) OR (TITLE-ABS-KEY ( preference OR preferences)))) OR ((TITLE-ABS-KEY (awareness)) OR (TITLE-ABS-KEY (barrier OR barriers)) OR (TITLE-ABS-KEY (facilitator OR facilitators)) OR (KEY (patient attitude)) OR (KEY (patient satisfaction)) OR (KEY (health personnel attitude)) OR (KEY (patient preference)))) AND ((TITLE-ABS-KEY (pharmacy OR pharmacies)) OR (TITLE-ABS-KEY (pharmacist OR pharmacists))) AND ((KEY (semi structured interview)) OR ( TITLE-ABS-KEY (qualitative)) OR (KEY (qualitative research))) AND (TITLE-ABS-KEY (Australia))) |
| Informit  | Pharmacy AND qualitative   |

## Appendix 2. Relationships between influential elements and resulted network\*



\* Elements' numbers in the figure match with the elements' numbers on table 3 where a full description of each element can be found. The size of the nodes is determined by the number of times (i.e., articles) that each element was reported.

Pat: element at the patient level; Pharm: element at the healthcare professional level (i.e., pharmacist); GP: element at the at the healthcare professional level (i.e., general practitioner); Rel: element related to the relationships (or interactions) between individuals; PhSet: element related to the community pharmacy setting; Serv: element related to the community pharmacy service; Sys: influential element at the community and healthcare system level.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

| Related elements |         | Description of the relationship   |
|------------------|---------|---|
| Pat09            | Pat12   | Patients who did not have a positive experience with CPSs were not motivated to receive future ones <sup>1</sup>  |
| Pat14            | Pat02   | Patients' language issues prevented them from becoming more aware of CPSs <sup>2</sup>  |
| Pat09            | Pharm15 | Patients' previous positive experiences of CPS were related to a suitable knowledge of the pharmacist <sup>3</sup>  |
| Pat09            | Pharm17 | Patients' previous positive experiences of CPS were related to positive humanistic attributes of the community pharmacist (i.e. friendly) <sup>3</sup>                                    |
| Pat09            | Rel33   | Patients' previous positive experiences in the pharmacy contributed to the formation of a closer relationship between the patient and the pharmacist <sup>3</sup>                         |
| Pat13            | Pharm15 | Patients with higher levels of emotional intelligence valued the knowledge and competency of community pharmacists <sup>4</sup>   |
| Pat13            | Pharm17 | Patients with lower levels of emotional intelligence valued the humanistic attributes of the community pharmacist in CPS <sup>4</sup>   |
| Pharm16          | Pat02   | Lack of multilingual community pharmacists prevented awareness of the availability of CPS in some ethnic patients <sup>2</sup>  |
| Pharm17          | Rel33   | The humanistic attributes of the pharmacist (e.g., approachability, sensitivity) shaped the relationships between the patient and the pharmacist <sup>3</sup>                             |
| Pharm17          | Serv47  | The humanistic attributes of the pharmacist (e.g., approachability) created an environment in which patients could ask questions, seek advice and better address their needs <sup>5</sup> |
| GP25             | Sys57   | GPs can see a higher value in CPSs when they address their time limitations <sup>6</sup>  |
| GP25             | Pharm15 | GPs' perceptions and understanding of the role of community   |

|         |        |   |
|---------|--------|---|
|         |        | pharmacists depends on whether pharmacists have received appropriate training and demonstrate suitable health-related knowledge and skills <sup>7</sup>                         |
| Rel38   | Rel34  | GP-Pharmacist combined meetings and training can promote collaborative relationships between the pharmacist and GP <sup>8</sup>   |
| Rel33   | Pat05  | Patients who had an on-going relationship with community pharmacists were more likely to see the value of pharmacists providing health services <sup>3</sup>                    |
| Rel33   | Serv50 | The existence of a relationship between the patient and the pharmacist can determine the success of follow-up mechanisms in the CPS <sup>4</sup>                                |
| Rel35   | GP25   | GPs who experienced a high level of communication with pharmacists saw value in the input pharmacists can make to their practice <sup>8</sup>                                   |
| Rel38   | GP25   | Developing multidisciplinary training with pharmacists and GPs could enhance GPs' understanding and perception of pharmacists' capabilities and role in healthcare <sup>8</sup> |
| PhSet39 | Rel34  | Physical accessibility and co-location of the pharmacy to the GP medical centre can promote collaborative relationships between the pharmacists and GPs <sup>8,9</sup>          |
| PhSet44 | Rel34  | Time constraints of the pharmacist limited the collaboration between the pharmacists and the nurse <sup>10</sup>  |
| Serv47  | Pat09  | When patients perceived that CPS were not patient-centred, they reported negative experiences <sup>3</sup>  |
| Serv47  | Rel33  | CPSs which are patient-centred can contribute to the development of a relationship between the patient and the pharmacist <sup>3,11</sup>                                       |
| Serv52  | Rel33  | Having the same pharmacist delivering the CPS each time can contribute to the development of a relationship between the patient and the pharmacist <sup>1</sup>                 |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

|        |       |  |
|--------|-------|--|
| Serv53 | Sys57 | Involving healthcare providers other than pharmacists (e.g., practice nurses) in the provision/coordination of CPS and related processes can positively influence GP time and workload constraints <sup>12</sup> |
| Sys57  | Rel35 | The workload and time of GPs influence the mode through which they interact and communicate with community pharmacists <sup>9</sup>  |
| Sys58  | GP27  | Complex administrative processes (e.g., tedious paperwork to refer patients to CPS) that require extra time from the GP (Sys57) may affect GPs' willingness to collaborate with CPSs <sup>12</sup>               |
| Sys59  | Rel34 | A system for sharing information can promote collaborative relationships between the pharmacist and GP <sup>8</sup>  |
| Sys60  | Rel34 | The presence of protocols to guide CPS delivery can contribute to improved GP–pharmacist relationships <sup>9</sup>  |

## References

1. Carter SR, Moles R, White L, et al. Exploring patients' motivation to participate in Australia's Home Medicines Review program. *Int J Clin Pharm* 2012;34:658-66.
2. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home Medicines Review Program: benefits and barriers. *Res Social Adm Pharm* 2012;8:4-16.
3. Mey A, Knox K, Kelly F, et al. Trust and safe spaces: Mental health consumers' and carers' relationships with community pharmacy staff. *Patient* 2013;6:281-9.
4. Snell L, White L. An exploratory study of the role of emotional intelligence and self-efficacy on service quality and adherence in a weight loss setting. *Serv Mark Q* 2011;32:228-46.
5. McMillan SS, Emmerton L. Nurse practitioners: an insight into their integration into Australian community pharmacies. *Res Social Adm Pharm* 2013;9:975-80.
6. Chong WW, Aslani P, Chen TF. Multiple perspectives on shared decision-making and interprofessional collaboration in mental healthcare. *J Interprof Care* 2013;27:223-30.
7. Dey RM, De Vries MJW, Bosnic-Anticevich S. Collaboration in chronic care: Unpacking the relationship of pharmacists and general medical practitioners in primary care. *Int J Pharm Pract* 2011;19:21-9.
8. Van C, Krass I, Mitchell B. General practitioner perceptions of extended pharmacy services and modes of collaboration with pharmacists. *J Pharm Pract Res* 2007;37:182-6.
9. Van C, Mitchell B, Krass I. General practitioner-pharmacist interactions in professional pharmacy services. *J Interprof Care* 2011;25:366-72.
10. Bui J, Day C, Hanrahan J, et al. Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. *Drug Alcohol Rev* 2014;34:495-8.
11. McMillan SS, Sav A, Kelly F, et al. How to attract them and keep them: The pharmacy attributes that matter to Australian residents with chronic conditions. *Int J Pharm Pract* 2014;22:238-45.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

12. Dhillon AK, Hattingh HL, Stafford A, et al. General practitioners' perceptions on home medicines reviews: a qualitative analysis. *BMC Fam Pract* 2015;16:16.

For peer review only

| <b>Assessment of the synthesis of qualitative research using the ENTREQ Statement for enhancing transparency in reporting the synthesis of qualitative research</b> |                                 |
|---|---------------------------------|
| <b>Item</b>   | <b>Page number</b>              |
| Aim   | 7                               |
| Synthesis methodology   | 8                               |
| Approach to searching   | 7-8                             |
| Inclusion criteria  | 7-8                             |
| Data sources  | 7                               |
| Electronic Search strategy  | Appendix 1 (Supplementary file) |
| Study screening methods   | 7-8                             |
| Study characteristics   | 12 (table 2)                    |
| Study selection results   | Figure 1                        |
| Rationale for appraisal   | 8                               |
| Appraisal items   | 8                               |
| Appraisal process   | 8                               |
| Appraisal results   | 10                              |
| Data extraction   | 8-9                             |
| Software  | 9                               |
| Number of reviewers   | 8-9                             |
| Coding  | 8-9                             |
| Study comparison  | 8                               |
| Derivation of themes  | 8-9                             |
| Quotations  | Not in this version             |
| Synthesis output  | 18 (table 3)                    |

# BMJ Open

## A qualitative meta-synthesis of barriers and facilitators that influence the implementation of community pharmacy services: perspectives of patients, nurses and general medical practitioners

|                                 |   |
|---------------------------------|---|
| Journal:                        | <i>BMJ Open</i>   |
| Manuscript ID                   | bmjopen-2016-015471.R2  |
| Article Type:                   | Research  |
| Date Submitted by the Author:   | 13-Jul-2017   |
| Complete List of Authors:       | Hossain, Lutfun; University of Technology Sydney<br>Fernandez-Llimos, Fernando; Universidade de Lisboa<br>Lockett, Tim; University of Technology Sydney<br>Moullin, Joanna; University of California San Diego<br>Durks, Desire; University of Technology Sydney<br>Franco-Trigo, Lucia; University of Technology Sydney<br>Benrimoj, Charlie; University of Technology, Sydney<br>Sabater-Hernandez, Daniel; University of Technology Sydney |
| <b>Primary Subject Heading</b>: | Health services research  |
| Secondary Subject Heading:      | Qualitative research  |
| Keywords:                       | Community pharmacy services, health service research, qualitative meta-synthesis, barriers, facilitators, determinants of practice  |
|                                 |   |

SCHOLARONE™  
Manuscripts

1

2

3

4 1 **A qualitative meta-synthesis of barriers and facilitators that influence the implementation**

5

6 2 **of community pharmacy services: perspectives of patients, nurses and general medical**

7

8 3 **practitioners**

9

10

11 4 **Authors:**

12

13

14

15 5 **Lutfun N. Hossain.** BPharm. Master Student; Graduate School of Health, University of

16 6 Technology, Sydney, Australia. Email: [Lutfun.Hossain@student.uts.edu.au](mailto:Lutfun.Hossain@student.uts.edu.au)

17

18

19

20 7 **Fernando Fernandez-Llimos.** PharmD, PhD. Assistant Professor; Research Institute for

21 8 Medicines, Department of Social Pharmacy, Faculty of Pharmacy, University of Lisbon,

22 9 Portugal. Email: [f-llimos@ff.ul.pt](mailto:f-llimos@ff.ul.pt)

23

24

25

26

27

28 10 **Tim Luckett.** BSc (Hons), PhD. Senior Lecturer; Faculty of Health, University of Technology

29 11 Sydney, Australia Email: [Tim.Luckett@uts.edu.au](mailto:Tim.Luckett@uts.edu.au)

30

31

32

33 12 **Joanna C. Moullin.** BPharm. PhD; Research Fellow; Department of Psychiatry, University of

34 13 California, San Diego (USA). Email: [jcmoullin@gmail.com](mailto:jcmoullin@gmail.com)

35

36

37

38 14 **Desire Durks.** BPharm. Master Student; Graduate School of Health, University of Technology,

39 15 Sydney, Australia. Email: [desire.durks@student.uts.edu.au](mailto:desire.durks@student.uts.edu.au)

40

41

42

43 16 **Lucia Franco-Trigo.** MPharm. PhD Student; Graduate School of Health, University of

44 17 Technology, Sydney, Australia. Email: [lucia.francotrigo@student.uts.edu.au](mailto:lucia.francotrigo@student.uts.edu.au)

45

46

47

48

49 18 **Charlie Benrimoj.** PharmD, PhD. Head of School; Graduate School of Health, University of

50 19 Technology, Sydney, Australia. Email: [shalom.benrimoj@uts.edu.au](mailto:shalom.benrimoj@uts.edu.au)

51

52

53

54 20 **Daniel Sabater-Hernández.** PharmD, PhD. Chancellor's Postdoctoral Research Fellow;

55 21 Graduate School of Health, University of Technology, Sydney, Australia. Fellow; Academic

56

57

58

59

60



22 Centre in Pharmaceutical Care, University of Granada, Spain. Email:

23 [daniel.sabaterhernandez@uts.edu.au](mailto:daniel.sabaterhernandez@uts.edu.au); daniel.sabaterhernandez@outlook.com

24 **Corresponding author: Daniel Sabater-Hernández**

25 Graduate School of Health, University of Technology Sydney.

26 Level 4, Building 7, 67 Thomas St, Ultimo (PO Box 123)

27 Phone: +61 2 9514 7201; Email: daniel.sabaterhernandez@uts.edu.au;

28 [daniel.sabaterhernandez@outlook.com](mailto:daniel.sabaterhernandez@outlook.com)

29 **Word count (excluding title page, abstract, references, figures and tables): 4263**

30 **ABSTRACT**

31 **Objectives:** The integration of community pharmacy services (CPSs) into primary care practice  
32 can be enhanced by assessing (and further addressing) the elements that enable (i.e.,  
33 facilitators) or hinder (i.e., barriers) the implementation of such CPSs. These elements have  
34 been widely researched from the perspective of pharmacists but not from the perspectives of  
35 other stakeholders who can interact with, and influence the implementation of CPSs. The aim of  
36 this study was to synthesise the literature on patients', general practitioners' (GPs) and nurses'  
37 perspectives of CPSs to identify barriers and facilitators to their implementation in Australia.

38 **Methods:** A meta-synthesis of qualitative studies was performed. A systematic search in  
39 PubMed, Scopus and Informit was conducted to identify studies that explored patients', GPs' or  
40 nurses' views about CPSs in Australia. Thematic synthesis was performed to identify elements  
41 influencing CPS implementation, which were further classified using an ecological approach.

42 **Results:** Twenty nine articles were included in the review, addressing sixty three elements  
43 influencing CPS implementation. Elements were identified as a barrier, facilitator or both, and  
44 were related to four ecological levels: individual patient (n=14); interpersonal (n=24);  
45 organizational (n=16); and community and healthcare system (n=9). It was found that patients,  
46 nurses and GPs identified elements reported in previous pharmacist-informed studies, such as  
47 pharmacist's training/education or financial remuneration, but also new elements, such as  
48 patients' capability to follow service's procedures, the relationships between GP and pharmacy  
49 professional bodies, or the availability of multidisciplinary training/education.

50 **Conclusions:** Patients, GPs and nurses can describe a large number of elements influencing  
51 CPS implementation. These elements can be combined with previous findings in pharmacists-  
52 informed studies to produce a comprehensive framework to assess barriers and facilitators to

CPS implementation. This framework can be used by pharmacy service planners and policy makers to improve the analysis of the contexts in which CPSs are implemented.

## KEY WORDS

Community pharmacy services [MeSH]; health service research [MeSH]; qualitative meta-synthesis; barriers; facilitators; determinants of practice.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The particular method chosen for this review (i.e., qualitative meta-synthesis) is aimed at synthesising qualitative literature and so enabled a rich description of the barriers and facilitators perceived by GPs, patients and nurses that can influence the implementation of CPSs in Australia.
- A systematic search was conducted in three comprehensive electronic databases (i.e., PubMed, Scopus and Informit), one of which (i.e., Informit) is particularly relevant to the specific context where the results will be applied.
- The papers included in this review were not restricted by the time at which they were published, since the aim of the study was to include all relevant papers that can inform about any influential element that has been noted in practice.
- A set of quality appraisal criteria was used to appraise all the studies included in this review to ensure minimal quality.
- Qualitative meta-synthesis was conducted by one researcher according to a three-stage method for thematic synthesis.
- This review was restricted to a specific implementation context (i.e., Australia), to which its results are directly relevant and will be immediately applied and actions will be taken.

**INTRODUCTION**

The implementation of new health interventions and services into established healthcare practices and systems has been found to be challenging.<sup>1-4</sup> The inherent complexity of both health services and healthcare systems may be fundamental to the implementation problem.<sup>5, 6</sup> According to current health planning approaches, the implementation of health services can be enhanced by comprehensively assessing the context in which they will be delivered. Analysis of the context should consider the stakeholders who can influence or be affected by the health service, as well as the social, physical, economic and policy environments that can enable or hinder the normalization of the service.<sup>2, 7</sup> Early identification of these elements (including how they relate to or interact with each other) is a key step for developing suitable strategies and interventions to enhance health service implementation.

In the implementation science literature, several terms are used to refer to the elements that can influence service implementation and practice change. Some generally known examples, which are commonly used interchangeably in the literature,<sup>8</sup> are: barriers and facilitators,<sup>9</sup> determinants of practice;<sup>7</sup> implementation factors;<sup>10</sup> or constructs.<sup>2</sup> The current use of these terms encloses different concepts. For the purpose of this review and to avoid the terminological debate we have used the term 'influential element' as a neutral term.

Amid increasing awareness of the uniqueness of the community pharmacy setting and the positive contribution pharmacists can make to healthcare,<sup>11</sup> there has been a shift towards pharmacists providing more professional, patient-centred services. However the implementation and sustainability of community pharmacy services (CPSs) and the integration of community pharmacists into primary healthcare teams remains a challenge worldwide.<sup>12, 13</sup> In consistence with this international trend, Australian community pharmacies are eager to provide CPSs, receive remuneration from the government for its provision, but are experiencing challenges in the implementation, uptake and sustainability of CPSs.<sup>14</sup> Extensive research has

been conducted to identify the elements that from the perspective of community pharmacists (i.e., service provider) can influence the implementation of CPSs.<sup>14-16</sup> However, considering the view of a single stakeholder group is insufficient to comprehensively analyse the complexity of a particular implementation context. These limited analyses can lead to the development of inadequate implementation strategies and interventions. Patients, general practitioners (GPs), and primary care nurses are key stakeholders who interact with or are affected by CPSs and may be able to strongly influence the implementation of such services. These stakeholders may have their own particular views about CPSs and so can complement the findings from previous pharmacy-informed research.<sup>14, 15</sup> Patients', nurses' and GPs' views and experiences regarding CPSs have been explored in several qualitative studies<sup>17-21</sup> but no review that collates and analyses such information exists. Qualitative meta-synthesis aims to synthesise qualitative literature to provide a new, more comprehensive interpretation of the findings that goes beyond the depth and breadth of the original studies and to broaden the range of concepts identified.<sup>22, 23</sup> Thus, the aim of this study was to synthesise such qualitative literature to describe the broad range of elements that, from the patients', GPs' and nurses' perspectives, can hinder or enable the implementation of CPSs in Australia.

## METHODS

**Search strategy, screening and eligibility criteria.** A systematic search was conducted in May 2015 in three electronic databases (i.e., PubMed, Scopus and Informit), without time limits, to identify qualitative studies addressing patients', nurses' or GPs' views about CPSs in Australia. A CPS was assumed to refer to an action or set of actions delivered in or organised by a community pharmacy to optimise the process of care, with the aim of improving health outcomes and the value of healthcare.<sup>24</sup> For the purpose of this review, CPSs are specific health programs that are implemented in addition to routine professional activities performed by community pharmacists, which do not require any specific or extra implementation effort (i.e.,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

they are part of normal community pharmacy practice). Since medicines dispensing is the main routine activity in the community pharmacy, it was not considered as a CPS and so excluded. Articles that did not address a specific CPS but inter-professional collaboration (i.e. between community pharmacists and other healthcare professionals) were included as they can also provide insight into the elements influencing the implementation of CPSs. Full search strategies are available on Appendix 1 (Supplementary File). In addition, the references from the included papers were searched manually for additional relevant studies. A two-step process was performed by one researcher to select studies for the analysis. As a first step, titles and abstracts were screened to identify and exclude non-relevant literature. In a second, full texts of the remaining articles were reviewed to exclude those that: (1) were not related to CPSs; (2) did not address patient, nurse and/or GP perspective; (3) did not use qualitative research methodology;<sup>25</sup> (4) did not clearly identify the stakeholder (i.e., patient, nurse or GP) as the source of the information; and (5) were not accessible in any of the research team university libraries, or unattainable following contact with the authors.

All the included articles were checked by the same researcher for 'elementary quality assessment' using the first three criteria delineated by Dixon-Woods et al<sup>26</sup> to appraise qualitative research: (1) was the research question clear? (2) Was the research questions suited to qualitative inquiry? (3) Were (a) sampling, (b) data collection, and (c) analysis clearly described? Articles were excluded when no answer, or an unclear answer, was given to at least one of the three questions.

**Synthesis.** Qualitative meta-synthesis was conducted by one researcher according to the three-stage method for thematic synthesis described by Thomas et al<sup>27</sup> The first stage of analysis involved free line-by-line coding of the original data (study participants' quotes) and the study authors' interpretation of the original data. The process of coding involves summarising text from the results and discussion sections of each article into one or more descriptive issues

(i.e. codes) to capture meaning. The second stage of the process involved grouping codes into one or more descriptive themes. Subsequent articles were coded into pre-existing themes, and new themes were created when considered necessary. To simplify the terminology throughout this article, themes were interpreted as elements (i.e., influential elements) that could positively (i.e., facilitators) or negatively (i.e., barriers) influence CPS implementation or practice change. A barrier was defined as *"any type of obstacle (material or immaterial) which can impede the dissemination, implementation and/or sustainability of a CPS"*; while a facilitator was defined as *"any type of element (material or immaterial) which can help to overcome barriers and/or accelerate the dissemination or implementation"* of a CPS.<sup>16</sup> Themes that were related to similar issues were further grouped to create one broad barrier or facilitator. The identified influential elements were reviewed by a second researcher to assess clarity, consistency, and understanding. At the third stage, barriers and facilitators were organised using an adapted version of the Ecological Model (Table 1),<sup>28</sup> which classified them into four different levels: patient, interpersonal, organisational, and community/system. The four levels defined in Table 1 were used as an overarching structure, with further sub-headings created during analysis, for appropriate allocation and organisation of the influential elements into the levels. The ecological model has been widely and successfully used for planning services in a variety of settings, targeting different populations and problems.<sup>29, 30</sup> Coding of papers that were identified manually was conducted last. NVivo Version 10 software (QSR International Pty Ltd; Australia) was used to help manage and analyse the data. Once all the influential elements were identified, a second round of analysis was conducted to identify where a connection or relationship was mentioned between two or more elements. Again, both study participants' quotes and study authors' data interpretation were reviewed for this purpose. A network representing the identified relationships was generated using a ForceAtlas2 layout<sup>31</sup> with Gephi, 0.8. This article has been written following existing guidelines for reporting the synthesis of qualitative research (the ENTREQ Statement).<sup>32</sup>



|   |  |
|---|--|
| Table 1. Levels where elements that can influence the implementation of community pharmacy services can exist (adapted from McLeroy et al <sup>28</sup> ) |  |
| Individual patient  | Influential elements related to the personal characteristics and ideas concerning individual patients (i.e., individual determinants), such as their knowledge, beliefs and skills, that can affect their utilisation of community pharmacy services.  |
| Interpersonal   | Influential elements related to the healthcare providers and non-healthcare personnel (i.e., individual determinants) who are involved with the community pharmacy service and with whom patients associate (e.g., family, friends, pharmacists, pharmacy assistants, GPs, nurses) and the formal and informal relationships between patients and healthcare professionals and healthcare professionals with other healthcare professionals. |
| Organisational  | Influential elements related to characteristics of the community pharmacy setting and their decision processes, and attributes of the community pharmacy service that can influence the success of implementation.   |
| Community and system  | Influential elements related to the larger society (i.e., environmental determinants), which consists of collectives of people in a geographical location, the relationships between organisations, the political players in the system and the rules, regulations and policies that have the power to control and/or influence the implementation of services.  |

RESULTS

The systematic and manual search identified 243 articles once duplicates were removed. After title and abstract screening, 124 full-text articles were assessed for eligibility of which 29 articles were included in the qualitative meta-synthesis (all of them fulfilled the appraisal criteria) (Figure 1). A description of the papers included in the review can be found in Table 2. Of the 29 included papers, 15 addressed patients' perspectives only, 2 addressed nurses' perspectives only, 6 addressed GPs' perspectives only, 2 addressed nurses' and GPs' perspectives together,



1  
2  
3 184 3 addressed patients' and GPs' perspectives together and 1 addressed the views of all three  
4  
5 185 participants. Twenty-three articles were related to a specific CPS, 2 were related specifically to  
6  
7 186 inter-professional collaboration, 3 were related to both CPSs and inter-professional  
8  
9 187 collaboration, and 1 addressed concordance-based healthcare. The articles employed semi-  
10  
11 188 structured interviews (n=23), and/or focus groups (n=11) as methods of data collection.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 2. General description of the articles included in the qualitative meta-synthesis

| Study                           | Description of participants  |    |   |    | Service explored/assessed topic  | Method |
|---------------------------------|--|----|---|----|--|--------|
|                                 | (n)  | Pt | N | GP |  |        |
| McMillan et al <sup>33</sup>    | Patients with a chronic condition, diverse culture and socioeconomic background from three geographical locations in Queensland (Logan-Beaudesert and Mount Isa), New South Wales (Northern Rivers) and Western Australia (Greater Perth) (n=89) | X  |   |    | Disease management and Medication management (i.e., chronic management service)                    | SSI    |
| Rieck & Pettigrew <sup>34</sup> | GPs working in practices in low, medium or high socioeconomic status suburbs across Perth (Western Australia) (n=22)   |    |   | X  | Disease management (i.e., chronic disease management service) and inter-professional collaboration | SSI    |
| Barbara et al <sup>35</sup>     | Patients who are immigrants of Maltese ethnicity, residing in Australia, with a confirmed diagnosis of T2DM, >50 years of  | X  |   |    | Disease management and Medication management (i.e., diabetes self-                                 | SSI    |

|                                |  |   |  |   |   |     |
|--------------------------------|--|---|--|---|---|-----|
|                                | age, able to adequately communicate verbally in English or Maltese, located in Sydney (n=24)   |   |  |   | management service)   |     |
| Bereznicki et al <sup>36</sup> | Patients (n=6) and GPs (n=10) previously involved in a community pharmacy based asthma intervention, in Tasmania   | X |  | X | Disease management (i.e., Asthma management service)                          | SSI |
| Cvetkovski et al <sup>17</sup> | Patients >18 years of age with a diagnosis of asthma (n=10); and GPs in small rural centres (n=8), from different locations based on the Australian Standard Geographical Classification                 | X |  | X | Disease management (i.e., Asthma management service)                          | SSI |
| Saba et al <sup>37</sup>       | Patients >18 year of age, English speaking, current smoker, medical diagnosis of asthma and/or any other condition alongside asthma in Sydney Central Business District and South Western suburbs (n=24) | X |  |   | Disease management (i.e., smoking cessation service for patients with asthma) | SSI |
| Shoukry et al <sup>38</sup>    | Patients who had bought/hired/trialled a Continuous Positive Airway Pressure machine (or accessories) through their pharmacy in the previous 12 months in the greater Sydney region (n=20)               | X |  |   | Disease management (i.e., obstructive sleep apnoea services)                  | SSI |

|                              |  |   |  |   |  |        |
|------------------------------|--|---|--|---|--|--------|
| Um et al <sup>39</sup>       | GPs with large expertise in weight management (n=3)  |   |  | X | Disease management (i.e., weight management service)                             | SSI    |
| Snell et al <sup>40</sup>    | Patients >18 years of age, English speaking, enrolled in a specific weight loss program for >2 weeks from different urban and regional suburbs in Sydney (n=20)  | X |  |   | Disease management (i.e., weight management service)                             | SSI    |
| Maher et al <sup>41</sup>    | Women who have at least one child <5 years old are able to read and speak English from different locations based on Australian Standard Geographical Classification (n=28)                                 | X |  |   | Condition management (i.e., Maternal nutrition service)                          | SSI    |
| Mey et al <sup>42</sup>      | Patients living independently, experiencing a mild to moderate mental illness (and carers) in Queensland, New South Wales and Western Australia (n=74*)  | X |  |   | Medication management (i.e., service for patients with mental health conditions) | FG/SSI |
| Hattingh et al <sup>43</sup> | Patients with a mental health condition (and carers) (n=74*) and healthcare professionals (n=13) located in urban, regional, rural and remote regions in Queensland, New South Wales and Western Australia | X |  |   | Disease management (i.e., service for patients with mental health conditions)    | FG/SSI |

|                              |  |   |   |   |   |        |
|------------------------------|--|---|---|---|---|--------|
| Clark et al <sup>44</sup>    | Refugee women (n=38)**   | X |   |   | Medication management (i.e., primary healthcare service)  | FG     |
| O'Connor et al <sup>45</sup> | Palliative care nurses working in community-based palliative care, residential aged care adopting a palliative approach or working in a dedicated hospice or palliative care unit in a hospital (n=44); and practising GPs (n=10), in Australian metropolitan and regional areas |   | X | X | Disease management and medication management (i.e., services to community-based palliative care patients) | FG/SSI |
| Carter et al <sup>46</sup>   | Patients who are English, Mandarin or Arabic speaking, who had received a home medicines review service within the last 6 months or had not received such a service but were eligible for it, in metropolitan or rural areas in Australia (n=80)                                 | X |   |   | Medication management (i.e., home medicines review)   | FG     |
| Lee et al <sup>47</sup>      | Patients living in retirement villages in Victoria who were using prescribed medicines (n=25); GPs (n=9) and nurses (n=1) with experience with home medicines review services and/or providing care to retirement-village residents.   | X | X | X | Medication management (i.e., home medicines review)   | FG/SSI |
| White et al <sup>48</sup>    | Patients of Chinese or Vietnamese origin who   | X |   |   | Medication management (i.e., home   | FG     |

|                                    |  |   |   |   |   |     |
|------------------------------------|--|---|---|---|---|-----|
|                                    | had never received a home medicines review service but were eligible for it, in two suburban areas in Sydney (n=17)  |   |   |   | medicines review)   |     |
| White et al <sup>18</sup>          | Patients who had received a home medicines review service in the past 6 months or who had never received such a service but were eligible for it, in New South Wales, Victoria, Queensland and South Australia (n=77)  | X |   |   | Medication management (i.e., home medicines review)                                 | FG  |
| Dhillon et al <sup>20</sup>        | GPs practising in metropolitan medical centres in Perth (n=24)   |   |   | X | Medication management (i.e., home medicines review)                                 | SSI |
| Swain et al <sup>49</sup>          | Patients taking multiple medications, with a reasonable understanding of English and linked to an Aboriginal Health Service in urban, regional, rural and remote settings in Queensland, Northern Territory, South Australia, New South Wales and Victoria (n=101) | X |   |   | Medication management (i.e., service aimed at enhance the quality use of medicines) | FG  |
| Du Pasquier & Aslani <sup>50</sup> | Patients >18 years of age, fluent in English, taking one prescription medication on a daily basis in Sydney (n=22)   | X |   |   | Medication management (i.e., adherence support service)                             | SSI |
| Gilmartin et                       | Nurses who worked at residential aged care   |   | X |   | Medication management (i.e., dose   | FG  |

|                           |  |   |   |   |  |     |
|---------------------------|--|---|---|---|--|-----|
| al <sup>19</sup>          | facilities and used dose administration aids in Victoria (n=5)   |   |   |   | administration aids service)   |     |
| Bui et al <sup>51</sup>   | Nurses working in public, opioid substitution therapy clinics in NSW (n=9)                                 |   | X |   | Disease management (i.e., opioid substitution therapy services)  | SSI |
| Van et al <sup>52</sup>   | GPs practising in private/medical/specialised settings in rural/suburb/city areas in Sydney (n=23)         |   |   | X | Inter-professional collaboration in the context of disease management and medication management (i.e., professional pharmacy services)   | SSI |
| Van et al <sup>53</sup>   | GPs in metropolitan and rural areas in New South Wales (n=15)**  |   |   | X | Inter-professional collaboration in the context of a disease management (i.e., diabetes medication assistance service) and medication management (i.e., home medicines review service) | SSI |
| Dey et al <sup>54</sup>   | GPs working in Western Sydney (n=7)**  |   |   | X | Inter-professional collaboration in the context of disease management (i.e., asthma management services)   | SSI |
| Chong et al <sup>55</sup> | GPs (n=4) and nurses (n=7) working with mental health consumers in a healthcare setting in New South Wales |   | X | X | Inter-professional collaboration in the context of disease management (i.e., mental health services)   | SSI |
| Cheong et                 | Patients >18 years of age, English speaking,   | X |   |   | Inter-professional collaboration in the  | SSI |

|   |  |   |  |   |   |        |
|---|--|---|--|---|---|--------|
| al <sup>56</sup>  | with a diagnosis of asthma, in inner-west Sydney metropolitan region (n=16)                |   |  |   | context of disease management (i.e., asthma management service)     |        |
| Bajramovic et al <sup>57</sup>  | Patients >18 years of age, taking at least one medication (n=7) and GPs (n=10) in Brisbane | X |  | X | Medication management (i.e., concordance based healthcare services) | FG/SSI |
| GP: General Practitioner; N: Nurse; Pt: Patient; SSI: Semi-structured interview; FG: Focus Group;<br>* Total number of patients and carers. Opinions of carers were clearly differentiated in the article and excluded from this review.<br>** No further description of participants was provided in the paper |  |   |  |   |   |        |

189



During the first stage of data extraction, 181 patient, 30 nurse and 91 GP codes were created. At the completion of the coding process, 63 influential elements were identified (Table 3). These elements were found to exist as a barrier, facilitator or both. In several studies patients, nurses and GPs were able to describe approaches or strategies to overcome specific barriers.<sup>17-20, 33-36, 39, 41, 43, 47, 51, 52, 57</sup> These strategies have been reported in Table 3 as additional facilitators (marked with an asterisk). During coding of the manually identified papers, it seemed that conceptual saturation may have been reached, since no new barriers or facilitators were identified.

|   |   |   |
|---|---|---|
| Table 3. Elements that can hinder (i.e., barrier) or enable (i.e., facilitator) the implementation of community pharmacy services as identified by patients, general practitioners and nurses |   |   |
|   | Effect on implementation and source of information (i.e., stakeholder)    |   |
|   | Barrier <sup>‡</sup>  | Facilitator <sup>†</sup>  |
| <i>Elements at the individual patient level</i>   |   |   |
| 1. Patients’ real or perceived need for healthcare (according to patients’ individual concerns, understanding or perception of their health problems).  | Pt <sup>18, 46, 47, 55, 56, GP<sup>17</sup></sup>                         | Pt <sup>18, 33, 35, 36, 41, 46, 48, 56, 57, N<sup>51, GP<sup>17</sup></sup></sup> |
| 2. Patients’ awareness of the availability of CPS   | Pt <sup>33, 47, 48, GP<sup>20, 47</sup></sup>                             |   |
| 3. Patient personal desire or preference for CPSs   |   | Pt <sup>41, 46, 48, 56</sup>  |
| 4. Patients’ understanding, perceptions and expectations of their own role in the CPS   | Pt <sup>36, 50, 56</sup>  | Pt <sup>17, 36, 56</sup>  |
| 5. Patients’ understanding, perceptions and expectations of the role of community pharmacists in healthcare   | Pt <sup>17, 18, 35, 36, 41, 42, 56, N<sup>51, GP<sup>20</sup></sup></sup> | Pt <sup>35, 37, 38, 41, 42, 50, 56</sup>  |
| 6. Patients’ understanding, perceptions and expectations of the role of the GP associated to the CPS  | Pt <sup>35, 36, 46-50, 56</sup>   |   |
| 7. Patients’ understanding, perceptions and expectations of collaboration between healthcare professionals  | Pt <sup>56</sup>  | Pt <sup>56</sup>  |

|   |   |   |
|---|---|---|
| 8. Patients' availability, time to participate in CPSs  | Pt <sup>33, 40</sup>                            | Pt <sup>40, 56</sup>  |
| 9. Patients' previous/background experiences with CPSs and multidisciplinary care   | Pt <sup>41, 42, 47, 56</sup>                    | Pt <sup>38, 42, 46, 47, 49, 56</sup>                                  |
| 10. Patient abilities; i.e., to follow the procedures of the CPS or to self-manage their health problems                      | Pt <sup>40, 56</sup> ; GP <sup>36, 52, 54</sup> | Pt <sup>37, 40, 48</sup>  |
| 11. Patients' satisfaction with the delivered CPSs and multidisciplinary care   |   | Pt <sup>36, 38, 40, 42, 46</sup> ; N <sup>51</sup>                    |
| 12. Patients' motivation towards CPSs   | Pt <sup>46</sup>                                | Pt <sup>37, 40, 46</sup>  |
| 13. Patients' level of emotional intelligence; i.e. ability to cope with negative experiences.                                | Pt <sup>40</sup>                                | Pt <sup>40</sup>  |
| 14. Patients' language, communication and cultural issues   | Pt <sup>44, 48</sup> ; GP <sup>20</sup>         |   |
| <i>Elements at interpersonal level</i>  |   |   |
| <i>a. Individual healthcare professionals (sub-level)</i>   |   |   |
| <i>a.1. Community pharmacist</i>  |   |   |
| 15. Knowledge, expertise, clinical and non-clinical skills (e.g. cultural competency) to adequately provide CPSs              | Pt <sup>42</sup> ; GP <sup>34, 52</sup>         | Pt <sup>18*, 20, 38, 40, 41*, 42, 44, 48</sup> ; GP <sup>39, 54</sup> |
| 16. Communication skills; including the capacity to speak other languages   | Pt <sup>48, 49</sup> ; N <sup>45</sup>          | Pt <sup>18, 33, 35, 37, 41, 48-50</sup>                               |
| 17. Humanistic attributes (e.g. being respectful, caring, non-judgemental, friendly, empathetic, supportive and approachable) | Pt <sup>40</sup>                                | Pt <sup>33, 35, 36, 38, 40-43, 46, 56</sup>                           |

|   |   |                                      |
|---|---|--------------------------------------|
| 18. Willingness, interest, motivation to provide CPSs and/or participate in multidisciplinary collaboration | N <sup>33, 37, 51, 56,</sup> , GP <sup>47</sup> | Pt <sup>35</sup>                     |
| a.2. Other community pharmacy staff members (e.g. pharmacy assistants)                                      |   |                                      |
| 19. Technical knowledge (e.g., about a product)   | Pt <sup>41, 42</sup>                            | Pt <sup>41</sup>                     |
| 20. Communication skills  | Pt <sup>42</sup>                                | Pt <sup>41</sup>                     |
| 21. Humanistic attributes   |   | Pt <sup>41</sup>                     |
| 22. Ability to work professionally (e.g., uphold patient confidentiality)                                   | Pt <sup>42, 43</sup>                            |                                      |
| 23. Experience working in the pharmacy  | Pt <sup>41, 42</sup>                            | Pt <sup>41</sup>                     |
| a.3. General Practitioner   |   |                                      |
| 24. Understanding, perceptions and expectations of their individual role with regard CPSs                   | GP <sup>52, 54</sup>                            |                                      |
| 25. Understanding, perceptions and expectations of pharmacist's capabilities and role in healthcare         | GP <sup>34, 36, 52-54</sup>                     | GP <sup>54, 17, 34, 36, 39, 57</sup> |
| 26. Awareness of the availability of CPS  | GP <sup>20</sup>                                |                                      |
| 27. Willingness, interest, motivation to collaborate with CPSs  | GP <sup>20</sup>                                | GP <sup>20, 54</sup>                 |
| a.4. Nurse  |   |                                      |
| 28. Understanding, perceptions and expectations of their individual role within, or in regards to,          | N <sup>19</sup>                                 |                                      |

|   |   |   |
|---|---|---|
| CPSs  |   |   |
| 29. Knowledge and skills to adequately participate in the delivery of CPS   | N <sup>19</sup>   | N <sup>19*</sup>  |
| 30. Attitude towards other healthcare professionals and their roles   |   | N <sup>19</sup>   |
| 31. Willingness, interest, motivation to collaborate with CPSs  | N <sup>19</sup>   | N <sup>19</sup>   |
| <i>b. Relationships (or interactions) between individuals (sub-level)</i>   |   |   |
| 32. Influence of friends and family on patients utilising CPSs (i.e., they may provide support, affect patient's adherence, or patient's enthusiasm with CPSs)                      | Pt <sup>40, 41, 48</sup>  | Pt <sup>17*, 35*, 41</sup>  |
| 33. Previous relationship between the patient and the pharmacist and its nature (e.g. trusting relationship)  | Pt <sup>18</sup> ; GP <sup>20</sup>                                       | Pt <sup>18, 33, 36, 38, 40-42, 46</sup> ; GP <sup>52</sup>                        |
| 34. Collaborative relationships between the pharmacist and other healthcare providers (e.g., GPs), and their nature   | Pt <sup>57</sup> ; N <sup>51</sup> ; GP <sup>34, 45, 47, 52, 53, 57</sup> | Pt <sup>35, 56</sup> ; N <sup>19, 51</sup> ; GP <sup>17*, 20, 52-54, 57</sup>     |
| 35. Communication channels and modes between pharmacists and other healthcare providers (e.g., GPs)   | N <sup>19, 45</sup> ; GP <sup>36, 52, 54, 55</sup>                        | Pt <sup>17, 18, 35</sup> ; N <sup>51</sup> ; GP <sup>17, 52-54</sup>              |
| 36. Existence of referral mechanisms between healthcare professionals, including also those between pharmacy support staff and pharmacists (i.e., care coordination and transition) | Pt <sup>42</sup> ; GP <sup>36, 52</sup> ; N <sup>51</sup>                 | Pt <sup>38, 41</sup> ; GP <sup>17, 20, 36, 39, 47, 52, 54</sup> ; N <sup>51</sup> |
| 37. Consistency in the information provided by the pharmacist with regards to the GP's recommendations  | GP <sup>45, 52, 53, 57</sup>  | GP <sup>52, 57</sup>  |

|  |  |   |
|--|--|---|
| 38. Availability of multidisciplinary education, training and meetings for pharmacists and GPs that enhance integrated, collaborative care   |  | Pt <sup>52*, 56*</sup> ; N <sup>51</sup> ;<br>GP <sup>17, 34, 52, 53</sup>                          |
| <i>Elements at the organisational level</i>  |  |   |
| <i>a. Community pharmacy setting (sub-level)</i>   |  |   |
| 39. Accessibility of the pharmacy setting (e.g. convenient location, co-location, no appointments required, opening hours)   | Pt <sup>17, 49</sup> ; N <sup>51</sup>                                   | Pt <sup>17, 33, 35, 37, 38, 40, 41, 56*, 57</sup> ; N <sup>51</sup> ;<br>GP <sup>47*, 52*, 53</sup> |
| 40. Structural characteristics of the pharmacy setting i.e. size, provision of counselling rooms, use of visual space for posters, child-friendly area                                       | Pt <sup>43</sup>   | Pt <sup>40, 41, 43*</sup>   |
| 41. Privacy of the setting, including the availability of a private consultation area and limited involvement of multiple staff members who would be aware of the patients' personal matters | Pt <sup>18, 41-43, 49, 56</sup> ; GP <sup>20</sup> ;<br>N <sup>45</sup>  | Pt <sup>38, 40, 43</sup>  |
| 42. Availability of suitable material resources to support the service (e.g. educational material for patients, medical devices, patient data management system, etc.)                       |  | Pt <sup>41, 42, 44</sup>  |
| 43. Sufficient qualified staff to perform CPS  | Pt <sup>44</sup> ; GP <sup>20, 47, 57</sup>                              | Pt <sup>48</sup>  |
| 44. Organization of the pharmacist's workload and time to deliver CPSs   | Pt <sup>41, 48, 49, 56</sup> ; N <sup>51</sup> ;<br>GP <sup>33, 47</sup> | Pt <sup>41, 57</sup>  |
| 45. Organisational commitment to implement a CPS   | Pt <sup>33, 41</sup> ; N <sup>51</sup>                                   |   |

|  |  |  |
|--|--|--|
| 46. Promotion of the CPS to facilitate its uptake  |  | Pt <sup>33*, 35*, 47.</sup> , GP <sup>20</sup>   |
| <i>b. Community pharmacy service</i>   |  |  |
| 47. Extent to which the CPS meets and is tailored to fit individual patient's needs or fills existing gaps in healthcare practice (this enhances the value of the service for patients and healthcare professionals) | Pt <sup>18, 35, 36, 42, 46, 47, 56.,</sup><br>GP <sup>52, 54</sup> | Pt <sup>18, 33, 35, 38, 41, 42,</sup><br>46-49, 56., N <sup>47.</sup> , GP <sup>20,</sup><br>39, 47, 52-55, 57 |
| 48. Quality of the CPS (e.g. validity, accuracy of the materials and tools used, CPSs provided in a timely manner, provision of both verbal and written information, professional advice and education, etc.)        | Pt <sup>46.</sup> , GP <sup>47, 57.</sup> , N <sup>19</sup>        | Pt <sup>18, 38, 40, 41.</sup> , GP <sup>20</sup>   |
| 49. Complexity of the CPS for use by healthcare professionals  | GP <sup>20.</sup> , N <sup>19, 51</sup>                            |  |
| 50. Extent to which CPSs provide ongoing support, follow-up and feedback to patients   | GP <sup>52</sup>   | Pt <sup>18, 33, 38, 40, 42, 43,</sup><br>47  |
| 51. Flexibility to use different communication channels (e.g. telephone, website) to interact with patients and healthcare providers   |  | Pt <sup>38, 40, 43*</sup>  |
| 52. Consistency in the community pharmacist delivering the CPS   |  | Pt <sup>38, 41, 46.</sup> , N <sup>19*</sup>   |
| 53. Involvement of other healthcare providers in delivering the CPS  |  | Pt <sup>41.</sup> , N <sup>19*</sup> , GP <sup>20*</sup>   |
| 54. Costs and duration of the CPS consultation for the patient   | Pt <sup>56, 57.</sup> , N <sup>51</sup>                            | Pt <sup>38, 57.</sup> , GP <sup>17, 20.,</sup><br>N <sup>51*</sup> ,   |

|  |                                     |  |
|--|-------------------------------------|--|
| <i>Elements at the community and health system level</i>   |                                     |  |
| 55. General consumer education about healthcare; promotion of CPS by the media   | Pt <sup>57</sup> ; GP <sup>57</sup> | Pt <sup>48, 57</sup> ; GP <sup>47*, 57</sup>                                       |
| 56. Collaboration, influences, conflicts between GP and pharmacist professional bodies   |                                     | GP <sup>34*</sup>  |
| 57. Organization of GPs' workload and time to collaborate with CPSs  | GP <sup>20, 47, 52, 54, 55</sup>    |  |
| 58. Complexity of system-level administrative processes (e.g. tedious paperwork) associated to the delivery of CPS; i.e., complying with the requirements of the department of health  | GP <sup>17, 20, 47, 53, 57</sup>    |  |
| 59. Availability of an electronic system for sharing information   | Pt <sup>18, 56</sup>                | Pt <sup>17*, 57</sup> ; N <sup>19*</sup> ; GP <sup>17, 20*, 36*, 50, 52*, 53</sup> |
| 60. Presence of agreed healthcare protocols, regulations, rules and policies to facilitate the delivery of CPSs  | Pt <sup>44</sup> ; N <sup>51</sup>  | Pt <sup>44</sup> ; GP <sup>20*, 52, 53</sup>                                       |
| 61. Limits on the healthcare budget; i.e., funding allocated to support CPS delivery   | GP <sup>17, 47, 54, 57</sup>        | Pt <sup>44, 56*</sup> ; GP <sup>17, 52, 57</sup>                                   |
| 62. Availability of financial incentives for service provision and inter-professional collaboration  |                                     | Pt <sup>56*</sup> ; N <sup>51*</sup>   |
| 63. Organisation of the healthcare system  | Pt <sup>56</sup> ; GP <sup>57</sup> |  |
| CPS: Community Pharmacy Service; GP: General Practitioner; Pt: Patient; N: Nurse   |                                     |  |
| ‡ Barrier: the element was mentioned to act as a BARRIER or hinder to the implementation of CPSs; † Facilitator: the element was mentioned to act as a FACILITATOR or enabler to the implementation of CPSs; (*) this element was reported as a potential strategy to overcome a barrier |                                     |  |



(i.e., facilitator).

199

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Individual patient level.** All the 16 elements at the patient level were identified by patients. GPs and nurses did not identify any additional patient-related barriers and facilitators. Influential elements at this level were related to the patients' needs, preferences, perceptions and expectations, capabilities or previous experiences with community pharmacists and services. Patients' health-related concerns, understanding or perception of their health problems are important elements that influence patients' need for healthcare and so their decisions to utilise CPSs. Most patients held positive views about CPSs and the role of the pharmacist in providing such services.<sup>40, 41, 47</sup> Some articles highlighted that positive experiences were related to the patient feeling comfortable and welcomed in the pharmacy.<sup>38, 40, 42</sup> When CPSs required a formal referral from the GP, some patients deterred from requesting the services. These patients perceived that by requesting a CPS they would be bothering the GP<sup>36</sup> or offending and compromising their relationship with the GP.<sup>18, 47, 48</sup> Patients also reported that having a negative experience with a CPS also deterred them from accessing and utilising such CPSs in the future.<sup>42</sup>

**Interpersonal level.** Influential elements at the interpersonal level were related to two categories or sub-levels: (1) *individual healthcare professionals* (which also includes professional pharmacy staff), and (2) *relationships (or interactions) between individuals* (which includes both the relationships between healthcare professionals and between those professionals and patients).

*Individual healthcare professionals.* 17 elements were identified and related to characteristics of the community pharmacists (n=4), nurses (n=4) and GPs (n=4) and characteristics of non-provider personnel (i.e., other community pharmacy staff members - e.g., pharmacy assistant) (n=5). Articles reported that GPs' and nurses' service support varied depending on their perceptions or understanding of CPSs and the role of pharmacists. Home medicine review services had a great deal of approval and support from the GP perspective.<sup>47, 52</sup> On the other side, pharmacists providing immunisations raised some conflicting views among GPs since they believed this was the role of the GP or nurse

practitioner.<sup>52</sup> Some studies highlighted that GPs had a limited understanding of the capabilities of the pharmacist as service providers with pharmacists perceived as drug sellers in a retail environment.<sup>34-36, 53, 56</sup> Both patients and GPs implied the need for pharmacists to undergo upskilling and training to be qualified to provide some CPSs.<sup>34, 39, 48</sup>

*Relationships (or interactions) between individuals.* Articles reported that well-established relationships between the pharmacist and the nurse or the GP, including collaborative relationships, were essential for the success of a CPS.<sup>17, 19, 20, 35, 51, 54</sup> Multidisciplinary education and training for healthcare professionals was suggested as a way to improve healthcare professional competence.<sup>56</sup> Similarly, characteristics of the relationship between the patient and the pharmacist (e.g., trust) was a key element that influenced pharmacy choice, contributed to the patient adhering to the CPS, and accepting the intervention.<sup>18, 33, 36, 38, 40-42, 46</sup> Some articles reported the influence of family and friends on patient utilisation of CPSs (e.g., providing support, influencing motivation),<sup>35, 56</sup> and others commented on the integration of partners into the CPS (e.g., provision of group sessions with partners).<sup>35, 38</sup>

**Organizational level.** Also at the organisational level, influential elements were divided into two sub-levels: (1) *the community pharmacy setting* (n=8) and (2) *the service itself* (n=8).

*The community pharmacy setting.* Some articles identified the accessibility of the pharmacy facilitated inter-professional relationships between GPs and pharmacists,<sup>52, 53</sup> and influenced patient<sup>17, 38, 41</sup> and nurse<sup>51</sup> participation in CPS. In some articles non-english speaking patients reported that the lack of multilingual staff limited their awareness and access to CPSs.<sup>44, 48</sup> Other articles noted GP and nurse concerns regarding the lack of pharmacies that provide CPSs<sup>51</sup> and insufficient accredited pharmacists to perform CPSs.<sup>47, 57</sup>

*The community pharmacy service.* Concerns regarding the validity and accuracy of the tools and instruments used (e.g. medical devices, medication charts) were raised by GPs and nurses.<sup>19, 52</sup> Patients and nurses commented that having the same service provider at each encounter facilitated rapport building between the patient and the pharmacist,<sup>38, 41, 46</sup> and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

caused fewer errors when it came to preparing dose administration aids.<sup>19</sup> Furthermore, patients, nurses and GPs reported on the involvement/participation of healthcare professionals other than pharmacists in the provision of CPSs,<sup>41</sup> or to act as a point of liaison,<sup>20</sup> to improve the quality and efficiency of the service. The cost of the service was a key element, mentioned by all stakeholders, that could either discourage<sup>51, 56</sup> or motivate<sup>38</sup> patients to utilise services. In particular it was mentioned that smaller, manageable cost payments for patients could facilitate CPS use.<sup>51</sup>

**Community and healthcare system level.** Nine influential elements were identified at this level. Several articles identified the need for adequate remuneration for GPs and pharmacists for participating in and providing CPSs,<sup>17, 44, 52, 54</sup> as well as the implementation of an electronic system of information sharing between these two healthcare professionals.<sup>19, 20, 36, 57</sup> GPs also cited the availability of competing, government-funded health programs, and their high level of workload and lack of time as contributing to their low participation in CPSs.<sup>47</sup> Where services were available, remunerated and widely supported by GPs and patients, such as home medicine reviews (i.e., a medication review service), GPs mentioned complex bureaucratic procedures (e.g. completing tedious documents) may discourage their use.<sup>17, 20, 47, 53, 57</sup> Despite this, the home medicine review service was generally considered successful by GPs and a frequently reported reason for this was the presence of a clear protocol guiding service delivery.<sup>20, 52, 53</sup> GPs also suggested increased and improved collaboration between pharmacy and GP professional representative bodies may improve awareness of the services and encourage participation. The media was perceived to have an important role in improving awareness of and promoting CPSs. Finally, some broad comments suggesting some additional issues at the higher levels of the healthcare system were mentioned, such as ‘better and more responsible organisation of the healthcare system’.<sup>57</sup>

With regards to the interactions between the identified influential elements, 12 articles out of 29 mentioned some form of a relationship between certain elements.<sup>20, 33, 40, 42, 46, 48, 51-55, 58</sup> As

shown in Appendix 2 (Supplementary File), a total of 27 relationships between 25 elements were found, with 10 elements presenting 2 or more relationships with others (2 elements showed 5 or more interactions). As a result of the limited, unsystematic information reported in the articles, a sparse network disclosing the recognized relationships between elements was obtained (Appendix 2 in Supplementary File).

## DISCUSSION

To the best of our knowledge this is the first review that summarises comprehensive information on the elements that, according to patients, nurses and GPs, can enable or hinder the implementation of CPSs. Patients, GPs and nurses are key members of the primary healthcare team and their support and expectations for CPSs can highly influence their implementation.<sup>1, 19, 52, 58-61</sup> Thus, by synthesising and organising the influential elements identified by these key stakeholders, this review can optimize future analyses of barriers and facilitators to the implementation of CPSs and so potentially enhance their integration into primary practice. Importantly, this work was intentionally restricted to a specific implementation context (i.e., Australia), to which its results are directly relevant and will be immediately applied. Focusing only on Australia is not considered a limitation of the study; rather it is a sensible decision that allows knowledge about a particular context of interest to be gained. Including studies conducted in contexts or healthcare systems other than Australia (e.g., United Kingdom, United States, etc.), where barriers and facilitators to CPS implementation can be dissimilar in nature and expressed differently, may have brought irrelevant or inappropriate information to this analysis, and so hinder the understanding of the context of interest. However, it should be noted that Australia is a country with a large experience in CPS implementation and where significant research has been conducted in this regard compared to other countries worldwide. Therefore, it is expected that the comprehensive list of influential elements identified in this context may be relevant to start investigating barriers and facilitators to CPS implementation in countries with less experience. Furthermore, the elements identified in this review can provide insight to

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

307 pharmacy service planners in other countries to guess and avoid some problems in the  
308 implementation of CPSs beforehand.

309 Barriers and facilitators to the implementation of CPSs in Australia have been well  
310 researched and reported from the perspective of community pharmacists.<sup>14, 15, 60, 62</sup> In this  
311 regard, the results of this review confirms that patients, nurses and GPs also recognise  
312 some of the influential elements reported in previous pharmacist-informed studies, such as  
313 the pharmacist's education and training, collaboration between the pharmacist and the GP,  
314 accessibility of the pharmacy setting, and financial remuneration. However, this study  
315 provides additional insight into further barriers and facilitators, across different ecological  
316 levels, that are relevant to other key stakeholder and so are less likely to be reported by  
317 pharmacists; for example: patients' capability to follow the procedures of the service, GPs'  
318 workload, nurses' attitudes towards other healthcare professionals/services, the actual  
319 relationships between GP and pharmacy professional bodies, or the availability of  
320 multidisciplinary training and education. These results highlight the importance of engaging  
321 key stakeholders other than pharmacists to better understand the contexts in which CPSs  
322 are implemented. In other words, disregarding the input of these stakeholders (or  
323 considering only the views of pharmacists), may lead to an incomplete and biased  
324 understanding of the implementation context, which, in turn, can result in service  
325 underutilisation, unsuccessful implementation and limited service impact.<sup>63</sup> Generally,  
326 involving relevant stakeholders throughout the development, implementation and evaluation  
327 of health programs is crucial to increase the chances of any of those initiatives being  
328 effective and successfully implemented.<sup>6, 29, 30, 64</sup> Indeed, this is equally relevant to CPS  
329 planning.<sup>65, 66</sup>

330 Semi-structured interviews, and/or focus group with healthcare professionals and patients  
331 appear to be appropriate methods to identify a large number of unique influential elements.<sup>67</sup>  
332 Thus pharmacy service planners can continue to utilise these methods to identify  
333 determinants of pharmacy practice in their own context. Although, the type of qualitative

method used may affect the type of barriers/facilitators identified, it is more likely that the aims of the studies included in this review, their target population and/or the specific service/topic addressed by the study may have had a stronger influence in the type of barriers or facilitator identified.

The results of this review can assist pharmacy service planners and researchers to better identify the elements that may be enabling or hindering the implementation of existing CPSs. By combining the list of influential elements generated in this review with previous findings in pharmacists-informed studies a comprehensive framework to assess barriers and facilitators to CPS implementation can be produced. Assessing and understanding the elements influencing pharmacy practice and service implementation must be a key early step in developing appropriate, multilevel programs (i.e., including interventions targeting elements at different levels) aimed at enhancing the integration of CPSs into the healthcare system.<sup>29, 30, 66, 68</sup> Also, influential elements should be prompted and assessed when designing new CPSs. Identifying elements prior to designing a new CPS may guide both the early adaptation of the service to the context, as well as the early development of tailored implementation programs to better fit (or change) the implementation context. As an analysis of influential elements is likely to yield a large number of items, it would not be feasible to address each and every one of those elements. Thus once elements have been identified for a specific context, further efforts are required to prioritise those elements that are most relevant and can be practically addressed.<sup>8, 69</sup> In this regard, McMillan et al<sup>70</sup> provide a summary of methods used to determine priorities and how they have been used in pharmacy practice research, which can guide pharmacy service planners in this regard.

The analysis conducted in this review revealed three concerns that must be considered to improve future studies aimed at identifying influential elements. On the one hand, some influential elements at the community and healthcare system level were too broadly described (i.e., 'organisation of the health system') and further exploration is needed to clearly understand the specific 'items' that they encompass. Presumably, the list of



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

determinants of practice described by Flottorp et al<sup>7</sup> (i.e., Tailored Implementation in Chronic Disease checklist) can provide more detail regarding influential elements at the higher community and healthcare system level and so can initially assist to better frame future analysis of barriers and facilitators to CPS implementation. Particularly, the determinants under the domains ‘Incentives and resources’; ‘Capacity for organizational change’; and ‘Social political and legal factors’ seem particularly relevant for this purpose. Importantly, to bring further insight on the elements at the community and healthcare system level it would be important to include and explore the perspectives of other potential key stakeholders, such as other healthcare providers (e.g., specialists), caregivers, representatives of healthcare organisations and professional bodies, policy makers, etc. Furthermore, future studies aimed at identifying barriers and facilitators to CPS implemetation must better describe and understand the relationships between elements.<sup>2, 7</sup> This may help to understand how elements influence each other and which elements are more suitable to be addressed (based on the overall effect that they can produce on other elements) when designing implementation efforts.

**Limitations.** The network analysis intended in this study was strongly constrained by the limited and unsystematically reported information about the relationships between influential elements. As a result, it was decided not to report further results of the network analysis beyond its pictorial representation. The potential of a full network analysis should be considered in future studies aimed at analysing elements that influence the implementation of CPSs. A suitable network analysis can help to better understand the complex relationships between these elements; detect the core elements that may primarily explain the implementation challenge; and provide insight on the key leverage points that should be targeted within the network to enhance service implementation. Ideally, accurate information on relevant attributes of the influential elements (and the interactions between them) should be collected by the authors of the primary studies to increase the potential of a network analysis; for example, the frequency of occurrence; the direction of the relationships; the



domain or level where the element is located (i.e., patients, healthcare professionals, professional interactions, etc.); the relative relevance of each element; or the effect on implementation outcomes (i.e., performance as barrier or facilitator).

Following the particular method chosen for this review (i.e., qualitative meta-synthesis),<sup>22, 23</sup> only primary research articles that used qualitative methods were included. Meta-synthesis enabled a rich description of elements perceived by GPs, patients and nurses to influence implementation of CPSs in Australia. Future reviews that synthesise the quantitative literature on this topic are encouraged. Appraising qualitative research is controversial because of the difficulty of using information about quality to inform syntheses (e.g. even studies with flaws in methodology can provide valuable information).<sup>26</sup> Furthermore, there is no gold standard on appraising qualitative studies.<sup>32</sup> The elementary quality assessment conducted in the current review was aimed at ensuring minimal quality while identifying a broad range of elements that might influence CPS implementation. Lastly, the papers included in this review were not restricted by the time at which they were published, since the aim of the study was to include all relevant papers that can inform about any influential element that has been noted in practice. It is important to acknowledge that as contexts can change over time, the effect of influential elements can also change, cease to exist or new elements can emerge. It is therefore important to regularly monitor elements and prioritise those that must be addressed.

## CONCLUSION

This qualitative meta-synthesis identified a broad range of elements that, according to patients, GPs and nurses, can enable (i.e., facilitators) or hinder (i.e., barriers) the implementation of CPSs. These influential elements are located at different ecological levels and should be considered together with those previously identified in pharmacy-informed studies to comprehensively analyse the barriers and facilitators to the implementation of CPSs. Future studies aimed at that purpose must involve multiple stakeholder groups (i.e.,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

414 others than only pharmacists) and better understand the relationships between influential  
415 elements to increase the usefulness and interest of their findings. Further to the identification  
416 of the influential elements, key stakeholders should keep involved in developing suitable,  
417 multilevel programs aimed at enhancing CPS implementation.

For peer review only

## 418 **ACKNOWLEDGEMENTS**

419 We would like to acknowledge Antonio E. Mendes (Universidade Federal do Parana, Brazil)  
420 for his collaboration in the network analysis.

## 421 **COMPETING INTERESTS**

422 All authors declare no competing interest

## 423 **FUNDING**

424 Lutfun N. Hossain was awarded a University of Technology Sydney (UTS) President's  
425 Scholarship and a UTS Chancellors Research Scholarship.

426 This work is part of a larger UTS Chancellor's Postdoctoral Research Fellowship awarded to  
427 Dr Daniel Sabater-Hernández (UTS ID number: 2013001605).

## 428 **DATA SHARING STATEMENT**

429 No additional data are available

## 430 **AUTHORS' CONTRIBUTION**

431 Conception or design of the work: Lutfun N. Hossain, Fernando Fernandez-Llimos, Tim  
432 Lockett and Daniel Sabater-Hernández.

433 Data collection: Lutfun N. Hossain, Desire Durks and Lucia Franco-Trigo.

434 Data analysis and interpretation: Lutfun N. Hossain, Joanna C. Moullin, Charlie Benrimoj and  
435 Daniel Sabater-Hernández.

436 Drafting the article: Lutfun N. Hossain, Fernando Fernandez-Llimos, Tim Lockett and Daniel  
437 Sabater-Hernández.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

438 Critical revision of the article: Lutfun N. Hossain, Joanna C. Moullin, Fernando Fernandez-  
439 Llimos, Tim Lockett and Daniel Sabater-Hernández.  
  
440 Final approval of the version to be published: Lutfun N. Hossain, Fernando Fernandez-  
441 Llimos, Tim Lockett, Joanna C. Moullin, Desire Durks, Lucia Franco-Trigo, Charlie Benrimoj  
442 and Daniel Sabater-Hernández.  
  
443

For peer review only

## REFERENCE

1. Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of health innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures. *Implement Sci* 2013;8:22.
2. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci* 2009;4:50.
3. Haines A, Kuruvilla S, Borchert M. Bridging the implementation gap between knowledge and action for health. *Bull World Health Organ* 2004;82:724-31.
4. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. *Lancet* 2003;362:1225-30.
5. Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health care. *BMJ* 2001;323:625-8.
6. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655.
7. Flottorp SA, Oxman AD, Krause J, et al. A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. *Implement Sci* 2013;8:35.
8. Baker R, Camosso-Stepinovic J, Gillies C, et al. Tailored interventions to address determinants of practice. *Cochrane Database Syst Rev* 2015;4:CD005470.
9. Gastelurrutia MA, Benrimoj SI, Castrillon CC, et al. Facilitators for practice change in Spanish community pharmacy. *Pharm World Sci* 2009;31:32-9.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

467 10. Moullin JC, Sabater-Hernández D, Benrimoj SI. Model for the evaluation of  
468 implementation programs and professional pharmacy services. *Res Social Adm Pharm*  
469 2016;12:515-22.

470 11. Sabater-Hernández D, Sabater-Galindo M, Fernandez-Llimos F, et al. A Systematic  
471 Review of Evidence-Based Community Pharmacy Services Aimed at the Prevention of  
472 Cardiovascular Disease. *J Manag Care Spec Pharm* 2016;22:699-713.

473 12. Mossialos E, Courtin E, Naci H, et al. From "retailers" to health care providers:  
474 Transforming the role of community pharmacists in chronic disease management.  
475 *Health Policy* 2015;119:628-39.

476 13. Kaae S, Christensen ST. Exploring long term implementation of cognitive services in  
477 community pharmacies - a qualitative study. *Pharm Pract (Granada)* 2012;10:151-8.

478 14. Berbatis C, Sunderland V, Joyce A, Bulsara M, Mills C. Enhanced pharmacy services,  
479 barriers and facilitators in Australia's community pharmacies: Australia's National  
480 Pharmacy Database Project. *Int J Clin Pharm* 2007;15:185-91.

481 15. Roberts A, Benrimoj S, Chen T, et al. Implementing cognitive services in community  
482 pharmacy: a review of facilitators used in practice change. *Int J Clin Pharm*  
483 2006;14:163-70.

484 16. Gastelurrutia MA, Fernandez-Llimos F, Garcia-Delgado P, et al. Barriers and facilitators  
485 to the dissemination and implementation of cognitive services in Spanish community  
486 pharmacies *Seguim Farmacoter* 2005;3:65-77.

487 17. Cvetkovski B, Armour C, Bosnic-Anticevich S. Asthma management in rural New South  
488 Wales: Perceptions of health care professionals and people with asthma. *Austr J Rural*  
489 *Health* 2009;17:195-200.

18. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home Medicines Review Program: benefits and barriers. *Res Social Adm Pharm* 2012;8:4-16.
19. Gilmartin JF, Marriott JL, Hussainy SY. Exploring factors that contribute to dose administration aid incidents and identifying quality improvement strategies: the views of pharmacy and nursing staff. *Int J Pharm Pract* 2014;22:407-14.
20. Dhillon AK, Hattingh HL, Stafford A, et al. General practitioners' perceptions on home medicines reviews: a qualitative analysis. *BMC Fam Pract* 2015;16:16.
21. Rayes IK, Abduelkarem AR. A qualitative study exploring physicians' perceptions on the role of community pharmacists in Dubai. *Pharm Pract (Granada)* 2016;14:738.
22. Mohammed MA, Moles RJ, Chen TF. Meta-synthesis of qualitative research: the challenges and opportunities. *Int J Clin Pharm* 2016;38:695-704.
23. Walsh D, Downe S. Meta-synthesis method for qualitative research: a literature review. *J Adv Nurs* 2005;50:204-11.
24. Moullin JC, Sabater-Hernández D, Fernandez-Llimos F, Benrimoj SI. Defining professional pharmacy services in community pharmacy. *Res Social Adm Pharm* 2013;9:989-95.
25. Hennink MM, Hutter I, Bailey A. Qualitative research methods. Los Angeles, Calif. ; London: SAGE; 2011.
26. Dixon-Woods M, Shaw RL, Agarwal S, et al. The problem of appraising qualitative research. *Qual Saf Health Care* 2004;13:223-5.
27. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. *BMC Med Res Methodol* 2008;8:1-10.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

513 28. McLeroy KR, Bibeau D, Steckler A, et al. An ecological perspective on health promotion  
514 programs. *Health Educ Quart* 1988;15:351-77.

515 29. Bartholomew LK, Markham CM, Ruiter RAC, Fernández ME, Kok G, Parcel GS.  
516 Planning health promotion programs: An Intervention Mapping approach. 4th ed. San  
517 Francisco, CA: Jossey-Bass; 2016.

518 30. Green LW, Kreuter MW. Health program planning: An educational and ecological  
519 approach. 4th ed. Boston: McGraw-Hill; 2005.

520 31. Jacomy M, Venturini T, Heymann S, et al. ForceAtlas2, a continuous graph layout  
521 algorithm for handy network visualization designed for the Gephi software. *PloS one*  
522 2014;9:e98679.

523 32. Tong A, Flemming K, McInnes E, et al. Enhancing transparency in reporting the  
524 synthesis of qualitative research: ENTREQ. *BMC Med Res Methodol* 2012;12:181.

525 33. McMillan SS, Sav A, Kelly F, et al. How to attract them and keep them: The pharmacy  
526 attributes that matter to Australian residents with chronic conditions. *Int J Pharm Pract*  
527 2014;22:238-45.

528 34. Rieck A, Pettigrew S. How physician and community pharmacist perceptions of the  
529 community pharmacist role in Australian primary care influence the quality of  
530 collaborative chronic disease management. *Qual Prim Care* 2013;21:105-11.

531 35. Barbara S, Krass I. Self management of type 2 diabetes by Maltese immigrants in  
532 Australia: Can community pharmacies play a supporting role? *Int J Pharm Pract*  
533 2013;21:305-13.

534 36. Bereznicki B, Peterson G, Jackson S, et al. Perceived feasibility of a community  
535 pharmacy-based asthma intervention: A qualitative follow-up study. *J Clin Pharm Ther*  
536 2011;36:348-55.



37. Saba M, Dan E, Bittoun R, et al. Asthma and smoking--healthcare needs and preferences of adults with asthma who smoke. *J Asthma* 2014;51:934-42.
38. Shoukry G, Wong K, Bartlett D, et al. Treatment experience of people with obstructive sleep apnoea seeking continuous positive airways pressure device provision through community pharmacies: a role for pharmacists? *Int J Pharm Pract* 2011;19:318-27.
39. Um IS, Armour C, Krass I, et al. Weight management in community pharmacy: what do the experts think? *Int J Clin Pharm* 2013;35:447-54.
40. Snell L, White L. An exploratory study of the role of emotional intelligence and self-efficacy on service quality and adherence in a weight loss setting. *Serv Mark Q* 2011;32:228-46.
41. Maher JH, Hughes R, Anderson C, et al. An exploratory investigation amongst Australian mothers regarding pharmacies and opportunities for nutrition promotion. *Health Educ Res* 2013;28:1040-50.
42. Mey A, Knox K, Kelly F, et al. Trust and safe spaces: Mental health consumers' and carers' relationships with community pharmacy staff. *Patient* 2013;6:281-9.
43. Hattingh HL, Knox K, Fejzic J, et al. Privacy and confidentiality: perspectives of mental health consumers and carers in pharmacy settings. *Int J Pharm Pract* 2015;23:52-60.
44. Clark A, Gilbert A, Rao D, et al. 'Excuse me, do any of you ladies speak English?' Perspectives of refugee women living in South Australia: barriers to accessing primary health care and achieving the Quality Use of Medicines. *Aust J Prim Health* 2014;20:92-7.
45. O'Connor M, Fisher C, French L, et al. Exploring the community pharmacist's role in palliative care: Focusing on the person not just the prescription. *Patient Educ Couns* 2011;83:458-64.

1  
2  
3 561 46. Carter SR, Moles R, White L, et al. Exploring patients' motivation to participate in  
4  
5 562 Australia's Home Medicines Review program. *Int J Clin Pharm* 2012;34:658-66.  
6  
7  
8 563 47. Lee CY, George J, Elliott RA, et al. Exploring stakeholder perspectives on medication  
9  
10 564 review services for older residents in retirement villages. *Int J Pharm Pract* 2012;20:249-  
11  
12 565 58.  
13  
14  
15 566 48. White L, Klinner C. Medicine use of elderly Chinese and Vietnamese immigrants and  
16  
17 567 attitudes to home medicines review. *Aust J Prim Health* 2012;18:50-5.  
18  
19  
20 568 49. Swain L, Barclay L. They've given me that many tablets, I'm bushed: I don't know where  
21  
22 569 I'm going: Aboriginal and Torres Strait Islander peoples' experiences with medicines.  
23  
24 570 *Austr J Rural Health* 2013;21:216-9.  
25  
26  
27 571 50. Du Pasquier S, Aslani P. Concordance-based adherence support service delivery:  
28  
29 572 Consumer perspectives. *Pharm World Sci* 2008;30:846-53.  
30  
31  
32 573 51. Bui J, Day C, Hanrahan J, et al. Senior nurses' perspectives on the transfer of opioid  
33  
34 574 substitution treatment clients from clinics to community pharmacy. *Drug Alcohol Rev*  
35  
36 575 2014;34:495-8.  
37  
38  
39 576 52. Van C, Krass I, Mitchell B. General practitioner perceptions of extended pharmacy  
40  
41 577 services and modes of collaboration with pharmacists. *J Pharm Pract Res* 2007;37:182-  
42  
43 578 6.  
44  
45  
46 579 53. Van C, Mitchell B, Krass I. General practitioner-pharmacist interactions in professional  
47  
48 580 pharmacy services. *J Interprof Care* 2011;25:366-72.  
49  
50  
51 581 54. Dey RM, De Vries MJW, Bosnic-Anticevich S. Collaboration in chronic care: Unpacking  
52  
53 582 the relationship of pharmacists and general medical practitioners in primary care. *Int J*  
54  
55 583 *Pharm Pract* 2011;19:21-9.  
56  
57  
58  
59  
60

- 584 55. Chong WW, Aslani P, Chen TF. Multiple perspectives on shared decision-making and  
585 interprofessional collaboration in mental healthcare. *J Interprof Care* 2013;27:223-30.
- 586 56. Cheong LH, Armour CL, Bosnic-Anticevich SZ. Multidisciplinary collaboration in primary  
587 care: Through the eyes of patients. *Aust J Prim Health* 2013;19:190-7.
- 588 57. Bajramovic J, Emmerton L, Tett SE. Perceptions around concordance--focus groups  
589 and semi-structured interviews conducted with consumers, pharmacists and general  
590 practitioners. *Health Expect* 2004;7:221-34.
- 591 58. McMillan SS, Emmerton L. Nurse practitioners: an insight into their integration into  
592 Australian community pharmacies. *Res Social Adm Pharm* 2013;9:975-80.
- 593 59. Roberts AS, Benrimoj SI, Chen TF, et al. Understanding practice change in community  
594 pharmacy: a qualitative study in Australia. *Res Social Adm Pharm* 2005;1:546-64.
- 595 60. Roberts AS, Benrimoj SI, Chen TF, et al. Practice change in community pharmacy:  
596 quantification of facilitators. *Ann Pharmacother* 2008;42:861-8.
- 597 61. Alonso-Perales MD, Lasheras B, Beitia G, et al. Barriers to promote cardiovascular  
598 health in community pharmacies: a systematic review. *Health Prompt Int* 2015:1-14.
- 599 62. Lowres N, Krass I, Neubeck L, et al. Atrial fibrillation screening in pharmacies using an  
600 iPhone ECG: a qualitative review of implementation. *Int J Clin Pharm* 2015;37:1111-20.
- 601 63. Hughes CM, Cadogan CA, Ryan CA. Development of a pharmacy practice intervention:  
602 lessons from the literature. *Int J Clin Pharm* 2015;38:601-6.
- 603 64. McKenzie JF, Neiger BL, Thackeray R. Planning, implementing, and evaluating health  
604 promotion programs: a primer. 6th ed. San Francisco, CA: Pearson - Benjamin  
605 Cummings; 2013.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

606 65. Franco-Trigo L, Hossain LN, Durks D, et al. Stakeholder analysis for the development of  
607 a community pharmacy service aimed at preventing cardiovascular disease. *Res Social*  
608 *Adm Pharm* Epub 2016 Jun 30.

609 66. Sabater-Hernández D, Moullin JC, Hossain LN, et al. Intervention mapping for  
610 developing pharmacy-based services and health programs: A theoretical approach. *Am*  
611 *J Health Syst Pharm* 2016;73:156-64.

612 67. Krause J, Van Lieshout J, Klomp R, et al. Identifying determinants of care for tailoring  
613 implementation in chronic diseases: an evaluation of different methods. *Implement Sci*  
614 2014;9:102.

615 68. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for  
616 characterising and designing behaviour change interventions. *Implement Sci* 2011;6:42.


617 69. Durks D, Fernandez-Llimos F, Hossain LN, Franco-Trigo L, Benrimoj SI, Sabater-  
618 Hernández D. Use of Intervention Mapping to enhance healthcare professional practice:  
619 a systematic review. *Health Educ Behav* *Forthcoming* 2017.

620 70. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques.  
621 *Int J Clin Pharm* 2016;38:655-62.

622

Figure 1. PRISMA flow diagram

For peer review only




254x190mm (300 x 300 DPI)

## Appendix 1. Search strategy and key words used in database search

| Database | Search strategy and keywords   |
|----------|--|
| PubMed   | ((opinion OR opinions) OR (view or views) OR (attitude or attitudes) OR (experience OR experiences) OR satisfaction OR (motivation or motivations) OR (perception OR perceptions) OR (preference OR preferences) OR "Attitude to Health"[MH] OR awareness[TW] OR (barrier OR barriers) OR (facilitator or facilitators)) AND (pharmacy OR pharmacies OR pharmacist OR pharmacists) AND ("Interviews as Topic"[MH] OR "Empirical Research"[MH] OR semi-structured OR qualitative OR ("Focus Groups"[TW] OR "focus group")) AND Australia[TIAB]  |
| Scopus   | ((TITLE-ABS-KEY (opinion OR opinions)) OR (TITLE-ABS-KEY (view OR views) ) OR (TITLE-ABS-KEY (attitude OR attitudes)) OR (TITLE-ABS-KEY (experience OR experiences)) OR (TITLE-ABS-KEY (satisfaction)) OR (TITLE-ABS-KEY (motivation OR motivations)) OR (TITLE-ABS-KEY (perception OR perceptions)) OR (TITLE-ABS-KEY ( preference OR preferences))) OR ((TITLE-ABS-KEY (awareness)) OR (TITLE-ABS-KEY (barrier OR barriers)) OR (TITLE-ABS-KEY (facilitator OR facilitators)) OR (KEY (patient attitude)) OR (KEY (patient satisfaction)) OR (KEY (health personnel attitude)) OR (KEY (patient preference)))) AND ((TITLE-ABS-KEY (pharmacy OR pharmacies)) OR (TITLE-ABS-KEY (pharmacist OR pharmacists))) AND ((KEY (semi structured interview)) OR ( TITLE-ABS-KEY (qualitative)) OR (KEY (qualitative research))) AND (TITLE-ABS-KEY (Australia)) |
| Informit | Pharmacy AND qualitative   |

Appendix 2. Relationships between influential elements and resulted network\*



\* Elements' numbers in the figure match with the elements' numbers on table 3 where a full description of each element can be found. The size of the nodes is determined by the number of times (i.e., articles) that each element was reported.

Pat: element at the patient level; Pharm: element at the healthcare professional level (i.e., pharmacist); GP: element at the at the healthcare professional level (i.e., general practitioner); Rel: element related to the relationships (or interactions) between individuals; PhSet: element related to the community pharmacy setting; Serv: element related to the community pharmacy service; Sys: influential element at the community and healthcare system level.



| Related elements |         | Description of the relationship   |
|------------------|---------|---|
| Pat09            | Pat12   | Patients who did not have a positive experience with CPSs were not motivated to receive future ones <sup>1</sup>  |
| Pat14            | Pat02   | Patients' language issues prevented them from becoming more aware of CPSs <sup>2</sup>  |
| Pat09            | Pharm15 | Patients' previous positive experiences of CPS were related to a suitable knowledge of the pharmacist <sup>3</sup>  |
| Pat09            | Pharm17 | Patients' previous positive experiences of CPS were related to positive humanistic attributes of the community pharmacist (i.e. friendly) <sup>3</sup>                                    |
| Pat09            | Rel33   | Patients' previous positive experiences in the pharmacy contributed to the formation of a closer relationship between the patient and the pharmacist <sup>3</sup>                         |
| Pat13            | Pharm15 | Patients with higher levels of emotional intelligence valued the knowledge and competency of community pharmacists <sup>4</sup>   |
| Pat13            | Pharm17 | Patients with lower levels of emotional intelligence valued the humanistic attributes of the community pharmacist in CPS <sup>4</sup>   |
| Pharm16          | Pat02   | Lack of multilingual community pharmacists prevented awareness of the availability of CPS in some ethnic patients <sup>2</sup>  |
| Pharm17          | Rel33   | The humanistic attributes of the pharmacist (e.g., approachability, sensitivity) shaped the relationships between the patient and the pharmacist <sup>3</sup>                             |
| Pharm17          | Serv47  | The humanistic attributes of the pharmacist (e.g., approachability) created an environment in which patients could ask questions, seek advice and better address their needs <sup>5</sup> |
| GP25             | Sys57   | GPs can see a higher value in CPSs when they address their time limitations <sup>6</sup>  |
| GP25             | Pharm15 | GPs' perceptions and understanding of the role of community   |

|         |        |   |
|---------|--------|---|
|         |        | pharmacists depends on whether pharmacists have received appropriate training and demonstrate suitable health-related knowledge and skills <sup>7</sup>                         |
| Rel38   | Rel34  | GP-Pharmacist combined meetings and training can promote collaborative relationships between the pharmacist and GP <sup>8</sup>   |
| Rel33   | Pat05  | Patients who had an on-going relationship with community pharmacists were more likely to see the value of pharmacists providing health services <sup>3</sup>                    |
| Rel33   | Serv50 | The existence of a relationship between the patient and the pharmacist can determine the success of follow-up mechanisms in the CPS <sup>4</sup>                                |
| Rel35   | GP25   | GPs who experienced a high level of communication with pharmacists saw value in the input pharmacists can make to their practice <sup>8</sup>                                   |
| Rel38   | GP25   | Developing multidisciplinary training with pharmacists and GPs could enhance GPs' understanding and perception of pharmacists' capabilities and role in healthcare <sup>8</sup> |
| PhSet39 | Rel34  | Physical accessibility and co-location of the pharmacy to the GP medical centre can promote collaborative relationships between the pharmacists and GPs <sup>8,9</sup>          |
| PhSet44 | Rel34  | Time constraints of the pharmacist limited the collaboration between the pharmacists and the nurse <sup>10</sup>  |
| Serv47  | Pat09  | When patients perceived that CPS were not patient-centred, they reported negative experiences <sup>3</sup>  |
| Serv47  | Rel33  | CPSs which are patient-centred can contribute to the development of a relationship between the patient and the pharmacist <sup>3,11</sup>                                       |
| Serv52  | Rel33  | Having the same pharmacist delivering the CPS each time can contribute to the development of a relationship between the patient and the pharmacist <sup>1</sup>                 |

|        |       |  |
|--------|-------|--|
| Serv53 | Sys57 | Involving healthcare providers other than pharmacists (e.g., practice nurses) in the provision/coordination of CPS and related processes can positively influence GP time and workload constraints <sup>12</sup> |
| Sys57  | Rel35 | The workload and time of GPs influence the mode through which they interact and communicate with community pharmacists <sup>9</sup>  |
| Sys58  | GP27  | Complex administrative processes (e.g., tedious paperwork to refer patients to CPS) that require extra time from the GP (Sys57) may affect GPs' willingness to collaborate with CPSs <sup>12</sup>               |
| Sys59  | Rel34 | A system for sharing information can promote collaborative relationships between the pharmacist and GP <sup>8</sup>  |
| Sys60  | Rel34 | The presence of protocols to guide CPS delivery can contribute to improved GP–pharmacist relationships <sup>9</sup>  |

References

1. Carter SR, Moles R, White L, et al. Exploring patients' motivation to participate in Australia's Home Medicines Review program. *Int J Clin Pharm* 2012;34:658-66.

2. White L, Klinner C, Carter S. Consumer perspectives of the Australian Home Medicines Review Program: benefits and barriers. *Res Social Adm Pharm* 2012;8:4-16.

3. Mey A, Knox K, Kelly F, et al. Trust and safe spaces: Mental health consumers' and carers' relationships with community pharmacy staff. *Patient* 2013;6:281-9.

4. Snell L, White L. An exploratory study of the role of emotional intelligence and self-efficacy on service quality and adherence in a weight loss setting. *Serv Mark Q* 2011;32:228-46.

5. McMillan SS, Emmerton L. Nurse practitioners: an insight into their integration into Australian community pharmacies. *Res Social Adm Pharm* 2013;9:975-80.

6. Chong WW, Aslani P, Chen TF. Multiple perspectives on shared decision-making and interprofessional collaboration in mental healthcare. *J Interprof Care* 2013;27:223-30.

7. Dey RM, De Vries MJW, Bosnic-Anticevich S. Collaboration in chronic care: Unpacking the relationship of pharmacists and general medical practitioners in primary care. *Int J Pharm Pract* 2011;19:21-9.

8. Van C, Krass I, Mitchell B. General practitioner perceptions of extended pharmacy services and modes of collaboration with pharmacists. *J Pharm Pract Res* 2007;37:182-6.

9. Van C, Mitchell B, Krass I. General practitioner-pharmacist interactions in professional pharmacy services. *J Interprof Care* 2011;25:366-72.

10. Bui J, Day C, Hanrahan J, et al. Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. *Drug Alcohol Rev* 2014;34:495-8.

11. McMillan SS, Sav A, Kelly F, et al. How to attract them and keep them: The pharmacy attributes that matter to Australian residents with chronic conditions. *Int J Pharm Pract* 2014;22:238-45.

12. Dhillon AK, Hattingh HL, Stafford A, et al. General practitioners' perceptions on home medicines reviews: a qualitative analysis. *BMC Fam Pract* 2015;16:16.

For peer review only

|                                    |    |   |                                 |
|------------------------------------|----|---|---------------------------------|
| PRISMA check-list                  |    |   |                                 |
| TITLE                              |    |   |                                 |
| Title                              | 1  | Identify the report as a systematic review, meta-analysis, or both.   | 1                               |
| ABSTRACT                           |    |   |                                 |
| Structured summary                 | 2  | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 3                               |
| INTRODUCTION                       |    |   |                                 |
| Rationale                          | 3  | Describe the rationale for the review in the context of what is already known.  | 5-6                             |
| Objectives                         | 4  | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  | 6                               |
| METHODS                            |    |   |                                 |
| Protocol and registration          | 5  | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.   | Not available                   |
| Eligibility criteria               | 6  | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.  | 7                               |
| Information sources                | 7  | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.  | 7                               |
| Search                             | 8  | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.   | Appendix 1 (Supplementary file) |
| Study selection                    | 9  | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).   | 6-7                             |
| Data collection process            | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  | 7                               |
| Data items                         | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.   | 7-8                             |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  | 7                               |
| Summary                            | 13 | State the principal summary measures (e.g., risk  | 8                               |

|                      |    |   |     |
|----------------------|----|---|-----|
| measures             |    | ratio, difference in means).  |     |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis. | 7-8 |

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




### Assessment of the synthesis of qualitative research using the ENTREQ Statement for enhancing transparency in reporting the synthesis of qualitative research

| Item                       | Page number                     |
|----------------------------|---------------------------------|
| Aim                        | 7                               |
| Synthesis methodology      | 8                               |
| Approach to searching      | 7-8                             |
| Inclusion criteria         | 7-8                             |
| Data sources               | 7                               |
| Electronic Search strategy | Appendix 1 (Supplementary file) |
| Study screening methods    | 7-8                             |
| Study characteristics      | 12 (table 2)                    |
| Study selection results    | Figure 1                        |
| Rationale for appraisal    | 8                               |
| Appraisal items            | 8                               |
| Appraisal process          | 8                               |
| Appraisal results          | 10                              |
| Data extraction            | 8-9                             |
| Software                   | 9                               |
| Number of reviewers        | 8-9                             |
| Coding                     | 8-9                             |
| Study comparison           | 8                               |
| Derivation of themes       | 8-9                             |
| Quotations                 | Not in this version             |
| Synthesis output           | 18 (table 3)                    |

## Correction: *Qualitative meta-synthesis of barriers and facilitators that influence the implementation of community pharmacy services: perspectives of patients, nurses and general medical practitioners*

Hossain LN, Fernandez-Llimos F, Lockett T, *et al.* Qualitative meta-synthesis of barriers and facilitators that influence the implementation of community pharmacy services: perspectives of patients, nurses and general medical practitioners. *BMJ Open* 2017;7:e015471. doi: 10.1136/bmjopen-2016-015471

In figure 1, the number below 'Records after duplicates removed' should be 243 not 278. The corrected figure is shown below.



**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

*BMJ Open* 2018;8:e015471corr1. doi:10.1136/bmjopen-2016-015471corr1

